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ABSTRACT 
 Amphotericin B (AmB) is a clinically vital, yet highly toxic antifungal agent that is 
dependent on the presence of membrane sterols to exert its biological activity. This natural 
product has been shown to form ion channels in model membrane systems and therefore 
represents a molecule with the capacity to perform protein-like function, i.e. the formation of a 
transmembrane ion channel. Efforts to improve the therapeutic index of AmB or harness its 
potential to act as a molecular prosthetic to treat diseases that arise from a lack of protein 
function would benefit from an atomistic understanding of the mechanism of action.  
 To elucidate this poorly understood mechanism, we developed a strategy focused upon 
the synthesis-enabled deletion of functional groups from the macrolide skeleton followed by 
determination of the biological and biophysical consequences. The first functional groups we 
targeted for deletion were the carboxylic acid and the mycosamine sugar appendages. Both of 
these functional groups had been predicted to be critical for the following roles: 1) stabilizing ion 
channel formation via an intermolecular salt-bridge interaction, 2) anchoring AmB to 
phospholipid bilayers and 3) binding to sterols. However, an alternative hypothesis states that 
AmB does not directly bind sterols but rather that sterol-induced global membrane properties are 
the source of the sterol dependency of AmB. This debate has been ongoing since the early 
1970’s and had yet to be resolved at the time this work began. 
The functional group deletion strategy proved to be remarkably effective. Ultimately, we 
found that polar interactions between the acid and mycosamine are not required for ion channel 
formation or antifungal activity. In addition, we found that electrostatic interactions between the 
acid and/or mycosamine and the zwitterionic phospholipid headgroup are not required for AmB 
to partition into phospholipid bilayers. Finally, it was discovered that AmB directly binds 
ergosterol and cholesterol and that the mycosamine appendage is strictly required for this 
binding interaction. Furthermore, this binding interaction was shown to be absolutely required 
for forming ion channels and killing yeast cells. Consequently, the long contentious theory that 
AmB and membrane sterols participate in a functionally vital small molecule-small molecule 
interaction was finally confirmed. Based upon these results, and related studies with another 
natural product, natamycin, we proposed a novel, potentially general, two mechanism model to 
account for AmB’s potent antifungal activity.  These discoveries provide a foundation for the 
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more effective utilization of AmB and demonstrate the capacity of synthetic organic chemistry to 
illuminate even the most elusive aspects of small molecule function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To C.E.C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
Acknowledgements 
First, I would like to thank my research advisor Prof. Marty Burke who taught me how 
powerful it is to understand problems at the fundamental level and to not be afraid to think big. I 
will come back to the lessons throughout my scientific career. Also his support, confidence and 
guidance allowed me to go to far outside my comfort zone to build the knowledge and 
infrastructure necessary to expand the biophysical capabilities of the group, for which I am very 
grateful. I would also like to thank my thesis committee, Prof. Scott Denmark, Prof. Paul 
Hergenrother and Prof. Wilfred van der Donk, for holding me to a high standard of scholarship 
during the course of my graduate studies. My undergraduate advisor Prof. Yitzhak Tor continued 
to be a valued source of advice and encouragement. Also, the organic secretaries, Becky 
Duffield, Susan Lighty and Stacy Olson, thanks for answering all the random questions I had 
over the years.  
I am grateful to the entire Burke group for all of their advice and support over the years 
and for making the lab a great place to do science. I would especially like to thank those that I 
worked directly with: Ian Dailey and Kaitlyn Gray, through their willingness to listen and 
comment on to my rather frequent off the wall ideas, helped me to develop my critical thinking 
skills. I also very much valued their friendships. Additionally, it was a great learning experience 
and a real pleasure working with undergraduate Dave Seibert and I am very happy to see how 
well he is progressing with his own graduate education at the University of Chicago Pritzker 
School of Medicine. Tom Anderson and Brandon Wilcock also made key contributions to the 
projects I worked on and I am very thankful for that. Of course, my baymates Matt Endo, Brice 
Uno and Pulin Wang deserve special thanks for creating such a fun, irreverent environment. 
Best. Bay. Ever. In addition, Steve Ballmer and Eric Gillis were good friends during my time in 
Illinois that I was lucky to meet.  
I also need to thank my parents, uncle, grandparents and brother for shaping who I am as 
a person and for their endless and tireless encouragement (even when I didn’t want it). My 
successes so far are a testament to their unconditional love and support. Finally I want thank 
Jenn for being such a wonderful and incredible partner. 
I also want to thank Dr. Ed Buck and Dr. Glenn Fried for their help in getting the planar 
lipid bilayer system up and running. I gratefully acknowledge the University of Illinois, the 
National Institutes of Health, the Robert F. Carr Fellowship and Professor Martin Burke for 
 vi 
funding. Bristol-Myers Squibb generously donated the amphotericin B used for the work 
described in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
Ac   acetate       
    
 
 
ACME   amplitude constrained multiplet evaluation 
 
AmB   amphotericin B 
 
 
 
 
 
 
AmdeB  amphoteronolide B 
 
 
 
 
 
AmE   amphotericin B methyl ester 
 
 
 
 
 
CBS   Corey-Bakshi-Shibata oxazaborolidine 
   catalyst  
 
 
COSY-PS  phase sensitive correlation spectroscopy 
 
 
CSA   (±)-10-camphorsulfonic acid  
 
 
d.r.   diastereomeric ratio 
 
 
DDQ   2,3-dichloro-5,6-dicyano-1,4-benzoquinone  
 
 
 
 
 
diS-C3(5)  3,3’-dipropylthiacarbocyanine iodide  
 
N
S
Me
I
N
S
Me
O
O
CN
CN
Cl
Cl
O
SO3HMe
Me
N B
O
Me
H Ph
Ph
O OH Me
HO
NH2
OH
O
OH
OMe
O
OHOMe
OHOH
OH
OHOHO
Me
MeHO
OH
O
OH
OH
O
OHOMe
OHOH
OH
OHOHO
Me
MeHO
O OH Me
HO
NH2
OH
O
OH
OH
O
OHOMe
OHOH
OH
OHOHO
Me
MeHO
Me
O
R
 viii 
DMAP   4-(dimethylamino)-pyridine 
 
 
 
 
DMF   dimethyl formamide  
 
 
 
 
DMPC  1,2-dimyristoyl-sn-glycero-3-  
   phosphocholine 
 
 
 
 
DMPU   1,3-dimethyl-3,4,5,6-tetrahydro2(1H)-pyrimidinone  
 
 
 
DMSO   dimethyl sulfoxide  
 
 
 
 
DPPA   1,2-dipalmitoyl-sn-glycero-3-phosphate  
 
 
 
 
 
DPPC   1,2-dipalmitoyl-sn-glycero-3- 
   phosphocholine 
 
 
 
 
EYPC   egg yolk phosphatidylcholine 
 
 
 
 
 
 
 
 
O
O O
O
P
O
O
O NMe3
O
Me
Me
77 14
(This is the dominant species, EYPC is 
a mixture of phosphocholines)
O
O O
O
P
O
O
O NMe3
O
Me
Me
14 14
O
O O
O
P
O
O
OH
O
Me
Me
14 14 Na
Me S
O
Me
N N
O
MeMe
O
O O
O
P
O
O
O NMe3
O
Me
Me
12 12
N
O
H
Me
Me
N
N MeMe
 ix 
 
FMOC-OSu  9-Fluorenylmethyl N-succinimidyl carbonate  
 
 
 
HPLC   high performance liquid chromatography 
 
 
ITC   isothermal titration calorimetry 
 
 
LUV   large unilamellar vesicle 
 
 
MeAmB  C(41)-methyl amphotericin B 
 
 
 
 
 
 
 
 
MeAmdeB  C(41)-methyl amphoteronolide B 
 
 
 
 
 
MIC   minimum inhibitory concentration 
 
 
MOE   molecular operating environment 
 
 
NAcAmB  N-acetyl amphotericin B  
 
 
 
 
 
 
 
 
 
 
O OH Me
HO
NHAc
OH
O
OH
OH
O
OHOMe
OHOH
OH
OHOHO
Me
MeHO
OH
O
OH
Me
OHOMe
OHOH
OH
OHOHO
Me
MeHO
O OH Me
HO
NH2
OH
O
OH
Me
OHOMe
OHOH
OH
OHOHO
Me
MeHO
O
O
O
N
O
O
 x 
 
NAcAmE  N-acetyl amphotericin B methyl ester  
 
 
 
 
 
NBS   N-bromosuccinimide  
 
 
NOE   nuclear Overhauser effect 
 
 
NOESY  nuclear Overhauser effect spectroscopy 
 
 
OPBC   1-oleoyl-2-(9,10-dibromosteroyl)-sn-glycero-  
   phophocholine 
 
 
 
POPC   1-palmitoyl-2-oleoyl-sn-3-glycero- 
  phophocholine 
 
 
pyr   pyridine 
 
 
REDOR  rotational double echo resonance spectroscopy 
 
 
SEC   size exclusion chromatography 
 
 
SSNMR  solid-state nuclear magnetic resonance spectroscopy 
 
 
SUV   small unilamellar vesicle 
 
 
TBDPS  t-butyldiphenyl silyl 
 
 
 
 
 
Si
Ph
Ph
t-Bu R
O
O O
O
P
O
O
O NMe3
O
Me
Me
77 14
O
O O
O
P
O
O
O NMe3
O
Me
Me
77 14
Br Br
NBr
O
O
O OH Me
HO
NHAc
OH
O
OH
OMe
O
OHOMe
OHOH
OH
OHOHO
Me
MeHO
 xi 
TES   triethylsilyl         
 
 
 
 
Tf   trifluoromethane sulfonate  
 
 
 
 
THF   tetrahydrofuran 
 
 
TLC   thin layer chromatography 
 
 
 
TMS   trimethyl silyl   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Si
Me
Me
Me R
S
O O
RF3C
Si
Et
Et
Et R
 xii 
TABLE OF CONTENTS 
 
CHAPTER 1: AMHOTERICIN B: CURRENT UNDERSTANDINGS OF THE  
MECHANISM OF ACTION........................................................................ 1 
 
CHAPTER 2: “TOP-DOWN” DEGRADATIVE SYNTHESES OF C(41)-METHYL  
  AMPHOTERICIN B, AMPHOTERONOLIDE B AND 
  C(41)-METHYL AMPHOTERONOLIDE B.............................................. 27 
  
  EXPERIMENTAL SECTION...................................................................... 43 
 
CHAPTER 3: FUNCTIONAL GROUP DELETIONS REVEAL THE  
  MYCOSAMINE-DEPENDENT STEROL BINDING OF 
  AMPHOTERICIN B..................................................................................... 95 
 
  EXPERIMENTAL SECTION...................................................................... 117 
 1 
Chapter 1 
Amphotericin B: Current Understandings of the Mechanism of Action 
 
1-1 AMPHOTERICIN B IS AN INDISPENSABLE ANTIFUNGAL AGENT 
 Systemic fungal infections are a major and mounting source of morbidity and mortality. 
For example, an epidemiological study of blood-borne infections (sepsis) found that incidences 
of reported fungal septicemias in the United States increased by 207% over the 21-year period 
from 1979 to 2000.1 Moreover, fungal pathogens account for approximately 10 percent of all 
reported hospital acquired infections, and Candida species are statistically tied for the third most 
common source of microbial bloodstream infections.2  In addition, the rate of fungal infections 
may actually be considerably underestimated because fungal pathogens are particularly 
challenging to diagnose, and there is a high occurrence of false negative results for fungal blood 
cultures.3  The toll extracted by these invasive mycoses on the American health care system is 
severe. Crude mortality rates for blood borne Candidiasis are very high, with an average of 39 
percent, although this rate can reach 60 percent for C. krusei infections.2 Additionally, the 
associated cost for treating these systemic fungal infections has been estimated to cost between 2 
to 4 billion dollars annually.4 Finally, the medical and demographic trends that are producing a 
population at risk for fungal septicemia, such as an ageing population, the overall increase in the 
length of hospital stays and the growing population of immunocompromised individuals, are 
expected to continue.5 Thus, there is an urgent and pressing need for safe and effective antifungal 
therapies.  
 Initially approved for clinical use in 
1958 by the FDA, the natural product 
amphotericin B (AmB, Figure 1.1) to this day 
remains the last line of defense in treating for 
invasive mycoses. The paradigmatic and most 
extensively studied member of a large class of 
antifungal natural products known as the 
polyene macrolides,6 amphotericin B has 
enjoyed a remarkable six decades of continuous clinical use. This extraordinary medicinal 
success can be traced to two key pharmacological properties: broad-spectrum fungicidal activity7 
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for AmB. 
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and the lack of significant microbial resistance.8 The therapeutic effectiveness of this molecule is 
encumbered, however, by the substantial toxicity associated with treatment, including cardio and 
renal toxicity as well as hemolytic anemia.9 In fact, the harshness of these adverse reactions have 
become rather infamous over the lifetime of AmB and have earned the molecule the label 
“amphoterrible” amongst the clinical community. While the clinical efficacy of AmB can be 
partially improved through the use of lipid-based delivery vehicles,10 a limited understanding of 
its mechanism of action has obstructed the further improvement of the therapeutic index of this 
indispensible member of the modern pharmacopeia.  
Currently, the leading hypothesis for the mechanism of action of AmB states that this 
molecule inserts into sterol-containing lipid bilayers and subsequently self-assembles into a 
transmembrane ion channel that disrupts the cellular electrochemical gradient, eventually leading 
to cell death.11 In this manner, amphotericin B also represents a small molecule with the capacity 
to perform a protein-like function i.e. the formation of a membrane-spanning ion channel. It has 
been envisioned12 that this functional mimicry could be harnessed to develop small molecules 
capable of replacing the role of missing or defective proteins in living systems, thereby operating 
as molecular prosthetics. Importantly, the realization of this vision, in addition to the 
development of new AmB derivatives with better pharmacological profiles, requires an atomistic 
understanding of the AmB ion channel. However, despite fifty years of intensive investigation, 
the nature of the AmB ion channel and the underlying physical basis for its formation and 
stabilization remain unclear. The barrel-stave ion channel model is currently accepted as the 
leading hypothesis for the mechanism of action of AmB. The evolution of this now textbook 
classic theory13 and the key studies that led to its formulation will be overviewed in the following 
section.  
 
1-2 AMPHOTERICIN B: FOUNDATIONAL STUDIES 
 In 1955 when AmB was initially isolated and found to be a potent antifungal agent,14 
systemic fungal infections were a virtual death sentence because of the lack of any effective 
therapy. For example, a commonly advocated treatment for oral thrush infections at the time was 
the inhalation of ethyl iodide.15 AmB moved very quickly, therefore, into clinical investigation15 
and use16 and has remained the standard of care for antifungal chemotherapy since the late 
1950’s.  
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At the same time AmB was being taken forward into the clinic, mechanistic studies 
aimed at determining the source of AmB’s fungicidal action were also being initiated. A short 
three years after the initial isolation of AmB, Gottlieb and coworkers17 discovered that the 
addition of a crude hexanes extract of carrots to the culture medium of the mold P. oxalicum 
could provide protection against the antifungal action of AmB. Chemical analysis of the hexanes 
extract suggested that the protective agent was a mixture of sterol molecules and this was 
confirmed when chemically isolated sterol mixtures were shown to antagonize the biological 
activity of AmB. The observed inhibitory effects of sterols led Gottlieb and coworkers to 
propose that polyene macrolides exert their antifungal activity by either interfering with the 
biosynthesis of sterols or by competitively inhibiting essential sterol dependent enzymes. 
However, Kinsky18 and Feingold19 alternatively suggested that the function of AmB was related 
to the presence of sterols in the membrane of the target organism. 
For example, Kinsky found that both rat erythrocytes (containing cholesterol) and N. 
crassa protoplasts (containing ergosterol) were susceptible to AmB. Conversely, the eubacterium 
B. megaterium, which lacks membrane sterols, was completely resistant to AmB.18 However, the 
interpretation of this experiment was complicated by the presence of the bacterial cell wall 
because it was also possible that the cell wall was trapping and sequestering the AmB, thereby 
preventing cellular toxicity. Hence, the next major step in the mechanistic understanding of AmB 
came with comparative studies using the model mycobacterium A. laidlawii. This microorganism 
does not have the protein machinery to biosynthesize sterols, but it will incorporate sterols into 
its plasma membrane if they are present in the environment. Importantly, however, sterols are 
not required for cellular viability, and A. laidlawii cultured in rigorously sterol-depleted media 
will simply have sterol-free plasma membranes. Taking advantage of this unique physiological 
property, Feingold set up an experiment using two parallel batches of A. laidlawii cultured under 
identical conditions except for one key difference. One batch was grown in the presence of 
cholesterol while the other was cultured under sterol-free conditions.19 Exposing each culture 
stock to AmB produced the striking result that A. laidlawii grown with cholesterol were rapidly 
killed by AmB, while the sterol-free group was totally refractory to AmB. Moreover, transferring 
the “resistant” strain to cholesterol-rich media rendered it susceptible to AmB and, conversely, 
dilution of the vulnerable organisms in sterol-free media induced AmB resistance. Although 
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these studies showed that the antimicrobial action of AmB is dependent on the presence of 
membrane sterols, the role of sterols in the mechanism of AmB very much remained unclear.  
Following these early studies, two different proposals were formulated to explain the 
absolute sterol dependence of AmB. These two models are termed the direct sterol hypothesis 
and the indirect sterol hypothesis. Originally proposed by Feingold and HsuChen in 1973,20 the 
indirect sterol hypothesis asserts that the action of AmB is dependent upon the sterol mediated 
global properties of the cell membrane. According to this hypothesis, the differences in the 
preorganization of the membrane induced by individual sterols are the source of the membrane 
selectivity of AmB. Thus, by the indirect sterol model, ergosterol best modulates the 
physiochemical characteristics of membrane bilayers in a manner that is conducive to the 
mechanism of action of AmB, leading to the overall selectivity of AmB for fungal membranes.  
The direct sterol hypothesis, advanced by Medoff and coworkers in 1974,21 alternatively states 
that AmB and membrane sterol engage in a direct binding interaction. Therefore, by the direct 
sterol hypothesis, the selective toxicity of AmB for fungal cells is derived from the higher 
binding affinity of AmB for ergosterol (the main fungal sterol) versus cholesterol (the main 
mammalian sterol). These two competing hypotheses have been hotly debated in the literature 
since their inception but so far the issue has remained unresolved. Importantly, distinguishing 
between these two hypotheses is critical to the rational development towards an improved 
therapeutic index. This subject will be discussed in more depth later in the chapter.  
These early studies with AmB, in addition to investigating the important, though 
undefined role of membrane sterols, were also focused on elucidating the mechanism of AmB’s 
cellular toxicity. For example, in 1961 Kinsky found that AmB induced growth inhibition of the 
mold N. crassa was accompanied by a significant decrease in the dry weight of the mycelial 
mats.23 Kinsky therefore proposed that AmB compromised the permeability properties of cellular 
membranes and this permeability enhancement was the source of AmB’s antifungal activity. 
Kinsky’s supposition was further supported by the finding18 that B. megaterium, which had also 
been shown to be resistant to AmB, was not susceptible to AmB induced cellular lysis. Further 
studies by de Kruijff and coworkers, using the same A. laidlawii model system discussed above, 
were also useful in testing Kinsky’s permeability hypothesis.24 For example, exposing 
cholesterol-free and resistant A. laidlawii to AmB did not increase the membrane permeability of 
these organisms. In contrast, when cholesterol-laden A. laidlawii were treated with AmB, a 
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marked loss of intracellular potassium was observed. Additional permeability studies with the 
pathogenic yeast C. albicans were also consistent with Kinsky’s hypothesis.25 Considering the 
capacity of AmB to permeabilize membranes and the possible role of permeability enhancement 
in antifungal activity, three different mechanisms of membrane disruption were formulated: 
gross membrane destruction, ionophoric transport and discrete single ion channel formation. 
 Distinguishing between these three scenarios relied heavily on the then newly established 
planar lipid bilayer technology, which proved to be a very valuable tool.26 This in vitro technique 
allows for precise electrophysiological measurements on isolated patches of membrane, the 
composition of which can be controlled to suit the experiment. In 1968, Andreoli and coworkers 
employed this technique and found that AmB decreased the electrical resistance of cholesterol 
containing thin lipid membranes by over six orders of magnitude without disrupting the physical 
integrity of the phospholipid bilayer. Moreover, consistent with the biological data, treating 
sterol-free planar lipid bilayers with AmB did not alter the resistance properties of the 
membrane.27 The stability of the membrane in the presence of AmB strongly argued against the 
gross destruction mechanism, but this initial result was unable to resolve the ion channel and 
carrier models.  
To differentiate these two mechanisms, Finkelstein and coworkers employed the model 
ionophore valinomycin for a series of comparative studies with AmB (Table 1.1).28 By 
measuring the membrane conductance as a function of the antibiotic concentration or of the 
temperature, strikingly different behaviors were seen for valinomycin and AmB. For example, in 
the presence of valinomycin, the conductance of the membrane increased linearly with 
increasing concentrations of valinomycin. Furthermore, increasing the temperature of the 
experiment produced an overall increase in the conduction of valinomycin treated membranes, 
behaviors consistent with the shuttling 
mechanism of valinomycin. AmB, 
however, produced very different 
results that we not consistent with the 
characteristics of ionophores. For 
instance, in the presence of increasing 
concentrations of AmB, the membrane 
conductance exhibited a power 
Table 1.1. The differential effects of valinomycin and AmB on 
planar lipid bilayers supported the hypothesis that AmB forms 
ion channels. 
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dependence on the concentration of the antibiotic. Additionally, when the temperature of AmB 
exposed membranes was increased, a significant decrease in membrane conductance was 
observed. The characteristics of AmB, therefore, were much more consistent with the formation 
of a self-assembled aggregate. Upon increasing temperature, Finkelstein proposed that complex 
was dissociating and consequently reducing the membrane conductivity.  
Further evidence consistent with the channel model was gained by studying the 
membrane permeability of small non-ionic solutes in the presence of AmB.29 These experiments 
showed a strong correlation between the hydrodynamic radius of the solutes and the ability of 
these molecules to pass through AmB treated membranes. All of the solutes used in this study 
had limited membrane permeability in the absence of AmB, but relatively small solutes such as 
urea and glycerol were able to permeate the bilayer to a much greater extent upon the addition of 
AmB. The AmB enabled permeability enhancement did not, however, translate to larger 
molecules such as glucose, which remained impermeable in the presence of AmB. Thus, this 
data indicated that AmB was forming a water filled pore of a defined size and, given the relative 
impermeability of glucose, Andreoli and coworkers predicted that this pore was between 7 and 
10 angstroms in diameter.  
Conclusive evidence for the putative AmB ion channel was finally obtained in 1976 with 
the direct experimental observation of 
single AmB ion channels using planar 
lipid bilayers.30  Remarkably, this small 
molecule ion channel displayed 
characteristics such as gating and ion 
selectivity that are typically associated 
with protein ion channels.30 Furthermore, 
the AmB ion channel could be reversibly 
blocked in a voltage-dependent fashion by 
the tetraethylammonium cation,31 similar to some protein-based ion channels.32 However, while 
the ability of AmB to form ion channels in model membranes had been established, the role of 
this ion channel in antifungal activity remained unclear and has been disputed.33 Most 
prominently, it has been proposed that the cellular toxicity of AmB is derived from the polyene-
induced oxidative damage of phospholipid bilayers.32b-e 
Figure 1.2 An example of the single channel 
electrophysiological data of AmB in cholesterol containing 
bilayers obtained by Ermishkin and coworkers. Each step 
from the I=0 line indicates the formation of a single AmB 
ion channel. 
 
From Ermishkin, et al Nature 1976, 262, 698-699. 
Copyright 1976, Nature Publishing Group.  
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 Collectively, these studies formed the basis for the AmB barrel-stave ion channel model. 
This hypothesis was independently and simultaneously advanced by de Kruijff,34 Andreoli,35 and 
Finkelstein36 in 1973-4 and is shown in Figure 1.3. This model proposes that eight AmB units 
self-assemble to form a transmembrane ion channel with the polyol portion of each molecule 
collectively pointing inward to create a water-filled pore that is conducive to ion conductance. 
Conversely, the non-polar polyene portions of the AmB monomers are oriented outward to 
interact with the hydrophobic lipid environment. In addition, later refinements of the barrel-stave 
model have made predictions regarding the role of specific chemical groups in forming and 
stabilizing this small molecule ion channel. Most prominently, three specific proposals have been 
made for the role(s) of the C(41) carboxylate and C(19) mycosamine, as shown in Figure 1.4. 
The first proposal (Figure 1.4A) is that the C(41) carboxylate and C(3’) amine participate in an 
intermolecular salt bridge/hydrogen bond to create a peripheral ring of polar interactions 
predicted to be critical for ion channel formation.37 Additionally, polar interactions between 
zwitterionic phospholipid headgroups and the C(41) carboxylate and/or C(19) mycosamine been 
proposed to anchor AmB into the membrane bilayer (Figure 1.4B).38 Finally, the carboxylate 
and/or mycosamine have also been predicted to mediate the direct binding of membrane sterols 
via a hydrogen bond to the 3β-sterol hydroxyl group (Figure 1.4C).21,39 As was mentioned 
previously, however, a competing hypothesis states that AmB does not directly bind membrane  
 
Figure 1.3. The barrel stave model for the AmB 
ion channel. In this model the hydroxyl groups 
collectively point towards each other to create a 
membrane-spanning hydrophilic pore while the 
polyene is directed outward towards the lipid 
bilayer. The blue spheres represent mycosamine. 
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sterols, but the sterol dependence of AmB instead arises from the indirect global effects that 
sterols impose on phospholipid bilayers. 
 The putative importance of the carboxylate and mycosamine is reinforced by the 
conspicuous biosynthetic origin of these two groups. When the biosynthesis of AmB was 
elucidated in 2001 it was found that the initial product of the polyketide synthase machinery is 
actually aglycone 1.2 (Figure 1.5), noticeably lacking both the C(41) carboxylic acid and C(19) 
mycosamine.40 These functionalities are installed post-polyketide synthase by dedicated enzymes 
that exhaustively oxidize the C(41) methyl group and glycosylate C(19) with mycosamine. 
Figure 1.4 Three proposals for the role of the C(41) carboxylate and C(19) mycosmaine in the antifungal 
mechanism of AmB. It has been hypothesized that the acid and mycosamine A) form an intermolecular salt-
bridge/hydrogen bond that stabilizes the AmB ion channel, B) interact electrostatically with the zwitterionic 
phospholipid headgroup and C) promote sterol binding by hydrogen bonding to the sterol 3β hydroxyl group. 
Adapted from Palacios, et al Proc. Natl. Acad. Sci. USA Early View, Copyright 2011, National Academy of 
Sciences. 
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Similar tailoring enzyme modifications have also been found for the related natural products41 
natamycin,42 nystatin,43 rimocidin,44 and candicidin.45 Additionally pointing to the potential 
critical role of the acid and mycosamine is the conservation of these two moieties in the same 
relative position in all but one of this collection of molecules, over 200 of which have been 
described.46  
Until recently, each one of these three hypotheses remained experimentally unconfirmed. 
The inability to furnish definitive conclusions to these questions of central mechanistic 
importance over five decades of research is symptomatic of the broader challenges associated 
with investigating molecular events occurring in the phospholipid bilayer environment. For 
example, the dynamic nature of membrane-localized phenomena, such as the self-assembled 
AmB ion channel aggregate, challenges current state of the art spectroscopic47 and 
computational48 techniques. In addition, two other commonly employed methods in membrane 
biophysical chemistry that have been used to interrogate the AmB ion channel, the covalent 
modification of lipids and/or the covalent modification of AmB, also have associated 
experimental complications. For instance, derivatization of a membrane component to 
investigate a particular chemical interaction can also substantially alter the physical 
characteristics of the parent bilayer. This is especially true for membrane sterols49 because small 
structural modifications, such as inverting the stereocenter of the 3β-hydroxyl group, can 
drastically change the molecular and macroscopic effects that membrane sterols impart on 
phospholipid bilayers.50 Changing these global membrane properties can also independently 
impact membrane-localized binding events, making the isolation and validation of binding 
events occurring within lipid bilayers extremely difficult. Furthermore, such lipid modification 
studies are challenging to translate to an in vivo experiment because of the high degree of lipid 
structural specificity that is often required for the proper maintenance of cellular physiology.51 
Alternatively, covalent modification of AmB itself can introduce unfavorable steric interactions, 
and therefore it may be unclear if a positive, stabilizing interaction is being removed or if 
negative steric clashing is being introduced. This potential consequence is particularly critical 
when considering the formation of the AmB ion channel, because of the exquisite sensitivity of 
small molecule self-assembly to steric effects.52  
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Given the inherent limitations of these general strategies, this thesis describes a different 
approach involving the synthesis enabled-deletion of protic functional groups from the macrolide 
skeleton and determination of the 
biological and biophysical 
consequences.53 This experimental 
algorithm is shown in Figure 1.6 and 
consists of three related modules: 1) 
synthesis of functional group deficient 
derivatives, 2) elucidation of the 
ground state three dimensional 
conformation of these derivatives and 
3) determination of the biological and 
biophysical consequences of each functional group deletion. This strategy is akin to the alanine 
scanning methodology that has proven to be extremely successful for determining the function of 
specific amino acid residues in complex proteins.54 In addition, Lemeuix used a similar deletion 
based approach in his pioneering studies of the blood group lectins.55 An additional and very 
advantageous element of the functional group deletion strategy is that the same probe molecules 
can be employed in vitro and in vivo. Thus, the functional group deletion strategy can directly 
link structure-function relationships determined via biophysical assays to the consequences of 
perturbing such functions in living cells.  
As will be discussed in detail in the following chapters, this experimental strategy proved 
to be remarkably effective. Ultimately, it was discovered that the putative polar interactions 
between functional groups at C(41) and C(19) are not necessary for pore formation (Figure 
1.4A). We also found that polar interactions between the C(41) carboxylate and/or C(19) 
mycosamine and the phospholipid headgroups are not required to anchor AmB to the membrane 
(Figure 1.4B). Alternatively, it was discovered that AmB directly binds ergosterol and that the 
mycosamine appendage is strictly required for this interaction (Figure 1.4C). Furthermore, this 
binding interaction was shown to be strictly required for forming ion channels and killing yeast 
cells. Consequently, the long contentious theory that AmB and membrane sterols participate in a 
functionally vital small molecule-small molecule interaction was finally confirmed. To put these 
Figure 1.6. Summary of the functional group deletion strategy. 
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results in context, the literature supporting each one of the hypotheses summarized in Figure 1.4 
will be critically overviewed. 
 
1-3 THE SALT-BRIDGE HYPOTHESIS 
 The initial evidence suggesting a polar interaction 
between the functional groups at C(41) and the mycosamine 
appendage at C(19) came from in vitro studies of covalently 
modified AmB derivatives. During electrophysiological 
investigations of AmB in 1979,37 Ermiskin and coworkers noted 
dramatic changes in the ion channel characteristics of AmB 
according to the state of the carboxylate and mycosamine. The 
chemistry of these two groups was varied by methylating the 
acid to produce amphotericin B methyl ester (AmE), and by 
acetylating the amine to give N-acetyl amphotericin B 
(NAcAmB). The results of these experiments are summarized in 
Table 1.2, which shows the dramatic decrease in channel lifetime 
that accompanied neutralization of one of the charged groups. In 
addition to reducing the channel lifetime, neutralization of one of the charged groups also had the 
effect of raising the concentration threshold required to observed single ion channels. However, 
once the derivative channels did form, both the AmE and NAcAmB ion channels appeared to 
have similar conductance properties to the native channel. Based upon these data, the authors 
proposed that blocking either of the charged groups disrupted electrostatic interactions between 
the C(41) acid and C(3’) amine. This hypothesis was later supported by molecular dynamics 
Figure 1.7. The salt bridge 
hypothesis. 
Table 1.2. The channel lifetime of AmB derivatives is drastically reduced when either of the two charged groups 
is neutralized. Adapted from reference 37. 
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studies of the barrel stave AmB ion channel by Khutorsky,56 McCammon,57 and Borowski.58 In 
each one of these molecular dynamics simulations a strong hydrogen bonding interaction 
between the C(41) carboxylate and C(3’) amine was noted, and thus was predicted to play a 
critical role in channel self-assembly.   
In vivo studies were further interpreted 
as supporting the putative salt bridge 
hypothesis in a physiologically relevant 
context. Specifically, in addition to the 
reduced capacity to form ion channels in 
planar lipid bilayers, it was also known that 
acetylating the C(3’) amine leads to a 
significant reduction in the capacity to 
permeabilize yeast cells and to exert 
antifungal activity.59 This was interpreted as 
supporting the requirement for this putative 
polar interaction in the membrane of living yeast cells. Interestingly, a variety of C(41) esters 
have been found to retain yeast permeabilizing and antifungal activities.59 However, as pointed 
out by Bolard and Borowski, these covalently modified derivatives retain a polar carbonyl group 
and thereby possess the capacity to form charge-dipole interactions with the mycosamine 
appendage and perhaps thereby stabilize channel self-assembly (Figure 1.8B).60   
  In an attempt to probe the alleged salt 
bridge interaction, Murata and coworkers 
recently synthesized the covalently linked 
dimers 1.3-1.5 (Figure 1.9).61 Following their 
synthetic preparation, the biological activity of 
these molecules was investigated, and it was 
found that the dimers displayed little to no 
antifungal activity. Based on the limited 
activity of these molecules, the authors 
proposed that while the amine and acid may 
form a strong hydrogen bond in the AmB ion 
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channel assemblage, some amount of space and/or flexibility is required for this interaction to be 
fully effective. Murata and coworkers reported further support for this prediction with molecular 
mechanics force field calculations of 1.3-1.5. The structure of directly linked 1.3 suffered a large 
degree of structural distortion, which Murata and coworkers attribute to the strain induced by the 
short amide covalent linkage. Thus, the inherent steric interference caused by covalently 
modified derivatives made this approach unable to cleanly probe the proposed importance of the 
salt bridge interaction between the C(41) carboxylate and C(3’) ammonium.  
 
1-4 THE PHOSPHOLIPID ANCHORING HYPOTHESIS   
 The hypothesis that phospholipids anchor AmB 
into the membrane via polar interactions between the 
phospholipid headgroup and the C(41) carboxylate and/or 
C(19) mycosamine was first prompted by a series of 
solution-phase NMR studies.37 Easwaran and coworkers 
studied the interaction of AmB with the saturated 
phospholipid 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) in CDCl3 and observed 
significant AmB dependent line broadening in the 31P 
spectra of the phospholipid headgroup. This data was 
interpreted by Easwaran and coworkers to be consistent 
with an interaction between the polar functionality on the 
C(19) mycosamine and the phospholipid headgroup. But 
since these data were collected under non-physiological conditions in CDCl3, the results of this 
study must be interpreted with caution. Nonetheless, using this NMR data to constrain the 
calculations, a molecular dynamics simulation of the proposed AmB:DPPC complex was also 
performed.62 In the simulated complex, the C(2’) and C(4’) oxygens of mycosamine were 
observed to form hydrogen bonds with the glycerol oxygens of the DPPC headgroup but no 
electrostatic interactions between the C(41) carboxylate or the C(3’) ammonium and the charged 
groups on the phospholipid were observed. However, other molecular dynamics simulations 
performed in the presence of phospholipid bilayers did observe electrostatic interactions between 
the zwitterionic phospholipid headgroup and the C(41) carboxylate and C(3’) ammonium.63 
Figure 1.10. The proposed polar 
interaction stabilizing the AmB-
phospholipid complex that anchors AmB 
into the membrane.  
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 The nature of this putative AmB-phospholipid interaction has also been investigated 
using surface pressure measurements of thin films of sterol-free lipids and AmB. The first of 
these studies used the simple model lipid 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA), 
which does not contain a choline headgroup.64 Analysis of a series of surface pressure-area 
curves with differing molar ratios of phospholipid and AmB showed highly non-ideal behavior 
for AmB-DPPA thin films. Miñones and coworkers interpreted these deviations from ideality to 
be evidence of AmB-DPPA complex formation. In addition, the maximum deviation from 
ideality occurred at a ratio of 2:1 AmB to DPPA and the authors ascribed this phenomenon to the 
formation of a relatively stable 2:1 AmB:DPPA complex held together via electrostatic 
interactions between the charged groups on AmB and DPPA. Murata and coworkers also 
claimed evidence for the formation of an AmB-lipid complex held together by electrostatic 
interactions based on solid-state nuclear magnetic resonance (SSNMR) studies of AmB in 
DMPC membranes.65 However, it is currently not clear how well fully saturated lipids, such as 
DPPA and DMPC, can serve as good models for eukaryotic cell membranes.66 More importantly, 
neither of these studies employed membrane sterols, which are necessary for the antifungal 
activity of AmB, and, therefore, the results of these experiments are difficult to interpret. 
The covalent modification approach has also been used to probe the phospholipid 
anchoring hypothesis. For example, utilizing a reductive amination to alkylate the C(3’) amine 
with an aldehyde bearing phospholipid, Murata and coworkers prepared dimers 1.6-1.9 (Figure 
1.11) to investigate the AmB-phospholipid interaction.67 The extremely poor aqueous solubility 
of these molecules made the experimental evaluation of their biophysical properties very 
difficult, however. For example, while all four dimers displayed membrane permeabilization 
Figure 1.11. Structures of the AmB-phospholipid conjugates used to probe the nature of the AmB-phopholipid 
interaction. This scheme was adapted from reference 67. 
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activity against sterol-free egg yolk phosphatidylcholine (EYPC) liposomes in a potassium efflux 
assay, the dimers had to be premixed with the lipids prior to liposome formation. Attempting to 
perform this experiment under more physiologically relevant conditions, that is adding a solution 
of the conjugates to a suspension of liposomes, was prevented by the insolubility of all four 
dimers. In addition, Murata and coworkers also cited the insolubility of the conjugates 1.6-1.9 as 
a possible reason for the total lack of antifungal activity of these molecules. Thus, the potential 
importance of polar interactions between AmB and phospholipids to anchor AmB to the 
membrane remained ambiguous.   
 
1-5 THE INDIRECT STEROL HYPOTHESIS   
In 1973 Feingold and HsuChen reported that, although cholesterol promoted the action of 
AmB in many lipid bilayer systems, in certain model membranes AmB function was attenuated 
by the presence of membrane embedded cholesterol (Figure 1.12).20 This unexpected result was 
interpreted to be the first experimental 
evidence that the mechanism AmB is 
dependent on the indirect, 
physiochemical effects of membrane 
sterols. This study used a glucose 
release assay to investigate the effect 
of different lipids on the membrane 
permeabilizing activity of AmB. When the glucose release assay was performed with egg 
lecithin vesicles, the incorporation of cholesterol into the liposomes markedly enhanced the 
membrane permeabilizing activity of AmB. However, when this same experiment was repeated 
with vesicles alternatively composed of dipalmitoyl lecithin, the addition of cholesterol to these 
vesicles greatly suppressed the extent of AmB induced glucose leakage. In light of the then 
current molecular understanding of phospholipid membranes, Feingold proposed that AmB is 
active only against phospholipid membranes with a relatively high degree of overall molecular 
order. For inherently disordered unsaturated lipids, such as egg lecithin, cholesterol confers a 
degree of ordering to the lipid chains. In contrast, for saturated lipids such as dipalmitoyl 
lethicin, cholesterol disrupts the tight interactions of the saturated acyl tails and leads to an 
overall decrease in ordering.  
Figure 1.12. Cholesterol had opposing effects on the activity of 
AmB for the two different vesicles systems used in reference 
20. 
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Later liposome-based studies were also interpreted to be consistent with this hypothesis. 
For example, Murata and coworkers also that found that cholesterol could act as an AmB 
antagonist under certain conditions.68 In this experiment, the addition of cholesterol to egg yolk 
phospatidylcholine (EYPC) liposomes, potentiated the membrane permeabilizing activity of 
AmB until the concentration of cholesterol in the membrane reached 20 percent (relative to 
lipid). When the amount of cholesterol was further increased to 30 percent, a reduction in the 
degree of ion permeability was recorded. Murata and coworkers proposed that the inhibitory 
effects of cholesterol were derived from the propensity of this sterol to thicken membrane 
bilayers.69  
Carreira and coworkers 
observed similar effects and concluded 
that the membrane selectivity and 
activity of AmB arises from the 
differential preorganization of the 
membrane imposed by different 
sterols.70 In their study, Carreira and 
coworkers70 used 100 nm 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) liposomes mixed with various 
amounts of ergosterol, cholesterol, 7-
dehydrocholesterol or 
dihydrocholesterol (Figure 1.12) in a 
potassium efflux assay to investigate 
the impact of sterol structure on the 
permeabilizing activity of AmB. Ergosterol or cholesterol-loaded liposomes displayed the 
maximum degree of efflux at five percent sterol (relative to lipid). Increasing the sterol content 
beyond five percent led to an overall decrease in the extent of ionic flux. Alternatively, 7-
dehydrocholsterol or dihydrocholesterol liposomes suffered the highest level of permeabilization 
at 13 percent sterol. Additional 7-dehydrocholsterol or dihydrocholesterol beyond 13 percent 
inhibited the efflux activity of AmB. Carreria and coworkers thus interpreted this data as being 
consistent with the indirect sterol hypothesis. 
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Even the notion that AmB requires membrane bound sterol for channel formation has 
been questioned. For example, Hartsel and coworkers71 demonstrated that AmB potently 
promoted the efflux of potassium from sterol-free EYPC small unilamellar vesicles (SUVs).72 
Membrane permeabilization was observed at AmB to lipid ratios as low as 1:1000 for these 
sterol-free SUV’s. Other groups have also documented this type of sterol independent 
permeabilization of liposomes by AmB.73 Moreover, utilizing patch clamp technology, Ortega-
Blake and coworkers reportedly observed the formation of single AmB ion channels in sterol-
free liposomes composed of DMPC, egg lecithin or isolated bacterial membrane extracts.74 The 
ion channels that formed in these in vitro sterol-free systems displayed similar 
electrophysiological properties as the AmB ion channels that have been documented in sterol 
containing membranes. Ortega-Blake and coworkers interpreted this observation as evidence that 
that sterols are not involved in the supramolecular AmB channel architecture. However, all of 
these studies were performed in model membranes, and the authors noted that supraphysiological 
concentrations of AmB were required to observe ion channels in sterol-free membranes, making 
the results of this experiment difficult to interpret. In addition, small unilamellar vesicles are 
considered to be poor experimental models to use for investigating membrane active species. 
Their small size correlates to a high radius of curvature and consequently makes them much 
more susceptible to membrane permeabilization than the more physiologically representative 
large unilamellar vesicles (LUV’s).75  
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1-6 THE DIRECT STEROL BINDING HYPOTHESIS 
 Originally advanced in 1974, the alternative theory for the 
sterol dependency of AmB proposes that AmB directly binds 
membrane sterols. In this model, the selective fungal toxicity of AmB 
therefore arises from the greater binding affinity of AmB for ergosterol 
(the main fungal sterol) over cholesterol (the main mammalian 
sterol).21 More specifically, the carboxylate at C(41) and/or the 
mycosamine sugar are predicted to mediate this putative small 
molecule small molecule interaction.38 Early data that was interpreted 
as supporting a direct AmB-sterol binding interaction came from 
sterol-dependent shifts in the UV/Vis and CD spectra of AmB in both 
solution phase and liposome based studies.76 These spectral shifts were 
mainly correlated to the permeability of liposomes,77 but not to any 
additional structural data. Thus, it has been conversely proposed that 
these sterol-dependent changes in the electronic absorption spectra of 
AmB are due to aggregation of the AmB monomers78 and not an AmB 
sterol interaction.  
Attempting to elucidate the putative AmB-sterol interaction, Borowski and coworkers 
used the sterol modification strategy to investigate the role of the C(19) mycosamine and C(41) 
carboxylate in sterol binding. This 
study examined the ability of 
AmB, NAcAmB and AmE to 
permeabilize liposomes loaded 
with one of the sterols shown in 
Figure 1.15.39 Borowski and 
coworkers found that NAcAmB 
had a reduced activity relative to 
AmB against liposomes containing 
any one of the sterols shown in 
Figure 1.15. Based upon this result, they suggested that the C(3’) amine hydrogen bonds with the 
3β sterol hydroxyl group to promote the AmB-sterol binding interaction. This interaction has  
Figure 1.14. The 
C(41) carboxylate 
and/or mycosamine are 
proposed to promote 
sterol binding. 
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also been proposed based upon 
molecular dynamics simulations of 
the AmB-sterol complex.58 
However, as with the salt-bridge 
studies outlined in Section 1-3, it is 
difficult to dissociate the effect of 
removing a hydrogen bonding 
interaction from steric clashing 
when covalently modified derivatives are used as probes. 
  In contrast to NAcAmB, AmE selectively permeabilized liposomes that contained either 
ergosterol or brassicasterol. These two sterols share the same unsaturated isoprenoid tail that is 
not common to the remaining four sterols (Figure 1.14). Borowski and coworkers therefore 
proposed that AmB binds sterols through two complementary forces: a water mediated hydrogen 
bond to the 3β sterol hydroxyl group (Figure 1.16), and van der Waals contacts between the 
sterol nucleus and the AmB polyene subunit. For AmB derivatives bearing a free acid, Borowski 
and coworkers proposed that the hydrogen bond network is very strong and therefore hydrogen 
bonding dominates the sterol-AmB binding interaction (Figure 1.16A). For AmB derivatives 
with an alkyl ester at C(41), however, the authors hypothesize that this hydrogen-bonding 
network is disrupted (Figure 1.16B) and consequently, van der Waals contacts drive the binding 
event. A similar model was also advanced by Gary-Bobo.79 However, this model does not take 
into account the ability of the C(41) alkyl esters to maintain polar interactions through the ester 
moiety.60 
Alternatively, it has also been proposed that the 
C(2’) alcohol present on mycosamine may form a 
hydrogen bond to the 3β sterol hydroxyl group. Using the 
covalent modification approach, the intramolecularly 
tethered AmB derivatives shown in Figure 1.17 were 
synthesized.80 However, reflecting the inherent limitation 
of the covalent modification approach, conformationally 
restrained 1.10-1.12 displayed significantly reduced 
antifungal activity relative to AmB. Nevertheless, Murata 
Figure 1.16. The proposed hydrogen bonding network that 
promotes the AmB-sterol binding interaction. Adapted from 
reference 39. 
Figure 1.17. Structures of the 
intramoleculary tethered derivatives used 
to investigate the AmB sterol interaction 
in reference 80. 
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and coworkers used the results of a conformational analysis of the linked derivatives to try to 
predict which polar groups on mycosamine interact with the 3β-sterol hydroxyl group. Based 
upon the conformation of the mycosamine appendage relative to the polyene subunit for the six-
carbon linked 1.11, Murata and coworkers proposed that the C(2’) hydroxyl group was the 
functional group on mycosamine in the best spatial orientation to interact with the sterol 3β 
hydroxyl group. This interaction predicted by Murata and coworkers has also been proposed 
based upon molecular dynamics simulations of AmB-sterol complexes.81 However, the 
prediction that the C(2’) alcohol forms the critical hydrogen bond with membrane sterols has 
been questioned by the recent demonstration by Carreira and Croatt that epi-C(2’) AmB fully 
retains native antifungal activity.82 
Further attempts to investigate the AmB-sterol interaction used enantiomeric 
cholesterol83 as a mechanistic probe for the role of sterol in the AmB ion channel. In contrast to 
the sterol-free patch clamp experiment described in the previous section, Rychnovksy and 
coworkers found that planar lipid bilayers containing either cholesterol or ent-cholesterol 
produced two distinct AmB ion channels. The electrophysiological divergence for the 
enantiomeric sterol systems was interpreted by the authors as evidence that AmB was directly 
binding the membrane sterols and this was leading to the formation of two different 
diastereomeric AmB ion channels.84 Furthermore, the concentration of AmB required to observe 
the formation of ion channels was greater for the ent-cholesterol system, which the authors 
interpreted as consistent with a reduced binding affinity of AmB for this unnatural sterol. 
However, it is challenging to reproduce this experiment in a live yeast cell to determine if this 
putative binding interaction is functionally relevant in vivo.85 
Finally, a recent SSNMR study utilizing deuterated versions of AmB, ergosterol and 
Figure 1.18. Structures of the deuterated isotopologues used in the SSNMR study claiming an AmB-ergosterol 
interaction. Adapted from reference 67. 
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cholesterol (Figure 1.17) produced conflicting results.67 Using the quadrupolar splitting of the 
deuterium peaks as a measure of molecular mobility in a POPC bilayer, Murata and coworkers 
observed that AmB and cholesterol have dissimilar mobilities under these conditions, suggesting 
little or no binding interaction between these two molecules. In contrast, when AmB was added 
to a POPC bilayer loaded with deuterated ergosterol analogue 1.14, the two molecules displayed 
similar mobilities, which the authors interpreted as being consistent with a direct binding 
interaction between AmB and ergosterol. Seeming to contradict this conclusion, when a 
rotational double echo resonance (REDOR)86 experiment was performed with untethered 13C-
labelled AmB and 19F labeled ergosterol, Murata 
and coworkers did not observe a through space 
interaction between the two molecules.87 Such 
an interaction would be expected if the 19F 
ergosterol and AmB were participating in a 
direct binding interaction. Conversely, a 
dephasing effect was observed for covalently 
tethered AmB-ergosterol conjugate 1.16 but this 
molecule was not biologically active.88 Thus, the 
importance, or even the existence, of the 
putative AmB-sterol interaction has remained 
unclear.  
  
 
 
 
 
 
 
 
 
 
 
Figure 1.19. Structures of the AmB-sterol covalent 
conjugates from reference 87.  
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1-7 SUMMARY 
 Collectively, the decades of research outlined above has shown that, despite being the 
standard of care for systemic mycoses for over fifty years, the molecular mechanism of action of 
AmB remains ambiguous. In particular, the role(s) of the C(41) carboxylate and C(19) 
mycosamine have eluded a precise understanding, though both are predicted to be vital for 
biological activity. Elucidating the function of these two groups is extremely challenging, 
however, because of the dynamic, multimolecular and membrane-based action of AmB. 
Investigations of this molecule have focused on four key experimental strategies: covalent 
modification of AmB, covalent and/or stereochemical sterol modifications, spectroscopic studies 
and computational methods. However, each one of these strategies has its limitations and, hence, 
the mechanism of AmB’s antifungal activity, and especially the specific roles of key functional 
groups, remains enigmatic. Therefore, there is a clear and unmet need for the definitive 
clarification of these ambiguities, particularly those surrounding the role(s) of the carboxylic acid 
and mycosamine. Our contributions to this goal utilizing the alternative, functional group 
deletion approach, are outlined in the following two chapters.    
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Chapter 2 
 
“Top-Down” Degradative Syntheses of C(41)-Methyl amphotericin B, amphoteronolide B and 
C(41)-Methyl amphoteronolide B 
 
 
 Investigating the role(s) played by mycosamine and the C(41) carboxylate in the 
mechanism(s) of action of amphotericin B required the development of a synthetic route to three 
functional group deficient derivatives: C(41)-Methyl amphotericin B, amphoteronolide B and 
C(41)-Methyl amphoteronolide B. This chapter details the synthetic strategy used to achieve all 
three derivatives from a common intermediate derived through synthetic manipulation of the 
natural product. In the course of these syntheses, significant hurdles had to be overcome. For 
example, the natural product itself presents a challenge because it is insoluble in common 
organic solvents and water, and is light, oxygen and acid sensitive, making the molecule difficult 
to handle. In addition, the mycosamine and the carboxylic acid had to be selectively deleted in 
this polyfunctional molecule without harming other sensitive chemical moieties, such as the 
lactone or the polyene. Building on important literature precedent from chemists at Smith Kline-
Beecham, we found that activating the C(41) carboxylic acid as a 2-pyridyl thioester was an 
effective method for selective reduction. Similarly building on studies by Nicolaou and 
Masamune, we found that mycosamine could be removed oxidatively using 2,3-Dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) in the presence of either an allyl ester or a primary iodide at 
the C(41)-position. Moreover, we found that the functional group at the C(41) position heavily 
influenced the diastereoselectivity of the carbonyl reduction at C(19) that was performed directly 
after  mycosamine removal. The configuration of the newly formed stereocenter at C(19) was 
established using coupling constant and NOE data in comparison to the natural product. In 
addition, the 3-dimensional conformation of the three functional group deficient derivatives and 
AmB were calculated using a Monte-Carlo simulation constrained by extensive two-dimensional 
NMR data. Thomas M. Anderson contributed to the development of the oxidative removal of 
mycosamine using DDQ and performed the NMR experiments used to determine the 
configuration at C(19) and the 3D ground state conformation of the four molecules with 
assistance from the author. Thomas Anderson also contributed the calculated structures shown in 
Figure 2.3. Portions of this chapter were taken with permission from Palacios, D.S.; Anderson, 
T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 13804-13805.  
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2-1 BACKGROUND 
 When I first joined Prof. Marty Burke’s research group in October of 2005, he suggested 
that I pursue a degradative synthesis of AmB to prepare the three functional group deficient 
derivatives shown in Scheme 2.1: amphoteronolide B (AmdeB, 2.2), C(41)-Methyl 
amphoteronolide B (MeAmdeB, 2.3),  and C(41)-Methyl amphotericin B  (MeAmB, 2.4). The 
object of preparing these molecules was to enable a suite of biological and biophysical assays to 
illuminate the poorly understood molecular mechanism of action of AmB. As of 2005, the only 
complete total synthesis of AmB was the report from the Nicoloau group in 1987.1 These authors 
also prepared the aglycone of AmB, amphoteronolide B (AmdeB). Although it was a landmark 
achievement that has since become a classic in the field, the length and complexity of the 
Nicolaou synthesis made its use challenging for the preparation of mechanistic probes. 
Alternatively, degradative syntheses of AmdeB2 and MeAmB3 were known in the literature, but, 
prior to our investigations, MeAmdeB had not been prepared. Finally, MeAmB4 and the doubly 
modified 8-deoxy amphoteronolide B5 have been prepared via genetic engineering of the AmB 
producing organism S. nodosus.  However, despite extensive attempts, it was not possible to 
obtain pure samples of MeAmB or the aglycones for biological testing.  
The MeAmB synthesized by chemists at Smith-Kline Beecham through degradative 
chemical synthesis was reported to have a four-fold diminished minimum inhibitory 
concentration (MIC) relative to the natural product against C. albicans.4 The biological activity 
of the AmdeB synthesized by Nicolaou and coworkers was not determined.3 Therefore, to 
provide much needed insight into the mechanistic role(s) played by the carboxylic acid and the 
mycosamine sugar (See Chapter 1), we pursued modular degradative syntheses of MeAmB, 
AmdeB and MeAmdeB that could provide these compounds in chemically pure form and in 
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quantities suitable for biological and biophysical investigation. 
  
2-2 SYNTHETIC STRATEGY 
 Recognizing that greater synthetic throughput and efficiency could be achieved by 
maximizing the number of common intermediates in the route, we designed a synthesis that 
consisted of four synthetic modules (Scheme 2.2). The first step would be a global protection to 
generate common intermediate 2.5, in part to provide a compound that was more amendable to 
manipulation. It had been shown previously that protected AmB derivatives were soluble in 
common organic solvents such as acetone and diethyl ether and could be purified by simple flash 
chromatography. From 2.5, we had to choose whether to first target the mycosamine or the acid 
for removal in order to access aglycone 2.9, en route to MeAmdeB. We decided to first 
implement the carboxylic acid reduction module to generate common intermediate 2.6, because 
we hypothesized that retention of mycosamine at C(19) would impart greater chemical stability 
than a secondary alcohol at this position. Continuing the path towards MeAmdeB, the carboxylic 
acid reduction would be followed by a deglycosylation sequence to generate aglycone 2.9, which 
would be globally deprotected to yield MeAmdeB 2.3. Similarly, AmdeB 2.2 could be obtained 
from a deglycosylation/global deprotection sequence from common intermediate 2.5. Finally, 
Scheme 2.2. Overview of the proposed synthetic route to access the three desired functional group deficient 
derivatives from AmB. The highlights of this route are the modular design to give common intermediates and the 
potential use of common reaction conditions. 
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global deprotection of common intermediate 2.6 could provide access to MeAmB 2.4. Initial 
efforts towards realizing this overall synthetic plan were focused on developing conditions to 
selectively reduce the carboxylic acid. 
 
2-3 DEVELOPMENT OF THE REDUCTION MODULE 
 Our objective was to find mild, chemoselective conditions to reduce the carboxylic acid 
without simultaneously reducing the macrolactone moiety. Our first attempt to achieve this goal 
is shown in Scheme 2.3. First, the amine was protected as an Fmoc-carbamate, and subsequent 
exposure to trimethylsilyl diazomethane generated methyl ester 2.10 in 71% yield over two 
steps. Dehydration of hemiketal 2.10 with trimethylsilyl trifluoromethanesulfonate (TMSOTf) 
effectively protected the hemiketal as a C(13)-C(14) dihydropyran.6 However, the TMS 
protecting groups were not expected to be stable to the downstream chemistry, so the TMS ethers 
were deprotected using HF/pyridine and the resulting free alcohols were reprotected as more 
robust triethylsilyl (TES) ethers with triethylsilyl trifluoromethane sulfonate (TESOTf). This 
provided methyl ester 2.11 in 65% yield over the deprotection/reprotection sequence.  
 
 
 
 
 
 
 
 
 
 
Unfortunately, this methyl ester proved to be completely resistant to reduction, presumably 
because of steric congestion about the C(41) position. The use of more forcing conditions for this 
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h, 71% over two steps; (c) TMSOTf, 2,6 lutidine, CH2Cl2, -78 → 0 °C, 30 min, 84%; (d) HF/pyridine, THF:pyr 
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. 
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reduction led to extensive decomposition of the starting material with loss of the Fmoc-
carbamate only being observed by mass spectrometry of crude reaction mixtures. 
Nicolaou reported that a methyl ester at the C(41) position could be selectively reduced in 
the presence of an unprotected alcohol at C(15).7 We therefore used this report to develop the 
second generation route as shown in Scheme 2.4. In stark contrast to the previous route, addition 
of sodium borohydride to a methanolic solution of free alcohol 2.11 rapidly reduced the methyl 
ester, providing the desired C(41) primary alcohol 2.15 in only 15 minutes at room temperature. 
Assisted delivery of the hydride to the methyl ester such as depicted by 2.14 may be responsible 
for the greatly enhanced reactivity of unprotected 2.11 versus silyl protected 2.12. The newly 
formed C(41) primary alcohol 2.15 could not, however, be site-specifically converted into a 
bromide, iodide or tosylate, despite extensive efforts. Therefore, to isolate the C(41) position, the 
sterically hindered t-butyldiphenylsilyl chloride (TBDPSCl) was employed to selectively protect 
the primary alcohol, giving the silyl ether in 79% yield. After this silation, the remaining 
secondary alcohols were orthogonally protected as acetates, giving the fully protected 
dihydropyan 2.16. However, all attempts to deprotect the silyl ether yielded only Ferrier 
rearrangement8 product 2.17 and not the desired silyl ether removal, despite efforts at 
optimization. Because the bulky TBDPS group requires relatively harsh conditions to be cleaved, 
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the silyl group could not be selectively removed without the Ferrier rearrangement also 
occurring. Consequently, the problems associated with silicon deprotection led us to abandon 
this second generation route. 
The second generation route showed that the C(41) carboxylate could be selectively 
reduced, but the presence of nine free secondary hydroxyl groups made the site-selective 
manipulation of the newly formed primary alcohol at C(41) extremely challenging. With this in 
mind, we drew from the degradative synthetic work performed by chemists at Smith-Kline 
Beecham,4 to generate a third generation route. Our strategy with this synthesis was to establish 
the chemical isolation of the C(41) position in the beginning of the route, thereby simplifying the 
chemistry downstream of the carboxylic acid reduction. As shown in Scheme 2.5, the synthesis 
began by converting AmB into the silyl protected intermediate 2.18 in 47% yield. This three-step 
sequence involved Fmoc protection of the amine, conversion of the hemiketal to a methyl ketal, 
and masking of the secondary alcohols as TES ethers using TESOTf. For the TESOTf step, it 
was critical that the reaction be run heterogeneously in hexanes because use of more polar 
solvents such as dichloromethane gave mixtures of the methyl ketal and the dihydropyran at 
Scheme 2.5. (a) Fmoc-OSu, DMF:MeOH 2:1, 23 °C, 12 h; (b) CSA, THF:MeOH 1:1, 0 °C, 1 h, 90% over 2 
steps; (c) TESOTf, 2,6 lutidine, hexanes, 0 °C, 3 h, 96%; (d) 2-pyridyl thiochloroformate, Et3N, Et2O, 30 min, 0 
°C, 91%; (e) LiBH4, Et2O, 23 °C, 2 h, 88%; (f) Tf2O, pyridine, CH2Cl2, -10 °C, 5 min, then Bu4NI, 0 °C, 1 h, 
26%; (g) LiEt3BH, THF, -10 °C, 20 min, 34%. 
O OH Me
HO
NH2
OH
O
OH
OH
O
OH
OH
2.1
a,b,c
O OH Me
TESO
NHFmoc
OTES
O
OTES
OH
O
OMe
TESO
2.18 O O
H Me
TESO
NHFmoc
OTES
O
OTES
S
O
OMe
TESO
2.19
Nd
e
O OH Me
TESO
NHFmoc
OTES
O
OTES
OH
OMe
TESO
2.20 O O
H Me
TESO
NHFmoc
OTES
O
OTESOMe
TESO
2.21
f
O OH Me
TESO
NHFmoc
OTES
O
OTES
Me
OMe
TESO
2.22
I g
 33 
C(13)-C(14). With the reactivity of the secondary alcohols sequestered, the free acid was then 
selectively activated using 2-pyridyl thiochloroformate.9 The resulting thioester could then be 
reduced under mild conditions with lithium borohydride to furnish primary alcohol 2.20 in 88% 
yield. In an attempt to obviate the use of 2-pyridyl thiochloroformate, which necessarily had to 
be freshly prepared from phosgene and 2-mercapto pyridine prior to use, we explored isobutyl 
chloroformate as a more convenient activator for the acid. However, the resulting mixed 
anhydride simply reverted back to free acid 2.18 upon reaction with lithium borohydride, and so 
ultimately 2-pyridyl thiochloroformate was used to prime the acid for reduction.  
At this point in the route, the primary alcohol at C(41) was now the only free alcohol 
present on intermediate 2.20, and so the only challenge left in the route was to simply activate 
the alcohol and displace the activated intermediate with an additional equivalent of hydride. 
Accordingly, the alcohol was primed for removal by the in situ generation of the primary triflate 
using triflic anhydride, which was immediately displaced with iodide to produce primary iodide 
2.21 in 26% yield over the two steps. Exposure of iodomethyl 2.21 to the nucleophilic hydride 
source lithium triethylborohydride (Super-Hydride®),10 generated protected C(41)-Methyl AmB 
2.22, thereby successfully concluding the reduction sequence.  
Surveying the route post-completion, it was apparent that the final activation/reduction 
sequence would require significant optimization efforts to provide assay quantities of MeAmB. 
The yield for each reaction was poor (26% for the two-step iodide installation and 34% for the 
reduction) and the product of the reduction, 2.22, could not be obtained in pure form because of 
chromatographically inseparable byproducts. Therefore, a final fourth generation route was 
developed to improve upon these significant yield deficiencies. 
Scheme 2.6. (a) I2, PPh3, imidazole, THF, 0 °C, 1 h, 78%; (b) HF/pyr, THF:pyr 5:3, 0 → 25 ºC, 6.5 h, 73%; (c) 
NaBH4, DMSO, 23 ºC, 8 h, 58%. 
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 The ultimate solution to the reduction module (Scheme 2.6) began with primary alcohol 
2.20 (produced as shown in Scheme 2.5), which was converted into primary iodide 2.21 under 
the action of triphenylphosphine and iodine11 in a 78% isolated yield. This new method of iodide 
installation was remarkably successful and tripled the yield of the analogous two-step iodide 
installation in the third generation route. Next, given the poor results obtained with very 
aggressive reductant lithium triethylborohydride, we instead chose to use the much milder 
sodium borohydride, which necessitated the use of highly polar aprotic solvents to effectively 
reduce the carbon-iodide bond.12 When primary iodide 2.21 was reacted with sodium 
borohydride in 1,3 dimethyl-3,4,5,6-tetrhydro-2-(1H)-pyrimidinone (DMPU) the primary iodide 
was indeed reduced to a methyl group. Unfortunately, under these conditions we also observed 
concomitant cleavage of the Fmoc carbamate. The yield for this double reduction, despite efforts 
to improve the reaction, was poor and irreproducible. The alternative use of dimethyl sulfoxide 
(DMSO) as the solvent for the reaction was also problematic, in this case because the very non-
polar TES protected 2.21 was insoluble in DMSO. To resolve this solubility issue, the TES 
ethers were cleaved with HF/pyridine to give primary iodide 2.23. The deprotected 2.23 was then 
was subjected to sodium borohydride in DMSO to successfully reduce the iodide and give C(41)-
Methyl AmB 2.24 in 58% yield and only two deprotection steps away from MeAmB. Thus, the 
goals of this fourth generation route were satisfactorily met. By chaining the method of iodine 
installation and using a less aggressive hydride source we were able to improve the overall yield 
of the carboxylic acid reduction relative to the third generation route. With the route for 
reduction module complete, our attention then focused on removal of mycosamine from the 
macrolactone.  
 
2-4 DEVELOPMENT OF THE DEGLYCOSYLATION MODULE 
 Achieving the modular synthetic plan outlined in Scheme 2.2 required that the 
mycosamine appendage be removable in the presence of either a protected acid or an activated 
methylene at the C(41) position. Pioneering work done by the Nicolaou3 and Masamune13 groups 
demonstrated that mycosamine could be removed oxidatively to yield a heptaenone with a 
methyl ester at C(41) under the action of either N-bromosuccinimde (NBS)2 or DDQ.14 Oxidative 
conditions were used because the acid sensitivity of AmB, and even more so the resulting 
aglycone, precluded the use of traditional deglycosylation conditions (i.e. strong aqueous acid).3 
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The reported yield for the deglycosylation was higher with DDQ than with NBS (50% vs. 18-
30%), so we began our deglycosylation studies on primary iodide 2.21 using DDQ as the 
oxidant.  
The oxidative deglycosylation proved to be a robust reaction- 2.21 reacted cleanly with DDQ 
(Scheme 2.7), to provide the desired heptaenone 2.25 in 62% yield as a beautiful, rich red solid. 
The next step was the reduction of the newly formed carbonyl at C(19). During the degradative 
synthesis of AmdeB, (Scheme 2.8 and Section 2-6) we observed that the reduction of heptaenone 
2.27 with sodium borohydride proceeded with excellent diastereoselectivity; only the desired 
diastereomer was observed. In addition, Nicolaou and coworkers had also observed a highly 
stereoselective reduction for a similar substrate during their degradative synthesis of AmdeB.2 
We were therefore confident that we would achieve a similar level of selectivity for the reduction 
of heptaenone 2.25. Instead we 
found that the reaction of 2.25 with 
sodium borohydride gave only a 
2:1 diastereomeric ratio (d.r.) in 
favor of the natural 19-(R) 
configuration (Table 2.1). Use of 
the (S)-Corey-Bakshi-Shibata 
(CBS) oxazaborolidine catalyst,14 however, provided the desired diastereomer in a synthetically 
useful 6:1 d.r. Interestingly, the (R)-CBS catalyst gave an equimolar ratio of the two 
diastereomers, slightly overturning the inherent selectivity of this large, complex substrate (Table 
2.1). The mechanism behind the large difference in stereoselectivity based upon the substituent 
at C(41) is not currently understood. With the unexpected stereochemical outcome in the 
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Scheme 2.7. (a) DDQ, CaCO3, THF, 23 ºC, 10 min, 62% 
Table 2.1 List of reagents and the 
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Scheme 2.8. In the degradative synthesis of amphoteronolide B, the 
conversion of heptaenone 2.27 to secondary alcohol 2.28 proceeded 
with very high diastereoselectivity using methanolic sodium 
borohydride as the reducing agent. 
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reduction of heptaenone 2.25, we set out to firmly establish the stereochemistry at the C(19) 
position using nuclear magnetic resonance (NMR) spectroscopy.  
 
2-5 DETERMINATION OF CONFIGURATION AT C-19 
 Based upon the known stereochemical preference of the (S)-CBS catalyst14 we were 
confident that the major diastereomer resulting from the (S)-CBS reduction of heptaenone 2.25 
was the desired 19-(R) stereoisomer, but we wanted additional verification of this assignment. 
For our stereochemical analysis, we compared the 3J H-H coupling constant data of the major 
diastereomer resulting from the reduction of heptaenone 2.25 (Scheme 2.7) to the analogous 
coupling constants for two reference compounds, N-Fmoc-C(41) methyl AmB 2.4 and N-acetyl 
AmB methyl ester (NAcAmE 2.27).  The known rigidity of the AmB macrolactone, found by our 
own (See Section 2-7)15 and previous16,17 studies, allowing coupling constants to be accurately 
predicted using the Altona-Karplus equation18, as shown in Figure 2.1. The Altona-Karplus 
predicted that both the J18a-19 and J18e-19 coupling constants should be less than 8 Hz for the 19-
(R) diastereomer. In contrast, for the 19-(S) stereoisomer, the J18a-19 coupling constant was 
expected to be greater than 8 Hz because of the antiperiplanar relationship of these two protons 
(Figure 2.1). The J18a-19 and J18e-19 coupling constants for 2.3 were therefore determined 
unambiguously using phase-sensitive correlation spectroscopy (COSY-PS)19 experiments and the 
Amplitude Constrained Multiplet Evaluation (ACME) program20 and compared to the calculated 
values (See Section 2-7 for more details of the NMR experiments. The final compound 2.3 
Table 2.2. Observed coupling constant 
data derived from ACME processed 
COSYPS data for 2.3, 2.27, and 2.29. Figure 2.1. A) The predicted coupling constants for the 
19-(R) and 19-(S) diastereomers given by the Altona-
Karplus equation. B) Perspective and Newman projections 
(looking down the C18-C19 bond) of the two diastereomers. 
 37 
was used for the stereochemical determination because the C(19) diastereomers were inseparable 
until the final HPLC purification, see Section 2-6 for details). Coupling constants for reference 
compounds C(41) methyl AmB 2.4 and NAcAmE 2.27 were also determined. As shown in Table 
2.1, both of the J18-19 coupling constants for MeAmdeB are significantly less then 8 Hz, 
consistent with the theoretical prediction for the 19-(R) configuration. Furthermore, the coupling 
constants for the reference compounds (for which the stereochemistry at C(19) was not altered) 
are very similar to 2.3, further confirming the assigned 19-(R) configuration.  
 
2-6 THE SYNTHESIS OF MEAMB, AMDEB AND MEAMDEB 
 With the development and optimization of the deglycosylation and reduction modules 
complete, the synthetic plan shown in Scheme 2.9 was implemented. The synthesis began with a 
global protection step to give carboxylic acid 2.18, an intermediate common to all three targeted 
derivatives. Next, as discussed in Section 2-3, the primary alcohol was generated via the 
intermediacy of the activated 2-pyridyl thioester. This primary alcohol was then converted to 
primary iodide 2.21, a valuable intermediate that could be funneled to either MeAmdeB or 
MeAmB. In addition, this molecule was persistent to storage, so this material was accumulated 
in significant quantities. To access MeAmdeB, the mycosamine appendage was removed with 
DDQ as discussed previously and the resulting heptaenone was reduced with the (S)-CBS 
catalyst to give secondary alcohol 2.30. Unfortunately, alcohol 2.30 proved to be impersistent to 
even short term (2-4 weeks) storage or acidic conditions. Because of the fragility of this 
molecule, once the path towards MeAmdeB was initiated, the intermediates had to be taken 
through the entire sequence without any delay. In addition, the two stereoisomers could not be 
separated at this point and the undesired diastereomer was carried through the route and 
separated from the final product by high performance liquid chromatography (HPLC). Reduction 
of the primary iodide proceeded smoothly using sodium borohydride in DMPU in 78% yield, 
setting the stage for a final global deprotection sequence. This highly optimized protocol began 
with global cleavage of the TES ethers using HF/pyridine. The crude product of this reaction was 
then immediately taken forward to generate the hemiketal using 2:1:1 THF:H2O:acetic acid. 
Subsequent purification by preparative HPLC completed the first synthesis of MeAmdeB, 
delivering the molecule in 38% yield over the final deprotection steps and >90% purity as 
determined by HPLC.  
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The synthesis of MeAmB began from the common intermediate, primary iodide 2.21. 
The silyl protecting groups were removed using HF/pyridine in 73% yield and the resulting 
Scheme 2.9. (a) (i) Fmoc-OSu, pyridine, DMF:MeOH 2:1, 23 °C, 12 h; (ii) CSA, THF:MeOH 1:1. 0 °C; 1 h, 
90% yield over two steps; (b) TESOTf, 2,6 lutidine, hexanes, 0 °C, 3 h, 96%; (c) 2-thiopyridyl chloroformate, 
Et3N, Et2O, 0 °C, 30 min, 91%; (d) LiBH4, Et2O, 23 °C, 2 h, 88%; (e) I2, PPh3, imidazole, THF, 0 °C, 1h, 78%; 
(f) DDQ, CaCO3, THF, 23 °C, 10 min, 67%; (g) (S)-CBS oxazaborolidine, Me2S•BH3, CH2Cl2, -10 °C, 30 min, 
6:1 d.r. 79%; (h) NaBH4, DMPU, 23 °C, 6 h, 78%; (i) (i) HF/pyridine, THF:pyridine 3:2, 0 °C, 6 h, (ii) 
AcOH:H2O:THF 1:1:2, 23 °C, 30 min; HPLC, 38% over two steps; (j) allyl bromide, i-Pr2NEt, DMF:MeOH 
10:1, 23 °C, 8 h, 86%; (k) DDQ, CaCO3, THF, 20 min, 23 °C, 65%; (l) NaBH4, THF:MeOH, 3:1, 0 °C, 30 min, 
>20:1 d.r. 77%; (m) HF/pyridine, THF:pyridine, 5:3, 0 → 23 °C, 6 h, 56%; (n) CSA, THF:H2O 2:1, 23 °C, 5 h; 
HPLC, 81%; (o) Pd(PPh3)4, thiosalicylic acid, THF, 23 °C, 13 h; HPLC, 50%; (p) HF/pyridine, THF:pyridine, 
5:3 0 → 23 ºC, 6.5 h, 73%; (q) NaBH4, DMSO, 23 ºC, 8 h, 58%; (r) (i) CSA, THF:H2O 2:1, 23 ºC, 30 min; (ii) 
piperidine, DMSO:MeOH, 4:1, 23 ºC, 3 h; HPLC, 56% over two steps. 
 
Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 
13804-13805. Copyright 2007 American Chemical Society. 
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deprotected primary iodide was treated with sodium borohydride in DMSO to give C(41) methyl 
intermediate 2.24. Following cleavage of the iodide, the methyl ketal was deprotected with 
aqueous camphorsulfonic acid (CSA) the crude the hemiketal was carried forward into the final 
deprotection step without further purification. A portion of this intermediate was purified by 
reverse phase HPLC for the purpose of determining the ground state conformation of this 
molecule (See Section 2-7). Deprotection of the Fmoc carbamate proceeded readily using the 
mild amine base piperidine and the resultant material was purified by preparative HPLC to 
provide MeAmB in 58% yield and >90% purity over the final two steps.  
The synthesis of AmdeB began with free acid 2.18 the compound common to all three 
syntheses. The path towards AmdeB began with the protection of the carboxylic acid as an allyl 
ester using allyl bromide and diisopropyl ethylamine21 in 86% yield. The allyl ester was 
subsequently treated with DDQ to cleanly remove mycosamine in 65% yield. The secondary 
alcohol 2.28 was formed without incident in 77% yield and greater than >20:1 d.r. using 
methanolic sodium borohydride as the reducing agent. Next, the TES groups were removed 
using HF/pyridine but initial attempts were met poor yields. Given the acid sensitivity of the 
conjugated allylic secondary alcohol, we suspected that the material was decomposing during 
silica gel chromatography and this conceit was confirmed by 2D-thin layer chromatography 
(TLC) analysis. Buffering the silica gel with triethylamine did not attenuate this decomposition 
and so the crude product necessarily had to be purified by C18 reverse phase flash 
chromatography. With this reverse phase purification protocol, we were able to obtain the 
deprotected allyl ester in an acceptable 56% yield. Next, the methyl ketal was deprotected using 
aqueous CSA and, remarkably, the time required for this hydrolysis to be complete was ten times 
longer than the equivalent transformation for MeAmB, presumably due to the electronically 
deactivating nature of the allyl ester. Following preparative reverse phase HPLC purification of 
the hydrolysis reaction, the allyl ester was removed using tetrakis(triphenyl phosphine)palladium 
and thiosalicylic acid.22 The crude deallylation product was also purified by preparative reverse 
phase HPLC to provide AmdeB in 48% yield and >90% purity as judged by HPLC.  
 In summary, the modular synthetic route originally proposed in Scheme 2.2 proved to be 
very successful in providing the desired functional group deficient derivatives. In all, 24 grams 
of the common intermediate 2.18 was synthesized and this material provided at least 10 mg of 
each of the three final products, after HPLC purification. In addition, the completion of these 
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syntheses accomplished the first stated goal in the research algorithm outlined in Figure 1.6, 
namely the synthesis of key functional group deficient AmB derivatives in quantities suitable for 
biophysical investigations. Before moving on to study the biological and biophysical impacts of 
these deletions, we had to determine of the ground state three-dimensional conformation of these 
derivatives. This endeavor will be described in the succeeding section.  
 
2-7 DETERMINATION OF THE GROUND STATE CONFORMATION 
 Interpretation of the biological and biophysical activity of AmdeB, MeAmB and 
MeAmdeB could be complicated if removal of the mycosamine and/or carboxylic acid 
engendered changes in the three-dimensional conformation of the macrolactone. If the functional 
group deletions alter the conformation of the molecule then differences in activity could be 
ascribed to shape change, rather than a loss of an intermolecular interaction.  To control for this 
possibility, the second objective of the functional group deletion research program is to evaluate 
the ground state conformation of all synthesized derivatives. Unprotected AmB, AmdeB and 
MeAmB were not amenable to these studies because of their poor solubility properties, so we 
instead used the suitably protected analogues of these molecules shown in Scheme 2.10. 
Importantly, it has been shown22 that covalent modifications of the acid or the amine do not 
affect the ground state conformation of the macrolactone. A combination of solution phase 
COSY-PS and nuclear Overhauser effect spectroscopy (NOESY) experiments were used to 
investigate the ground state conformation of the three functional group deficient derivatives and 
AmB. Unlike conventional COSY experiments, the COSY-PS pulse sequence can distinguish 
between active and passive coupling constants in the two dimensional crosspeak.24 Individual 
two dimensional crosspeaks are then processed using ACME, which fits these data to yield very 
Scheme 2.10. The four molecules used for conformational studies. 
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accurate coupling constant information. We used this process to generate a detailed map of the 
coupling constants for the macrolides in Scheme 2.10. These data were then converted into 
dihedral angles using the Altona-Karplus equation. Additional conformational constraints were 
obtained through two-dimensional NOESY measurements of inter-proton distances. 
 The coupling constant derived dihedral angles and through-space proton correlations 
were then used as parameters for a Monte-Carlo based energy minimization using Molecular 
Operating Environment (MOE)23 to perform the calculations. The results of these minimizations, 
as show in Figure 2.2, clearly demonstrate that the conformation of the macrolactone is 
unaffected by the functional group deletions. The conformations of the four macrolides are 
virtually identical, with a computed RMSD of only 0.08 Å. This conservation of shape greatly 
facilitates interpretation of biological and biophysical data because any observed differences in 
activity would be the direct result of a lack of a chemical interaction, rather than deformation of 
molecular shape.  
 
  
 
 
 
 
 
 
 
 
2-8 SUMMARY 
 The initial implementation of the functional group deletion strategy required facile access 
to the targeted derivatives AmdeB, MeAmB and MeAmdeB. A flexible synthetic route that took 
advantage of common synthetic intermediates and reaction conditions was designed and 
implemented. Essential to the success of this synthetic plan was the discovery of conditions for 
the selective reduction of the C(41) carboxylic acid, and the removal of mycosamine under non-
acidic conditions. It was found that the carboxylic acid could be reduced after activation as a 2-
Figure 2.2. Overlay of the ground state of 2.3, 2.27, 2.29, and 2.30 as determined by solution-phase NMR 
studies. Only the macrolactone is shown for clarity.  
 
Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 
13804-13805. Copyright 2007 American Chemical Society. 
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pyridyl thioester and the mycosamine subunit could be removed by the action of DDQ. The 
overall synthesis of all three derivatives proved successful, and at least 10 mg of each derivative 
was readily synthesized. Additionally, extensive NMR data was collected and used to calculate 
ground state three-dimensional conformation of the three functional group deficient derivatives 
and the natural product. The calculations showed that the macrolide conformation is not distorted 
as a result of the chemical deletions, a discovery that greatly simplifies interpretation of the 
planned biological and biophysical experimentation that will be discussed in the succeeding 
chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
2-9 EXPERIMENTAL SECTION 
Materials.  Commercially available materials were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), Fisher Scientific (Hampton, NH), and Silicycle (Quebec, Canada) and used 
without further purification unless noted otherwise.  Amphotericin B was a generous gift from 
Bristol-Myers Squibb Company.  All solvents were dispensed from a solvent purification system 
that passes solvents through packed columns according to the method of Pangborn and 
coworkers24 (THF, Et2O, CH2Cl2 : dry neutral alumina; DMSO, DMF, CH3OH : activated 
molecular sieves).  Hexanes, 2,6-lutidine, triethylamine, and pyridine were freshly distilled under 
nitrogen from CaH2. Camphorsulfonic acid was recrystallized from ethyl acetate.  Water was 
doubly distilled or obtained from a Millipore (Billerica, MA) MilliQ water purification system. 
 
Reactions. Due to the light and air sensitivity of amphotericin B, all manipulations were carried 
out under low light conditions and compounds were stored under an anaerobic atmosphere. All 
reactions were performed in oven- or flame-dried glassware under an atmosphere of argon unless 
otherwise indicated.  Reactions were monitored by analytical thin layer chromatography 
performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25mm).  
Compounds were visualized using a UV (λ254) lamp or stained by an acidic solution of p-
anisaldehyde.  Alternatively, reactions were monitored by RP-HPLC using an Agilent 1100 
Series HPLC system equipped with a SunfireTM C18 5 micron 10 x 250 mm column (Waters 
Corp. Milford, MA) with UV detection at 406 nm and the indicated eluent and flow rate. 
 
Purification and Analysis.  Flash chromatography was performed as described by Still and 
coworkers25 using the indicated solvent on E. Merck silica gel 60 230-400 mesh or on Silicycle 
17% carbon C18 230-400 mesh reverse phase silica gel.  1H NMR spectra were recorded at 23 °C 
on a Varian Unity Inova Narrow Bore spectrometer operating at a 1H frequency of 500 MHz 
with a Varian 5 mm 1H{13C/15N} pulsed-field gradient Z probe or a Varian Unity Inova 
spectrometer operating at a 1H frequency of 600 MHz with a Varian 5 mm 1H{13C/15N} pulsed-
field gradient X,Y,Z probe. Chemical shifts (δ) are reported in parts per million (ppm) downfield 
from tetramethylsilane and referenced internally to the residual protium in the NMR solvent 
(CHD2OD, δ = 3.31, center line, CD3C(O)CHD2, δ = 2.05, center line) or to added 
tetramethylsilane.  Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
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doublet, t = triplet, dd = doublet of doublets, m = multiplet, b = broad, app = apparent), coupling 
constant (J) in Hertz (Hz) and integration. For compounds S5 (a more soluble derivative of 1), 2, 
20 (a more soluble derivative of 3), and 22 (a more soluble derivative of 4), proton and coupling 
constant assigments were made using a variety of two-dimensional NMR techniques including 
phase-sensitive COSY experiments combined with amplitude constrained multiplet evaluation 
(ACME)20 (see Section III for a detailed discussion). 13C spectra were recorded at 23 °C with a 
Varian Unity Inova spectrometer operating at a 13C frequency of 125 MHz with a 5 mm Nalorac 
gradient {13C/15N}1H quad probe or a Varian Unity Inova spectrometer operating at a 13C 
frequency of 150 MHz and equipped with a Varian 5 mm 600 DB Auto X probe. Chemical shifts 
(δ) are reported downfield of tetramethylsilane and are referenced to the carbon resonances in the 
NMR solvent (CD3OD, δ = 49.0, center line, CD3C(O)CD3, δ = 29.8, center line) or to added 
tetramethylsilane (δ = 0.00). MS analysis was performed with an Applied Biosystems Micromass 
Ultima system with ESI ionization.  High resolution mass spectra (HRMS) were obtained at the 
University of Illinois mass spectrometry facility.  All synthesized compounds (2-4 and 7-22) 
gave HRMS within 5 ppm of the calculated values. The purity of amphotericin B and its 
derivatives was determined by HPLC analysis using a Waters SunFire Prep C18 OBD 5 micron 
30 x 150 mm Lot # 168I161701 column with detection at 406 nm and an eluent of acetonitrile 
and aqueous ammonium acetate unless otherwise indicated. 
 
Part 1. Synthesis of AmB Derivatives 
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Methyl ketal 2.31 
A round bottom flask was charged with amphotericin B (1.5 g, ~55% pure, ca. 0.891 mmol, 1 
eq) and Fmoc-succinimide (0.840 g, 2.48 mmol, 2.8 eq) which were dissolved in a mixture of 
DMF:MeOH 2:1 (105 mL) at 23 °C.  Pyridine (0.84 mL, 10.22 mmol, 11.5 eq) was subsequently 
added and the reaction was stirred for 12 hours.  The reaction mixture was then poured into 
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diethyl ether (1.8 L) stirring at 0 °C.  After stirring for 30 minutes at 0 °C the resulting yellow 
precipitate was isolated via Büchner filtration using Whatman 50 filter paper to afford a yellow 
solid. The residual solvent was removed by coevaporating with acetonitrile (3 x 20 mL) and 
storing under vacuum for one hour.  The resulting powder (1.69 g, ca. 0.8 mmol) was dissolved 
in THF:MeOH 1:1 (50 mL) and cooled to 0 °C.  To this solution was added camphorsulfonic 
acid (0.100 g, 0.438 mmol, 0.55 eq) and the resulting mixture was stirred for 1 hour at 0 °C.  The 
reaction was then quenched at 0 °C with triethylamine (0.06 mL, 0.438 mmol, 0.55 eq) and 
gravity filtered. The filtrate was concentrated in vacuo until a yellow solid began to precipitate.  
The resulting supersaturated solution was poured into hexanes:diethyl ether 1:1 (800 mL) and the 
yellow precipitate was collected via Büchner filtration and washed with ethyl acetate:diethyl 
ether 1:1 (200 mL) to yield 2.31 as a yellow solid (1.33 g, ~70% purity, ca. 0.80 mmol, ca. 90% 
over two steps). This material was carried forward without further purification. 
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TLC (CH2Cl2:MeOH 5:1) 
 Rf  = 0.15, stained by anisaldehyde 
 
HPLC  
tR = 13.2 min; flow rate = 4 mL/min, gradient of 5 → 95% MeCN in 5 mM ammonium 
acetate over 15 min. 
 
1H NMR (500 MHz, pyridine d-5:CD3OD 10:1) 
δ 7.86 (d, J = 7.5 Hz, 2H), 7.73 (t, J = 8 Hz, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.28 (dd, J = 2, 
8 Hz, 2H), 6.59-6.34 (m, 12H), 6.23 (dd, J = 6.5, 14 Hz, 1H), 5.66 (dd, J = 10, 15 Hz, 
1H), 4.97 (bs, 1H), 4.92 (bs, 1H), 4.69 (bs, 1H), 4.54 (app t, J = 9.5 Hz, 1H), 4.52-4.31 
(m, 4H) 4.31 (bs, 1H), 4.26-4.20 (m, 3H), 4.07-4.01 (m, 2H), 3.87 (app dd, J = 7.5, 16.5 
Hz, 2H), 3.67-3.63 (m, 2H), 3.58 (app d, 10.5 Hz, 1H) 3.48 (app d, J = 8.5 Hz, 1H), 3.28 
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(s, 3H), 2.77-2.54 (m, 5H), 2.45 (dd, J = 3.5, 16.5 Hz, 1H), 2.08-2.00 (m, 4H), 1.88-1.72 
(m, 7H), 1.68-1.64 (app d, J = 14 Hz, 1H), 1.52 (d, J = 6 Hz, 3H), 1.39 (d, J = 6.5 Hz, 
3H), 1.29 (d, J = 6.5 Hz, 3H), 1.20 (d, J = 7 Hz, 3H). 
 
13C NMR (125 MHz, pyridine d-5:CD3OD 10:1) 
δ 171.7, 158.0, 144.8, 144.7, 141.8, 137.3, 134.6, 134.5, 134.3, 134.0, 133.4, 133.3, 
133.2, 133.1, 132.8, 132.5, 132.2, 128.2, 127.6, 125.9, 125.8, 120.4, 101.9, 99.1, 78.1, 
75.4, 74.6, 74.5, 71.8, 71.6, 71.1, 70.7, 68.2, 67.7, 67.2, 66.8, 58.1, 46.3, 44.6, 43.5, 43.1, 
42.7, 42.5, 41.5, 41.3, 39.3, 36.1, 34.1, 30.8, 30.5, 30.1, 29.7, 29.3, 24.9, 24.2, 23.3, 18.7, 
18.4, 17.4, 14.1, 14.0, 12.2, 11.0. 
 
HRMS (ESI)  
 calculated for C63H85NO19 (M + Na)+: 1182.5614  
found:      1182.5608 
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TESOTf, 2,6 lutidine, 
hexanes, 3 h, 0 °C, 96%
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P = Triethylsilyl  
 
Nonatriethylsilyl ether 2.18 
Prior to the reaction 2.31, was azeotropically dried via coevaporation with acetonitrile (3 x 20 
mL) and was left under vacuum for a minimum of eight hours. The resulting yellow powder (3.9 
g, ~ 70% purity, ca. 2.35 mmol, 1 eq) was suspended in hexanes (110 mL). 2,6-lutidine (7.0 mL, 
60.5 mmol, 26 eq) was added and the resulting suspension was then cooled to 0 °C.  Triethylsilyl 
triflate (10.6 mL, 47.0 mmol, 20 eq) was added dropwise over 10 minutes and the resulting 
yellow suspension was stirred for 2 hours at 0 °C.  Additional 2,6-lutidine (1.8 mL, 18.3 mmol, 
6.5 eq) was then added followed by additional triethylsilyl triflate (2.5 mL, 11.1 mmol, 5 eq) 
dropwise over 5 minutes.  After 15 minutes of stirring additional 2,6-lutidine (1.8 mL, 18.3 
mmol, 6.5 eq) was added followed by additional triethylsilyl triflate (2.5 mL, 11.1 mmol, 5 eq) 
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dropwise over 5 minutes.  The mixture was stirred at 0 °C for 1 hour following completion of the 
final addition and was then quenched at 0 °C with saturated aqueous sodium bicarbonate (250 
mL).  The resulting emulsion was diluted with diethyl ether (500 mL) and the layers were 
separated.  The organic phase was washed with saturated aqueous sodium bicarbonate (1 x 100 
mL) and water (3 x 50 mL), and the combined aqueous washings were back-extracted with 
diethyl ether (3 x 100 mL).  The combined organic phases were then washed with 1M aqueous 
copper sulfate (10 x 25 mL).  The combined copper sulfate layers were then back-extracted with 
diethyl ether (5 x 50 mL).  The combined organic layers were washed with water (3 x 50 mL) 
and brine (1 x 50 mL). This second set of aqueous washings was back extracted with diethyl 
ether (3 x 50 mL) and the combined organic layers were dried over sodium sulfate and 
concentrated in vacuo.  Purification of the crude yellow oil by flash chromatography (SiO2; 
hexanes:diethyl ether 20:1 → 7:1) furnished 2.18 as an orange solid (4.94 g, 2.26 mmol, 96%).  
 
O OH Me
PO
NHFmoc
OP
O
OP
OH
O
OMeOMe
OPOP
OP
OPOPO
Me
MePO
2.18
P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 2:1) 
  Rf = 0.38, visualized by UV 
 
1H NMR (500 MHz, acetone d-6)  
δ 7.90 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7 Hz, 2H), 7.45 (t, J = 7.5 Hz, 2H), 7.37 (t, J = 7.5 
Hz, 2H) 6.63-6.56 (m, 3H), 6.49-6.14 (m, 9H) 5.98 (dd, J = 5.5, 15.5 Hz, 1H), 5.52 (dd, J 
= 10, 15 Hz, 1H), 5.42 (d, J = 10 Hz, 1H), 4.74 (bs, 1H), 4.67 (bs, 1H), 4.57 (s, 1H), 
4.54-4.45 (m, 2H), 4.37 (dd, J = 6.5, 10 Hz, 1H), 4.28 (app t, J = 6 Hz, 2H), 4.17 (t, J = 
10 Hz, 1H), 4.02 (app t, J = 9 Hz, 2H), 3.92 (d, J = 2.5 Hz, 1H),  3.89 (app d, J = 8.5 Hz, 
1H), 3.73 (bs, 1H), 3.65-3.60 (m, 2H), 3.48 (app t, J = 9 Hz, 2H), 3.33 (dd, J = 6.5, 8.5 
Hz, 1H), 3.16 (s, 4H), 2.62 (d, J = 7 Hz, 1H) 2.51-246 (m, 2H), 2.35 (t, J = 10.5 Hz, 1H) 
2.17 (dd, J = 7, 15 Hz, 1H), 2.04 (dd, 7.5, 15.5 Hz, 1H), 1.97-1.62 (m, 10H), 1.56-1.52 
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(m, 1H) 1.27 (d, J = 6.5 Hz, 3H), 1.20 (d, J = 6 Hz, 3H), 1.11-0.92 (m, 87H), 0.82-0.59 
(m, 54H).  
 
13C NMR (125 MHz, acetone d-6) 
δ 174.3, 170.5, 158.2, 156.4, 145.0, 142.2, 139.5, 137.2, 135.8, 135.6, 135.2, 134.5, 
134.2, 134.0, 132.4, 132.3, 132.1, 132.0, 131.2, 130.6, 128.5, 127.9, 127.8, 125.8, 125.7, 
120.8, 120.6, 101.5, 98.0, 76.8, 75.0, 74.5, 74.1, 73.5, 73.4, 71.1, 68.9, 67.5, 67.3, 67.2, 
58.1, 57.5, 48.1, 48.0, 44.3, 43.4, 42.2, 41.5, 40.7, 35.6, 27.6, 24.4, 20.0, 19.3, 18.9, 11.1, 
7.65, 7.61, 7.51, 7.49, 7.34, 7.30, 7.27, 7.15, 6.37, 6.18, 5.88, 5.87, 5.83, 5.78, 5.76, 5.63. 
 
HRMS (ESI)  
calculated for C117H211NO19Si9 (M + Na)+: 2209.3397  
 found:      2209.3303 
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2-pyridyl thiochloroformate,
Et3N, Et2O, 30 min, 0 °C, 
91%
P = Triethylsilyl
O OH Me
PO
NHFmoc
OP
O
OP
OH
O
OMeOMe
OPOP
OP
OPOPO
Me
MePO
2.18
P = Triethylsilyl
N
 
 
2-pyridylthioester 2.32 
To a stirred solution of 2.18 (4.9 g, 2.24 mmol, 1 eq) in diethyl ether (90 mL) at 0 °C was added 
triethylamine (0.40 mL, 2.91 mmol, 1.3 eq). 2-thiopyridyl chloroformate (4 mL, 4 mmol, 1.8 eq, 
1M in CH2Cl2) was added and the solution was stirred for 30 minutes at 0 °C. The formation of a 
precipitate was observed as the reaction progressed. The mixture was then diluted with diethyl 
ether (200 mL) and the solids were removed via Büchner filtration using Whatman 50 filter 
paper.  The filtrate was concentrated in vacuo to give crude 2.32 as a yellow solid.  Purification 
by flash chromatography (SiO2; hexanes:diethyl ether 10:1 → 3:1) afforded 2.32 as an orange 
solid (4.65 g, 2.04 mmol, 91%).   
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TLC (hexanes:diethyl ether 2:1)                                                                                                                                        
 Rf = 0.76, visualized by UV 
 
1H NMR (500 MHz, acetone d-6) 
δ 8.71 (d, J = 3.5 Hz, 1H), 7.94 (dt, J = 1.5, 7.5 Hz, 1H), 7.86 (d, J = 7.5 Hz, 2H), 7.73-
7.68 (m, 3H), 7.43-7.31 (m, 5H), 6.59-6.52 (m, 3H), 6.46-6.11 (m, 9H) 5.97 (dd, J = 5.5, 
16 Hz, 1H), 5.49 (dd, J = 9.5, 15 Hz, 1H), 5.28 (d, J = 10 Hz, 1H), 4.78 (bs, 1H), 4.65 
(bs, 1H), 4.62 (s, 1H), 4.52-4.43 (m, 3H), 4.33 (dd, J = 7, 10.5 Hz, 1H), 4.23 (app t, J 
=6.5 Hz, 2H), 4.14 (t, J = 10 Hz, 1H), 4.06 (t, J = 9.0 Hz, 1H), 4.00 (bs, 1H), 3.91 (d, J = 
2.5 Hz, 1H), 3.85 (dd, J = 2, 8.5 Hz, 1H), 3.70-3.66 (m, 3H), 3.61 (dd, J = 4, 10.5 Hz, 
1H), 3.44-3.37 (m, 2H), 3.13 (s, 3H), 2.71 (t, J = 10 Hz, 1H), 2.58 (d, J = 6.5 Hz, 1H), 
2.43 (app dd, J = 7, 9 Hz, 1H), 2.32 (dd, J = 6.5, 15 Hz, 1H) 2.12-2.08 (m, 2H) , 1.93-
1.83 (m, 3H), 1.79-1.62 (m, 7H), 1.53-1.50 (m, 1H), 1.22 (d, J = 5.5 Hz, 3H), 1.17 (d, J = 
6 Hz, 3H), 1.10-0.90 (m, 87H), 0.81-0.56 (m, 54H). 
 
13C NMR (125 MHz, acetone d-6)                                                                                                     
δ 197.5, 169.9, 163.5, 155.6, 151.5, 151.0, 144.5, 141.6, 138.3, 137.8, 135.1, 135.0, 
134.5, 133.7, 133.3, 131.9, 131.8, 131.6, 131.3, 130.7, 130.0, 129.5, 127.8, 127.2, 127.1, 
125.2, 125.1, 124.1, 120.1, 100.7, 97.2, 76.0, 74.0, 73.7, 73.6, 73.4, 72.8, 72.7, 70.5, 68.5, 
67.2, 66.8, 66.7, 66.6, 64.8, 57.2, 47.6, 47.4, 43.5, 42.7, 42.0, 40.9, 40.1, 35.0, 34.7, 26.9, 
19.3, 18.7, 18.3, 10.5, 7.01, 6.89, 6.88, 6.72, 6.68, 6.65, 6.59, 5.80, 5.56, 5.29, 5.28, 5.24, 
5.21, 5.16, 5.02. 
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HRMS (ESI) 
 calculated for C122H214N2O18SSi9 (M + Na)+: 2302.3424 
 found:       2302.3328 
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23 °C, 88%
P = Triethylsilyl
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Primary alcohol 2.20 
To a stirred solution of 2.32 (4.6 g, 2.02 mmol, 1 eq) in diethyl ether (100 mL) at 23 °C was 
added dropwise a solution of lithium borohydride in THF (2M, 10 mL, 20 mmol, 10 eq).  The 
solution was stirred for 2 hours and then cooled to 0 °C and quenched by addition over 5 minutes 
of saturated aqueous ammonium chloride (100 mL).  The two layers were separated and the 
organic phase was diluted with diethyl ether (100 mL). The organic phase was washed with 
saturated ammonium chloride (1 x 20 mL), water (3 x 20 mL) and brine (1 x 20 mL).  The 
combined aqueous washings were back-extracted with diethyl ether (1 x 50 mL) and the 
combined organic layers were dried over sodium sulfate and concentrated in vacuo.  Purification 
of the resulting residue by flash chromatography (SiO2; hexanes:diethyl ether 20:1 → 5:1) 
furnished 2.20 as a yellow solid (3.87 g, 1.78 mmol, 88%).  
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 1:1)  
Rf =0.67, visualized by UV 
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1H NMR (500 MHz, acetone d-6)  
δ 7.86 (d, J = 8 Hz, 2H), 7.69 (d, J = 7.5 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 
Hz, 2H), 6.53-6.10 (m, 12H), 6.05 (dd, J = 6.5, 15.5 Hz, 1H), 5.50 (dd, J = 9.5, 15 Hz, 
1H), 5.32 (d, J = 10 Hz, 1H) 4.77 (s, 1H), 4.68 (app t, J = 6 Hz, 2H), 4.46 (dd, J = 6.5, 
10.5 Hz, 1H), 4.32 (dd, J = 6.5, 10.5 Hz, 1H), 4.23 (app t, J = 6.5 Hz, 2H), 4.18 (dt, J = 
5,10.5 Hz, 1H),  4.11 (t, J = 10.5 Hz, 1H), 3.99 (m, 1H), 3.91 (d, J = 3 Hz, 2H), 3.86-380 
(m, 4H), 3.70-3.67 (m, 2H), 3.65-3.59 (m, 3H), 3.46 (t, J = 9 Hz, 1H), 3.34 (app dd, J = 
6.5, 8.5 Hz, 1H), 3.11 (s, 3H), 2.56-2.54 (m, 2H), 2.45-2.38 (m, 2H), 2.10 (dd, J = 4.5, 
12.5 Hz, 1H), 2.02-2.00 (m, 1H), 1.94-1.61 (m, 10H), 1.52-1.49 (m, 1H), 1.24 (d, J = 6.5 
Hz, 3H), 1.17 (d, J = 6 Hz, 3H), 1.06-0.890 (m, 87H), 0.77-0.57 (m, 54H). 
 
13C NMR (125 MHz, acetone d-6) 
δ 170.0, 155.8, 144.4, 141.6, 138.6, 135.2, 134.7, 134.1, 133.3, 132.5, 132.4, 132.2, 
131.9, 130.8, 130.4, 130.1, 127.9, 127.3, 127.2, 125.2, 125.1, 120.2, 100.4, 97.3, 92.4, 
76.1, 75.0, 73.8, 73.4, 72.8, 70.4, 67.4, 66.9, 66.7, 66.6, 66.1, 58.4, 57.5, 49.6, 47.3, 47.1, 
44.0, 43.4, 42.7, 40.8, 35.1, 26.8, 19.3, 18.3, 7.01, 6.88, 6.72, 6.68, 5.72, 5.51, 5.23, 5.16, 
5.12, 4.99. 
 
HRMS (ESI)  
 calculated for C117H213NO18Si9 (M + Na)+: 2195.3604 
 found:      2195.3503 
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PPh3, imidazole, I2, THF. 
1 h, 0 °C, 78%
P = Triethylsilyl  
 
Iodomethyl 2.21 
Prior to the reaction, 2.20 was azeotropically dried via coevaporation with benzene (3 x 25 mL) 
and left under vacuum for a minimum of eight hours. The resulting yellow solid (3.8 g, 1.74 
mmol, 1 eq) was dissolved in THF (60 mL) and cooled 0 °C. To this solution was added 
imidazole (0.355 g, 5.22 mmol, 3 eq), triphenyl phosphine (0.912 g, 3.48 mmol, 2 eq), and iodine 
(0.880 g, 3.48 mmol, 2 eq). The resulting brown solution was stirred for 1 hour at 0 °C and then 
quenched with the addition of saturated aqueous sodium bisulfite (50 mL).  The two phases were 
separated and the organic layer was diluted with diethyl ether (50 mL).  The organic layer was 
washed with saturated aqueous sodium bisulfite (1 x 20 mL), water (3 x 20 mL), and brine (1 x 
20 mL).  The combined aqueous washings were back-extracted with diethyl ether (1 x 20 mL).  
The combined organic layers were dried over sodium sulfate and concentrated in vacuo.  
Purification of the resulting residue by flash chromatography (SiO2; hexanes:diethyl ether 20:1 
→ 7:1) furnished 2.21 as an orange solid (3.10 g, 1.36 mmol, 78%) and recovered 2.20 as a 
yellow solid (0.545 g, 0.251 mmol, 14%).   
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 2:1)  
 Rf = 0.79, visualized by UV 
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1H NMR (500 MHz, acetone d-6) 
 δ 7.86 (d, J = 7.5 Hz, 2H), 7.69 (d, J = 6.5 Hz, 2H), 7.41 (t, J = 7 Hz, 2H), 7.32 (t, J = 
7.5 Hz, 2H), 6.54-6.10 (m, 12H), 6.04 (dd, J = 6, 15.5 Hz, 1H), 5.50 (dd, J = 9.5, 14.5 
Hz, 1H), 5.30 (d, J = 10 Hz, 1H), 4.87 (s, 1H) 4.72 (bs, 1H), 4.67 (bs, 1H), 4.46 (dd, J = 
6.5, 10.5 Hz, 1H), 4.34 (dd, J = 6.5, 10.5 Hz, 1H), 4.22 (app t, J = 6 Hz, 2H), 4.14-4.04 
(m, 3H), 4.00 (bs, 1H) 3.84 (app d, J = 7 Hz, 1H), 3.76 (t, J = 9 Hz, 1H), 3.72-3.69 (m, 
3H) 3.63-3.61 (m, 2H), 3.50 (app d, J = 8 Hz, 1H), 3.46 (t, 9.5 Hz, 1H), 3.41-3.37 (m, 
2H), 3.14 (s, 3H), 2.57 (bs, 2H), 2.43 (app dd, J = 9, 15 Hz, 1H), 2.27 (dd, J = 7.5, 14.5 
Hz, 1H), 2.16 (dd, J = 5, 12.5 Hz, 1H), 1.93-1.86 (m, 3H), 1.81-1.74 (m, 6H) 1.65-1.61 
(m, 2H), 1.49 (bs, 1H), 1.25 (d, J = 6 Hz, 3H), 1.16 (d, J = 6 Hz, 3H), 1.06-0.86 (m, 
87H), 0.77-0.55 (m, 54H).  
 
13C NMR (125 MHz, acetone d-6) 
δ 170.0, 155.7, 144.7, 144.4, 141.6, 138.5, 135.1, 134.6, 134.5, 134.0, 133.2, 132.4, 
132.3, 132.0, 130.9, 130.2, 127.9, 127.2, 125.2, 125.1, 120.2, 100.4, 97.3, 76.1, 74.0, 
73.4, 72.8, 70.5, 69.9, 68.3, 66.9, 66.7, 66.5, 57.5, 47.4, 47.2, 45.9, 43.8, 42.8, 42.0, 40.6, 
40.3, 35.1, 33.5, 26.8, 19.3, 18.6, 18.3, 10.7, 9.23, 7.04, 7.03, 6.92, 6.91, 6.79, 6.77, 6.73, 
6.69, 5.80, 5.55, 5.48, 5.31, 5.28, 5.24, 5.20, 5.17. 
 
HRMS (ESI) 
 calculated for C117H212INO17Si9 (M + Na)+: 2305.2621 
 found:      2305.2617 
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DDQ, CaCO3, THF, 10 min
23 °C, 67%
P = Triethylsilyl  
 
Heptaenone 2.25 
Prior to the reaction, calcium carbonate was dried via storage under vacuum for a minimum of 
eight hours in the presence phosphorus pentoxide desiccant. Also, 2.21 was azeotropically dried 
via coevaporation with benzene (3 x 25 mL) and left under vacuum for a minimum of eight 
hours. The resulting orange solid (2.45 g, 1.07 mmol, 1 eq) was dissolved in THF (50 mL) at 23 
°C and calcium carbonate (1.07 g, 10.7 mmol, 10 eq) was added. DDQ (0.364 g, 1.61 mmol, 1.5 
eq) was added and the reaction mixture immediately transitioned to a dark red color. The mixture 
was stirred for 10 minutes and then quenched with saturated aqueous sodium bicarbonate (250 
mL).  The resulting red emulsion was extracted with dichloromethane (10 x 100 mL).  The 
combined organic extracts were washed with brine (1 x 100 mL), dried over sodium sulfate, and 
concentrated in vacuo.  Purification of the resulting residue by flash chromatography (SiO2; 
hexanes:diethyl ether 20:1 → 9:1) afforded 2.25 as a deep red solid (1.21 g, 0.717 mmol, 67%).   
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 2:1)  
Rf = 0.48, visualized by eye 
 
 1H NMR (500 MHz, acetone d-6)  
δ 7.84 (dd, J = 11.5, 16 Hz, 1H), 7.11 (dd, J = 11.5, 14.5 Hz, 1H), 6.80 (dd, J = 11, 15 
Hz, 1H), 6.61-6.54 (m, 2H), 6.49-6.14 (m, 7H), 6.08 (d, J = 15.5 Hz, 1H), 5.52 (dd, J = 
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9.5, 15 Hz, 1H), 4.47-4.44 (m, 1H), 4.27 (app t, J = 10.5 Hz, 1H), 4.16-4.07 (m, 3H), 
3.96 (dd, J = 3, 9 Hz, 1H), 3.75-3.63 (m, 4H), 3.46 (dd, J = 3, 10.5 Hz, 1H), 3.01 (dd, J = 
10.5, 12 Hz, 1H), 2.90 (s, 3H), 2.66 (dd, J = 4, 18 Hz, 1H), 2.60 (dd, J = 9.5, 18 Hz, 1H) 
2.47-2.42 (m, 2H), 2.26 (app t, J = 10.5 Hz, 1H), 2.10 (dd, J = 5, 12 Hz, 1H), 2.00 (app t, 
J = 10.5 Hz, 1H), 1.93-1.72 (m, 8H), 1.65 (app d, J =12.5 Hz, 1H), 1.47 (app t, J = 10.5 
Hz, 1H), 1.15 (d, J = 6 Hz, 3H), 1.11 (t, J = 8 Hz, 10H), 1.05-0.96 (m, 51H), 0.89 (t, J = 
7.5 Hz, 9H), 0.84 (q, J = 8 Hz, 6H), 0.76-0.51 (m, 36H).  
 
13C NMR (125 MHz, acetone d-6) 
δ 199.4, 169.4, 148.1, 142.8, 140.2, 139.4, 138.6, 137.6, 136.5, 131.5, 131.1, 130.9, 
130.4, 130.3, 130.2, 129.6, 100.4, 76.1, 73.5, 73.0, 72.9, 70.9, 68.2, 67.2, 66.4, 47.8, 46.5, 
46.4, 43.2, 42.7, 42.6, 40.7, 40.3, 36.5, 34.6, 27.2, 24.6, 23.2, 19.5, 19.1, 7.11, 6.90, 6.84, 
6.67, 6.62, 5.94, 5.50, 5.38, 5.23, 5.21, 5.08, 4.97. 
 
HRMS (ESI)  
calculated for C84H161O12ISi7 (M + Na)+: 1707.9316 
found:      1707.9270 
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BH3•Me2S, THF, 30 min
-10 °C, 6:1 d.r., 79%
P = Triethylsilyl
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Allylic alcohol 2.26 
Prior to the reaction, 2.25 was azeotropically dried via coevaporation with benzene (3 x 10 mL) 
and was left under vacuum for a minimum of eight hours. To a stirred solution of borane 
dimethyl sulfide complex (27 µL, 0.270 mmol, 1.2 eq), and (S)-2-methyl-CBS-oxazaborolidine 
(0.225 mL, 0.225 mmol, 1 eq, 1M in toluene) in dichloromethane (1 mL) at -10 °C was added 
2.25 (380 mg, 0.225 mmol, 1 eq) dropwise as a solution in dichloromethane (6.5 mL).  The 
resulting solution was stirred for 30 minutes at -10 °C and during this time a color change from 
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deep red to pale orange was observed. The reaction was quenched at -10 °C with saturated 
aqueous ammonium chloride (10 mL) and diluted with dichloromethane (50 mL).  The two 
layers were separated and the organic layer was washed with saturated aqueous ammonium 
chloride (1 x 20 mL), water (3 x 20 mL), and brine (1 x 20 mL).  The combined aqueous 
washings were back-extracted with dichloromethane (1 x 50 mL). The combined organic extracts 
were dried over sodium sulfate and concentrated in vacuo. Purification of the resulting residue 
by flash chromatography (SiO2; hexanes:diethyl ether 19:1 → 6:1) furnished 2.26 (300 mg, 
0.177 mmol, 6:1 d.r., 79%). 
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 2:1)  
Rf = 0.35, stained by anisaldehyde 
 
1H NMR (500 MHz, acetone d-6)  
δ 6.48-6.10 (m, 13H), 5.53 (dd, J = 9.5, 15 Hz, 1H), 4.71 (bs, 1H), 4.52 (bs, 1H), 4.25 
(bs, 1H), 4.10 (t, J = 10 Hz, 1H), 4.06-3.98 (m, 2H), 3.88 (app d, J = 1.5, 1H) 3.80 (app t, 
J = 9 Hz, 2H), 3.68-3.61 (m, 4H), 3.37 (app d, J = 10 Hz, 1H), 3.13 (s, 3H), 2.55 (t, J = 6 
Hz, 2H), 2.42 (app dd, J = 7, 14 Hz, 1H), 2.17 (dd, J = 5, 10.5 Hz, 1H), 1.99-1.84 (m, 
5H), 1.78-1.69 (m, 5H), 1.62-1.61 (m, 3H), 1.53-1.47 (m, 1H), 1.17 (d, J = 6 Hz, 3H), 
1.06-0.95 (m, 69H), 0.75-0.62 (m, 42H). 
 
13C NMR (125 MHz, acetone d-6) 
δ 173.6, 142.7, 141.7, 137.9, 137.7, 136.9, 136.3, 136.0, 135.9, 135.6, 135.5, 134.5, 
134.4, 133.8, 130.7, 104.0, 79.6, 77.0, 76.1, 73.9, 73.4, 72.0, 71.9, 70.4, 70.3, 50.9, 50.8, 
50.6, 49.1, 47.5, 46.4, 45.9, 44.2, 43.9, 42.4, 40.1, 38.6, 30.3, 28.2, 22.7, 22.0, 14.2, 12.5, 
10.6, 10.4, 10.2, 9.32, 9.09, 9.03, 8.82, 8.75, 8.73. 
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HRMS (ESI)  
calculated for C84H163O12ISi7 (M + Na)+: 1709.9472 
found:      1709.9456 
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NaBH4, DMPU, 6 h, 23 °C, 
78%
P = Triethylsilyl  
 
C(41)-methyl 2.33 
Prior to the reaction, 2.26 was azeotropically dried via coevaporation with benzene (3 x 25 mL) 
and left under vacuum for a minimum of eight hours. The resulting orange solid (775 mg, 0.459 
mmol, 1 eq) was dissolved in DMPU (15 mL) at 23 °C and sodium borohydride (87 mg, 2.3 
mmol, 5 eq) was added. The solution was stirred for 6 hours and was then quenched with 
saturated aqueous ammonium chloride (5 mL). The resulting yellow emulsion was diluted with 
hexanes (50 mL) and the mixture washed with water (5 x 10 mL) and brine (1 x 10 mL). The 
combined aqueous washings were back-extracted with hexanes (25 mL). The combined organic 
extracts were dried over sodium sulfate and concentrated in vacuo. Purification of the resulting 
residue by flash chromatography (SiO2; hexanes:diethyl ether 20:1→10:1) yielded 2.33 as an 
orange solid (557 mg, 0.356 mmol, 78%). 
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether, 2:1) 
 Rf  = 0.28, stained by anisaldehyde 
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1H NMR (500 MHz, acetone d-6) 
δ 6.49-6.10 (m, 13H), 5.52 (dd, J = 9.5, 15 Hz, 1H), 4.71 (app t, J = 6.5 Hz, 1H), 4.47 
(bs, 1H), 4.28-4.24 (m, 1H), 4.10 (t, J = 10 Hz, 1H), 4.00-3.97 (m, 1H), 3.85 (d, J = 4 Hz, 
1H), 3.82 (dd, J = 2.5, 9 Hz, 1H) 3.76-3.67 (m, 3H), 3.62 (dd, J = 4.5, 10.5 Hz, 1H), 3.56 
(app t, J = 8.5 Hz, 1H), 3.10 (s, 3H), 2.55 (t, J = 6.5 Hz, 2H), 2.42 (app dd, J = 9, 16 Hz, 
1H), 2.01-1.97 (m, 2H), 1.93-1.84 (m, 3H), 1.80-1.74 (m, 3H), 1.73-1.70 (m, 2H) 1.68-
1.62 (m, 3H), 1.53-1.50 (m, 1H), 1.36-1.27 (m, 2H) 1.17 (d, J = 6 Hz, 3H), 1.06-0.94 (m, 
72H), 0.75-0.61 (m, 42H). 
 
13C NMR (125 MHz, acetone d-6) 
δ 170.1, 139.1, 138.2, 134.3, 134.2, 133.4, 132.7, 132.5, 132.4, 132.1, 132.0, 131.0, 
130.9, 130.2, 128.5, 127.2, 100.5, 76.1, 73.5, 72.6, 71.6, 70.7, 70.4, 68.7, 68.5, 67.0, 66.8, 
47.2, 47.1, 44.1, 42.9, 42.8, 40.8, 40.4, 39.5, 35.1, 26.8, 19.2, 18.5, 13.3, 10.7, 10.6, 7.04, 
7.01, 6.90, 6.71, 6.69, 5.78, 5.57, 5.31, 5.27, 5.24, 5.22. 
 
HRMS (ESI)  
 calculated for C84H164O12Si7 (M+Na)+: 1584.0506 
found:      1584.0481 
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1)HF/pyridine, THF:pyridine
3:2, 6 h, 0 °C
2) AcOH:H2O:THF, 1:1:2
30 min, 23 °C; HPLC, 38% 
over two steps
 
 
C41-Methyl amphoteronolide B 2.4 
To a stirred solution of 2.26 (50 mg, 0.032 mmol) in THF:pyridine 3:2 (5 mL) at 0 °C was added 
dropwise 70% HF/pyridine complex (320 µL). The solution was stirred for 6 hours at 0 °C and 
was then quenched with the addition of trimethylsilyl ethoxide (2 mL). The solution was 
concentrated in vacuo and the resulting residue was dissolved in THF (1 mL) and AcOH:H2O 
1:1 (1 mL). The solution was stirred for 30 minutes and was then concentrated in vacuo. The 
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resulting orange solid was immediately dissolved in DMSO (1.5 mL) and purified by preparative 
RP-HPLC (Waters SunFire Prep C18 OBD 5 micron 30 x 150 mm Lot # 168I161701 300 µL 
injection volume, 25 mL/min flow rate, MeCN:H2O 1:19 → 19:1, over 25 minutes) to yield 
C(41)-methyl amphoteronolide B 2.4 as a yellow solid (9 mg, 0.012 mmol, 38% over two steps).  
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HPLC 
tR = 24.9 min, flow rate = 25 mL/min, gradient of 5 → 95% MeCN in H2O over 25 min. 
 
1H NMR (600 MHz, pyridine d-5, CD3OD 10:1) 
 δ 6.83 (dd, J  = 10.8, 14.7 Hz, 1H, H-22), 6.77 (dd, J  = 10.8, 15 Hz, 1H, H-24), 6.70 (dd, 
J19,20 = 8.9 Hz, J20,21 = 15 Hz, 1H, H-20), 6.60 (dd, J = 11.4, 14.4 Hz, 1H, H-23), 6.55-
6.35 (m, 9H), 5.79 (app d, J36,37 = 3.1 Hz, 1H, H-37), 5.55 (dd, J32,33 = 15.6, J33,34  = 9.9 
Hz, 1H, H-33), 4.87 (app t, J10a,11  = 1.3 Hz, J10e,11 = 10.9 Hz, J11,12a = 1.2 Hz, J11,12e = 10.7 
Hz, 1H, H-11), 4.77 (m, J18a,19 = 3.9, J18e,19 = 5.5 Hz, J19,20 = 8.9 Hz, 1H, H-19), 4.65 (m, 
J2e,3 = 9.2 Hz, J3,4a = 4.3, J3,4e = 10.9 Hz, J16,17 = 10.8 Hz, J17,18a = 8.1 Hz, 2H, H-3, H-17), 
4.20 (app dt, J14e,15 = 2.1, J14a,15 = 11.5 Hz, J15,16 = 10.8 Hz, 1H, H-15), 4.12 (app t, J4a,5 = 
1.8, J4e,5 = 10.3 Hz, J5,6a = 1.1, J5,6e = 11.5 Hz, 1H, H-5), 4.03 (app dd, J8,9 = 3.2 Hz, J9,10a  
= 2.3, J9,10e = 11.7 Hz, 1H, H-9), 3.60 (app dd, J7e,8 = 2.4, J7a,8 = 11.3 Hz, J8,9 = 3.2 Hz, 
1H, H-8), 3.44 (app d, J34,35 = 10.0 Hz, J35,36 = 2.6 Hz, 1H, H-35), 2.68 (m, J33,34 = 9.9 Hz, 
J34,35 = 10.0 Hz, 1H, H-34), 2.62 (dd, J2a,2e  = 16.2 Hz, J2e,3 = 9.2 Hz, 1H, H-2e), 2.49-2.44 
(m, J14e,15 = 2.1 Hz, J18e,19 = 5.5 Hz, 3H, H-2a, H-14e, H-18e), 2.37-2.34 (m,  J6a,7a = 10.6 
Hz, J6e,7a = 5.7 Hz, J7a,8 = 11.3, 1H, H-7a), 2.19-2.15 (m, J9,10e = 11.7 Hz, J10e,11 = 10.9 Hz, 
1H, H-10e) 2.13-2.10 (m, J35,36 = 2.6 Hz, J36,37 = 3.1 Hz, 1H, H-36), 2.02 (ddd, J17,18a = 8.1 
Hz, J18a,18e = 14.4 Hz, J18a,19 = 3.9 Hz, 1H, H-18a), 1.99-1.95 (m, J5,6e = 11.5 Hz, J6e,7a = 
5.7 Hz, J6e,7e = 13.5 Hz, J11,12e = 10.7 Hz, 2H, H-6e, H-12e), 1.85-1.74 (m, J3,4e = 10.9 Hz, 
J4e,5 = 10.3 Hz, J6e,7e = 13.5 Hz, J7e,8 = 2.4 Hz, J11,12a = 1.2 Hz, J14a,15 = 11.5 Hz, 4H, H-4e, 
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H-7e, H-12a, H-14a), 1.72-1.66 (m, J5,6a = 1.1 Hz, J6a,7a = 10.6 Hz, J15,16 = 10.8 Hz, 2H, 
H-6a, H-16), 1.63 (app dt, J3,4a = 4.3 Hz, J4a,4e = 14.1 Hz, J4a,5 = 1.8 Hz, 1H, H-4a), 1.56 
(app dd, J9,10a = 2.3Hz, J10a,10e = 14.4 Hz, J10a,11 = 1.3 Hz, 1H, H-10a), 1.45 (d, J37,38 = 6.6 
Hz, 3H, H-38), 1.34 (d, J16,41 = 6 Hz, 3H, H-41), 1.31 (d, J34,40 = 6 Hz, 3H, H-40), 1.24 (d, 
J36,39 = 7.2 Hz, 3H, H-39). 
 
13C NMR (150 MHz, pyridine d-5 : CD3OD, 10:1) 
δ 172.1, 141.4, 137.5, 135.1, 134.8, 134.2, 133.6, 133.4, 133.1, 132.8, 132.7, 129.1, 98.3, 
78.7, 76.3, 75.3, 75.2, 72.2, 71.4, 70.4, 69.7, 68.5, 48.2, 46.7, 45.1, 44.4, 43.8, 43.0, 41.5, 
41.2, 41.0, 36.6, 31.9, 30.2, 29.8, 19.1, 17.4, 14.1, 12.8. 
 
HRMS (ESI) 
 calculated for C41H64O12 (M + Na)+: 771.4295 
found:     771.4268 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Representative chromatogram of HPLC purified MeAmdeB. 
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P = TriethylsilylP = Triethylsilyl  
 
Allyl ester 2.34 
To a stirred solution of 2.18 (4.95 g, 2.26 mmol, 1 eq) in DMF:MeOH 10:1 (82.5 mL) at 23 °C 
was added allyl bromide (7.5 mL, 85.9 mmol, 38 eq) and diisopropyl ethyl amine (1.75 mL, 9.9 
mmol, 4.4 eq).  The solution was stirred for 8 hours and then diluted with water:saturated 
aqueous sodium bicarbonate 1:1 (250 mL).  The aqueous phase was extracted with diethyl ether 
(4 x 100 mL) and the combined organic extracts were washed with brine (1 x 50 mL), dried over 
sodium sulfate and concentrated in vacuo.  Purification of the resulting residue by flash 
chromatography (SiO2; hexanes:diethyl ether 20:1 → 10:1) yielded 2.34 as a yellow solid (4.33 
grams, 1.94 mmol, 86%). 
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P = Triethylsilyl  
 
TLC (hexanes:diethyl ether 2:1) 
 Rf = 0.85, visualized by UV 
 
1H NMR (500 MHz, acetone d-6) 
δ 7.87 (d, J = 7.5 Hz, 2H), 7.69 (d, J = 7.5 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.34 (t, J = 
7.5 Hz, 2H), 6.57-6.50 (m, 2H), 6.48-6.13 (m, 10H), 6.06-5.99 (m, 1H), 5.98 (dd, J = 5.5, 
16 Hz, 1H), 5.49 (dd, J = 9.5, 14.5 Hz, 1H), 5.43 (dd, J = 1.5, 17 Hz, 1H), 5.34 (d, J = 10 
Hz, 1H), 5.29 (d, J = 10.5 Hz, 1H), 4.74 (dd, J = 6, 13.5 Hz, 1H), 4.63-4.51 (m, 3H), 
4.49-4.41 (m, 3H), 4.33 (dd, J = 6.5, 10.5 Hz, 1H), 4.26-4.23 (m, 2H), 4.12 (t, J = 10 Hz, 
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1H), 4.02-3.97 (m, 2H), 3.90 (d, J = 3 Hz, 1H), 3.85 (dd, J = 2.5, 6.5 Hz, 1H), 3.71-3.67 
(m, 2H), 3.66-3.62 (m, 3H), 3.45 (t, J = 8.5 Hz, 1H), 3.43-3.30 (m, 1H), 3.13 (s, 3H), 
2.58-2.56 (m, 2H) 2.43 (app dd, J = 9, 16 Hz, 1H), 2.36 (t, J = 10.5 Hz, 1H), 2.00-1.96 
(m, 2H), 1.93-1.90 (m, 2H), 1.84-1.58 (m, 8H), 1.50 (bs, 1H), 1.23 (d, J = 6 Hz, 3H), 
1.17 (d, J = 6 Hz, 3H), 1.07-0.89 (m, 87H), 0.78-0.56 (m, 54H). 
 
13C NMR (125 MHz, acetone d-6) 
δ 172.9, 170.5, 156.3, 145.0, 144.9, 142.2, 142.1, 139.3, 135.6, 135.5, 135.0, 134.5, 
134.2, 133.6, 133.4, 132.4, 132.3, 132.1, 131.6, 131.2, 130.6, 128.4, 127.8, 127.7, 125.8, 
125.7, 120.7, 119.0, 101.4, 98.6, 76.6, 75.7, 74.5, 74.0, 73.9, 73.4, 73.2, 71.0, 68.9, 67.6, 
67.4, 67.3, 67.2, 65.9, 58.1, 57.5, 48.1, 48.0, 47.8, 44.2, 43.3, 42.2, 41.4, 40.7, 36.2, 35.6, 
27.4, 22.9, 19.9, 19.2, 18.8, 15.5, 11.1, 7.58, 7.53, 7.43, 7.42, 7.29, 7.23, 7.20, 7.19, 7.07, 
6.30, 6.11, 5.84, 5.82, 5.81, 5.76, 5.72, 5.70, 5.58. 
 
HRMS (ESI) 
 calculated for C120H215NO19Si9 (M + Na)+: 2249.3710 
 found:      2249.3630 
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Heptaenone 2.27 
Prior to the reaction, calcium carbonate was dried via storage under vacuum for a minimum of 
eight hours in the presence of phosphorus pentoxide desiccant. Also, 2.18 was azeotropically 
dried via coevaporation with benzene (3 x 25 mL) and left under vacuum for a minimum of eight 
hours. The resulting yellow solid (4.33 g, 1.94 mmol, 1 eq) was dissolved in THF (100 mL) at 23 
°C and calcium carbonate (1.94 g, 19.4 mmol, 10 eq) was added. DDQ (0.660 g, 2.91 mmol, 1.5 
eq) was added and an immediate color change to dark red was observed. This mixture was stirred 
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for 20 minutes and then quenched with the addition of 100 mL saturated aqueous sodium 
bicarbonate.  The resulting emulsion was diluted with water (300 mL) and extracted with 
dichloromethane (10 x 250 mL).  The combined organic extracts were washed with brine (1 x 
150 mL) and concentrated in vacuo.  Purification of the resulting residue by flash 
chromatography (SiO2; hexanes:Et2O 20:1 → 6:1) yielded 2.27 as a dark orange solid (2.06 g, 
1.26 mmol, 65%).   
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P = Triethylsilyl  
 
TLC (hexanes:Et2O 2:1) 
 Rf = 0.44, visualized by eye 
 
1H NMR (500 MHz, acetone d-6) 
δ 7.84 (dd, J = 11, 15.5 Hz, 1H), 7.13 (dd, J = 11.5, 14.5 Hz, 1H), 6.81 (dd, J = 11, 14.5 
Hz, 1H), 6.62-6.55 (m, 2H), 6.49-6.14 (m, 7H), 6.05 (d, J = 15.5 Hz, 1H), 6.01 (app ddd, 
J = 6, 10, 16 Hz, 1H), 5.51 (dd, J = 10, 15 Hz, 1H), 5.42 (dd, J = 1.5, 17.5 Hz, 1H), 5.27 
(dd, J = 1.5, 10.5 Hz, 1H), 4.68 (app d, J = 5.5 Hz, 2H), 4.50 (dd, J = 5, 10.5 Hz, 1H), 
4.45 (dd, J = 5.5, 10 Hz, 1H), 4.28 (app t, J = 10.5 Hz, 1H), 4.13-4.08 (m, 2H), 3.96 (dd, 
J = 3, 9.5 Hz, 1H), 3.77 (t, J = 10.5 Hz, 1H), 3.72-3.64 (m, 4H), 3.20 (dd, J = 11, 12.5 
Hz, 1H), 2.92 (s, 3H), 2.70 (dd, J = 4, 18 Hz, 1H), 2.62 (dd, J = 10, 18 Hz, 1H), 2.46 (app 
dd, J = 9, 16 Hz, 1H), 2.40 (t, J = 10.5 Hz, 1H), 2.30 (app t, J = 11 Hz, 1H), 2.13 (d, J = 
12 Hz, 1H), 1.96-1.86 (m, 4H), 1.83-1.76 (m, 4H), 1.67 (app d, J = 12.5 Hz, 1H), 1.50 
(app t, J = 10.5 Hz, 1H), 1.17 (d, J = 6 Hz, 3H), 1.15 (t, J = 8 Hz, 9H), 1.09-0.96 (m, 
60H), 0.89 (q, J = 8.5 Hz, 6H), 0.78-0.54 (m, 36H) 
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13C NMR (125 MHz, acetone d-6) 
δ 199.3, 172.1, 169.9, 149.2, 143.7, 140.8, 140.2, 139.2, 138.3, 137.1, 133.2, 132.0, 
131.6, 131.3, 130.7, 130.6, 130.5, 130.1, 118.6, 101.2, 76.7, 74.1, 73.6, 71.5, 70.4, 68.9, 
67.8, 67.0, 65.9, 57.9, 48.4, 47.1, 44.6, 43.5, 43.1, 40.9, 40.7, 39.9, 35.1, 27.7, 20.0, 19.7, 
10.9, 7.66, 7.45, 7.44, 7.39, 7.21, 7.16, 6.98, 6.50, 6.06, 5.80, 5.77, 5.63, 5.54, 5.50.  
 
HRMS (ESI) 
 calculated for C87H164O14Si7 (M + Na)+: 1652.0404 
found:      1652.0461 
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Allylic alcohol 2.28 
Prior to the reaction 2.27 was azeotropically dried via coevaporation with benzene (3 x 25 mL) 
and left under vacuum for a minimum of eight hours. The resulting red solid (2.05 g, 1.26 mmol, 
1 eq) was dissolved in THF:MeOH 3:1 (12 mL) the resulting solution was cooled to 0 °C and 
sodium borohydride (0.480 g, 12.6 mmol, 10 eq) was added. The solution was stirred for 30 
minutes and a color change from dark red to light orange was observed during the course of the 
reaction. The reaction was then quenched at 0 °C by the addition of saturated aqueous 
ammonium chloride (100 mL). The resulting emulsion was diluted with diethyl ether (250 mL). 
The two layers were separated and the organic phase was washed with water (3 x 50 mL) and 
brine (1 x 50 mL). The combined aqueous washings were back-extracted with diethyl ether (1 x 
100 mL) and the combined organic extracts were dried over sodium sulfate and concentrated in 
vacuo.  Purification of the resulting residue by flash chromatography (SiO2; hexanes:diethyl 
ether 20:1 → 4:1) furnished 2.28 as a pale orange solid (1.59 g, 0.974 mmol, > 20:1 dr, 77%). 
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TLC (hexanes:diethyl ether 2:1) 
 Rf  = 0.25, stained by anisaldehyde 
 
1H NMR (500 MHz, acetone d-6) 
δ 6.52-6.13 (m, 13H), 5.98 (app ddd, J = 6, 10.5, 16.5 Hz, 1H), 5.55 (dd, J = 9.5, 15 Hz, 
1H), 5.40 (dd, J = 1.5, 16 Hz, 1H), 5.24 (dd, J = 1, 6.5 Hz, 1H), 4.70 (app t, J = 6.5 Hz, 
1H), 4.63 (app t, J = 5.5 Hz, 2H), 4.52 (bs, 1H), 4.44 (dt, J = 4.5, 10.5 Hz, 1H), 4.24 (m, 
1H), 4.14 (t, J = 9.5 Hz, 1H), 4.06 (dq, J = 3, 7.5 Hz, 1H), 4.04-3.99 (m, 1H), 3.95 (d, J = 
3.5 Hz, 1H), 3.86 (dd, J = 2.5, 9 Hz, 1H), 3.73-3.70 (m, 2H), 3.65 (dd, J = 4.5, 10.5 Hz 
1H), 3.17 (s, 3H), 2.58 (app t, J = 2 Hz, 1H), 2.44 (app dd, J = 9, 15.5 Hz, 1H), 2.34 (t, J 
= 10 Hz, 1H), 2.12 (dd, J = 4.5, 12.5 Hz, 1H) 2.07-2.05 (m, 2H), 2.05-1.99 (m, 1H), 1.97-
1.59 (m, 10H), 1.52 (bs, 1H) 1.18 (d, J = 6 Hz, 3H), 1.08-0.95 (m, 69H), 0.78-0.59 (m, 
42H). 
  
13C NMR (125 MHz, acetone d-6) 
δ 172.8, 170.6, 139.0, 135.0, 134.9, 134.1, 133.5, 133.1, 133.0, 132.6, 131.8, 131.5, 
130.8, 128.1, 126.0, 118.4, 101.4, 76.7, 74.0, 71.0, 69.0, 67.5, 67.4, 65.6, 57.7, 48.1, 47.8, 
44.4, 43.5, 42.4, 41.3, 40.7, 35.6, 30.7, 29.2, 27.4, 19.8, 19.1, 7.62, 7.59, 7.48, 7.30, 7.27, 
7.12, 6.38, 6.17, 5.89, 5.83, 5.79, 5.64. 
 
HRMS (ESI) 
 calculated for C87H166O14Si7 (M + Na)+: 1654.0506 
found:      1654.0493 
 
 
 66 
OH
O
OH
O
O
OMeOMe
OHOH
OH
OHOHO
Me
MeHO
2.34
HF/pyridine, THF:pyridine
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P = Triethylsilyl  
 
Polyol 2.34 
To a stirred solution of 2.28 (1.55 g, 0.949 mmol, 1 eq) in THF (7 mL) in a polypropylene vial at 
0 °C was added a chilled (0 °C) solution of 70% HF/pyridine complex (10 mL) in THF:pyridine 
5:3 (160 mL). The resulting solution was allowed to warm to 23 °C and stirred for 6 hours. The 
reaction was then cooled to 0 °C and quenched by the addition of saturated aqueous sodium 
bicarbonate (500 mL). The resulting yellow emulsion was extracted with CH2Cl2:MeOH 5:1 (5 x 
200 mL). The combined organic extracts were washed with brine (1 x 100 mL), dried over 
sodium sulfate and concentrated in vacuo.  Purification of the resulting residue by flash 
chromatography (C18 bonded SiO2; MeCN:H2O 1:1) furnished 2.34 as an orange solid (0.442 g, 
0.531 mmol, 56%). 
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TLC (CH2Cl2:MeOH 10:1) 
 Rf = 0.25, stained by anisaldehyde 
 
HPLC 
tR = 18.90 min; flow rate = 4 mL/min, gradient of 5 → 95% MeCN in 5 mM ammonium 
acetate over 25 min. 
 
1H NMR (500 MHz, CD3OD) 
δ 6.43-6.13 (m, 12H), 5.98 (app ddd, J = 6, 10.5, 16 Hz, 1H), 5.80 (dd, J = 7.5, 15 Hz, 
1H), 5.47 (dd, J = 9.5, 14 Hz, 1H), 5.38 (dd, J = 1.5, 16 Hz, 1H), 5.24 (dd, J = 1, 10.5 Hz, 
 67 
1H), 4.66 (d, J = 5 Hz, 2H), 4.48 (app dd, J = 7, 11.5 Hz, 1H), 4.20-4.12 (m, 3H), 3.99 
(dq, J = 3.5, 10.5 Hz, 1H), 3.91 (dd, J = 8.5, 12.5 Hz, 1H), 3.71 (app t, J =6 Hz, 1H), 3.53 
(app d, J = 10 Hz, 1H), 3.26 (dd, J = 7.5, 9.5 Hz, 1H), 3.22 (app d, J = 12.5 Hz, 1H), 3.19 
(s, 3H), 2.39 (app dd, J = 7, 9.5 Hz, 1H), 2.31 (dd, J = 10.5, 15.5 Hz, 1H), 2.22 (dd, J = 
3.5, 16.5 Hz, 1H), 2.11 (dd, J = 5, 13 Hz, 1H), 1.90-1.81 (m, 4H), 1.72-1.61 (m, 4H), 
1.51-1.26 (m, 8H), 1.19 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 7.5 Hz, 
3H). 
 
13C NMR (125 MHz, pyridine d-5:CD3OD 10:1) 
δ 173.0, 171.4, 140.1, 135.4, 134.4, 134.2, 134.1, 133.6, 133.2, 133.1, 132.9, 132.8, 
132.7, 132.4, 131.8, 128.5, 101.7, 77.7, 75.2, 74.5, 71.5, 70.5, 67.9, 67.7, 67.6, 67.4, 66.7, 
66.5, 65.1, 57.0, 44.6, 43.5, 43.1, 42.9, 42.3, 41.3, 41.2, 38.9, 36.0, 33.9, 32.1, 30.5, 29.0, 
24.7, 23.9, 23.1, 18.6, 18.5, 17.5, 13.9, 12.2, 10.9. 
 
HRMS (ESI) 
 calculated for C45H68O12 (M + Na)+: 855.4507 
found:     855.4482 
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Amphoteronolide B allyl ester 2.30  
To a stirred solution of 2.34 (10 mg, 0.012 mmol, 1 eq) in THF:H2O 2:1 (1.2 mL) at 23 °C was 
added camphorsulfonic acid (0.6 mg, 0.003 mmol, 0.25 eq). The solution was stirred for 5 hours 
and was then diluted with THF (2 mL) and quenched by addition of solid sodium bicarbonate. 
The mixture was stirred vigorously for five minutes and the solids were removed by filtration 
through a pad of Celite. The filtrate was concentrated in vacuo and the resulting yellow solid was 
dissolved in THF (1.5 mL) and purified by prep RP-HPLC (Waters SunFire Prep C18 OBD 5 
micron 30 x 150 mm; 300 µL injection volume, 25 mL/min flow rate, MeCN:H2O 1:19 → 19:1, 
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over 25 minutes) to yield amphoteronolide B allyl ester 2.30 as a yellow powder (8 mg, 0.0098 
mmol, 81%). 
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HPLC 
tR = 28.6 min; flow rate = 25 mL/min, gradient of 5 → 95% MeCN in H2O over 25 min. 
 
1H NMR (500 MHz, pyridine d-5:CD3OD 10:1) 
δ 6.83 (dd, J = 11, 15 Hz, 1H, H-22), 6.77 (dd, J = 11, 15 Hz, 1H, H-24), 6.69 (dd, J19.20 
= 9.5 Hz, J20,21 = 15.5 Hz, 1H, H-20), 6.61 (dd, J = 14.5, 15 Hz, 1H, H-26), 6.54-6.35 (m, 
9H), 6.04-5.96 (app ddd, J42,43 = 6.5, J43,44cis = 11 Hz, J43,44trans = 17 Hz, 1H, H-43), 5.80 
(app d, J36,37 = 1.9 Hz, 1H, H-37), 5.55 (dd, J32,33 = 15 Hz, J33,34 = 10.1 Hz, 1H, H-33), 
5.42 (dd, J44cis,44trans = 1.5 Hz, J43,44trans = 17.5 Hz, 1H, H-44trans), 5.30 (app t, J16,17 = 
10.6 Hz, J17,18e = 0.9 Hz, J17,18a = 8.7 Hz, 1H, H-17), 5.14 (dd, J44cis,44trans = 1.5 Hz, J43,44cis 
= 10.5 Hz, 1H, H-44cis), 5.06 (app dt, J14e,15 = 3.5 Hz, J14a,15 = 11.0 Hz, J15,16 = 10.7 Hz, 
1H, H-15), 4.87 (t, J10a,11 = 3.1 Hz, J10e,11 = 10.3 Hz, J11,12a = 3.4 Hz, J11,12e = 11.3 Hz, 1H, 
H-11), 4.80-4.73 (m, J18e,19 = 6.0 Hz, J19,20 = 8.8 Hz, 3H, H-19, H-42(2)), 4.64 (app t, J2a,3 
= 4.7 Hz, J2e,3 = 9.2 Hz, J3,4a = 3.9 Hz, J3,4e = 10.1 Hz, 1H, H-3), 4.13 (app t, J4a,5 = 4.4 
Hz, J4e,5 = 9.5 Hz, J5,6a = 5.4 Hz, J5,6e = 10.3 Hz, 1H, H-5), 4.04 (app d, J8,9 = 3.0 Hz, J9,10a 
= 3.3 Hz, J9,10e = 10.7 Hz, 1H, H-9), 3.61 (app d, J7e,8 = 2.8 Hz, J7a,8 = 11.2 Hz, J8,9 = 3.0 
Hz, 1H, H-8), 3.43 (app d, J34,35 = 9.8 Hz, J35,36 = 2.6 Hz, 1H, H-35), 2.85 (t, J15,16 = 10.7 
Hz, J16,17 = 10.6 Hz, 1H, H-16), 2.66 (m, J33,34 = 10.1 Hz, J34,35 = 9.8 Hz, 1H, H-34), 2.61 
(dd, J2a,2e = 17 Hz J2e,3 = 9.2 Hz, 1H, H-2e), 2.51 (dd, J14a,14e = 12 Hz J14e,15 = 3.5 Hz, 1H, 
H-14e), 2.46 (dd, J2a,2e = 16.5, J2a,3 = 4.7, 1H, H-2a), 2.41 (dd, J17,18e = 0.9 Hz, J18a,18e = 
14 Hz, J18e,19 = 6.0 Hz, 1H, H-18e), 2.37 (m, J7e,8 = 2.8 Hz, 1H, H-7e), 2.19-2.15 (m, J9,10e 
= 10.7 Hz, J10e,11 = 10.3 Hz, J17,18a = 8.7 Hz. 2H, H-10e, H18a), 2.10 (m, J35,36 = 2.6 Hz, 
J36,37 = 1.9 Hz, 1H, H-36), 2.00-1.95 (m, J5,6e = 10.3 Hz, J11,12e = 11.3 Hz, 2H, H-6e, H-
12e), 1.85-1.80 (m, J3,4e = 10.1 Hz, J4e,5 = 9.5 Hz, J7a,8 = 11.2 Hz, J14e,15 = 3.5 Hz,  3H, H-
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4e, H-7a, H-14e), 1.78-1.70 (m, J5,6a = 5.4 Hz, J11,12a = 3.4 Hz, 2H, H-6a, H-12a), 1.61 
(app t, J3,4a = 3.9 Hz, J4a,5 = 4.4 Hz, 1H, H-4a), 1.56 (app d, J9,10a = 3.3 Hz, J10a,10e = 14.5 
Hz, J10a,11 = 3.1 Hz, 1H, H-10a), 1.46 (d, J37,38 = 6.5 Hz, 3H, H-38), 1.31 (d, J34,40 = 6 Hz, 
3H, H-40), 1.25 (d, J36,39 = 7 Hz, 3H, H-39). 
 
13C NMR (150 MHz, pyridine d-5:CD3OD, 10:1) 
δ 173.5, 172.2, 140.9, 137.5, 135.0, 134.8, 134.7, 134.1, 133.7, 133.5, 133.4, 133.3, 
133.2, 133.1, 132.9, 132.8, 129.1, 118.0, 98.6, 78.8, 76.3, 75.2, 72.2, 71.1, 70.4, 69.7, 
68.5, 68.1, 67.0, 66.7, 65.4, 59.0, 47.6, 45.9, 45.1, 43.8, 43.0, 42.8, 41.1, 41.0, 39.4, 36.6, 
31.8, 30.2, 29.5, 26.0, 24.4, 23.5, 19.1, 17.4, 12.9. 
 
HRMS (ESI) 
 calculated for C44H66O14 (M+Na)+: 841.4350 
found:      841.4369 
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Amphoteronolide B 2.2 
Prior to the reaction, 2.30 was azeotropically dried via coevaporation with acetonitrile (3 x 5 mL) 
and left under vacuum for a minimum of eight hours. The resulting yellow solid (20 mg, 0.024 
mmol, 1 eq) was dissolved in THF (1.5 mL) at 23 °C and thiosalicylic acid (20 mg, 0.12 mmol, 5 
eq). Palladium tetrakis(triphenylphosphine) (27 mg, 0.024 mmol, 1 eq) was added and the 
solution was stirred for 13 hours, during which time the formation of a precipitate was observed. 
The reaction was then concentrated in vacuo and the residue was triturated with cold (0 °C) 
diethyl ether (5 x 5 mL). The yellow solid was then dissolved in DMSO (1.5 mL) and purified by 
preparative RP-HPLC (Waters SunFire Prep C18 OBD 5 micron 30 x 150 mm; 250 µL injection 
volume, 25 mL/min flow rate, 5 → 75% MeCN in 10 mM NH4OAc over 25 minutes) to afford 
amphoteronolide B 2.2 (9 mg, 0.012 mmol, 50%) as a yellow powder. 
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HPLC 
tR: 21.6 min; flow rate = 25 mL/min, gradient of 0 → 75% MeCN in 10 mM ammonium 
acetate over 25 min. 
 
1H NMR (pyridine d-5:CD3OD 10:1) 
δ 6.76-6.67 (m, 2H), 6.59-6.55 (m, 2H), 6.45-6.35 (m, 10H), 5.72 (app d, J = 5 Hz, 1H), 
5.16 (app t, J = 10 Hz, 1H), 4.92 (bs, 1H), 4.78 (bs, 2H), 4.57 (app t, J = 10 Hz, 1H), 4.05 
(app t, 9.5 Hz, 1H), 3.95 (app d, J = 10.5 Hz, 1H), 3.65 (app d, J = 4 Hz, 1H), 3.52 (app 
d, J = 10.5 Hz, 1H), 3.41 (app d, J = 9 Hz, 1H), 2.64 (bs, 2H), 2.56 (dd, J = 10, 16.5 Hz, 
1H), 2.43-2.40 (m, 2H), 2.24 (bs, 2H), 2.10-2.05 (m, 2H), 1.95-1.90 (m, 2H), 1.79-1.65 
(m, 5H), 1.58 (app d, J = 13.5 Hz, 1H), 1.51 (app d, J = 11 Hz, 1H), 1.41 (d, J = 6.5 Hz, 
3H), 1.28 (d, J = 6.5 Hz, 3H), 1.21 (d, J = 7 Hz, 3H). 
 
HRMS 
 Calculated for C41H62O14 (M+Na)+: 801.4037 
found:      801.4039 
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Polyol 2.35 
To a stirred solution of 2.21 (500 mg, 0.219 mmol) in THF (7 mL) in a polypropylene vial at 0 
°C was added chilled (0 °C) 70% HF/pyridine complex (2.2 mL, 77 mmol, 350 eq) diluted with 
THF:pyridine 5:3 (40 mL).  The solution was allowed to warm to 25 °C and stirred for 6.5 hours. 
The solution was subsequently cooled to 0 °C and quenched with the addition of saturated 
aqueous sodium bicarbonate (100 mL).  The resulting yellow emulsion was extracted with 
CH2Cl2:MeOH 5:1 (5 x 100 mL).  The combined organic extracts were washed with brine (1 x 
25 mL), dried over sodium sulfate and concentrated in vacuo.  Purification of the resulting 
Figure 2.4. Representative chromatogram of HPLC purified AmdeB. 
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residue by flash chromatography (SiO2; DCM:MeOH 100:1 → 15:1) afforded 2.35 as a yellow 
solid (202 mg, 0.160 mmol, 73%).   
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TLC (DCM:MeOH 10:1)  
Rf = 0.5, stained by anisaldehyde 
 
HPLC  
tR = 23.40 min; flow rate = 4 mL/min, gradient of 5 → 95% MeCN in 5 mM ammonium 
acetate over 25 min. 
 
1H NMR (500 MHz, CD3OD) 
δ 7.79 (d, J = 7.5 Hz, 2H), 7.68 (dd, J = 4.5, 7.5 Hz, 2H), 7.39 (t, J = 7 Hz, 2H), 7.31 (t, J 
= 8 Hz, 2H), 6.41-6.14 (m, 12H), 5.86 (dd, J = 6.5, 14 Hz, 1H), 5.55 (dd, J = 9, 14 Hz, 
1H), 5.14 (bs, 1H), 4.82 (s, 1H), 4.63 (t, J = 7 Hz, 1H), 4.36 (app d, J = 7 Hz, 2H), 4.23 
(t, J = 7 Hz, 1H), 4.15-4.11 (m, 1H), 3.97-3.93 (m, 2H), 3.86 (dt, J = 5.5, 10 Hz, 1H), 
3.80 (t, J = 9.5 Hz, 1H), 3.75 (d, J = 9 Hz, 1H), 3.72-3.68 (m, 1H), 3.64 (dd, J = 2.5, 9 
Hz, 1H), 3.52 (app d, J = 10.5 Hz, 1H), 3.36-3.31 (m, 1H), 3.23 (app d, J = 9.5 Hz, 1H), 
3.18 (s, 3H), 2.38 (app dd, J = 7.5, 15.5 Hz, 1H), 2.29 (dd, J = 9, 16.5 Hz, 1H), 2.23 (dd, 
J = 3, 16.5 Hz, 1H), 2.15 (dd, J = 5, 13 Hz, 1H), 1.86-1.83 (m, 1H), 1.80-1.75 (m, 1H), 
1.69-1.54 (m, 8H), 1.50-1.39 (m, 9H), 1.30 (d, J = 5.5 Hz, 3H), 1.20 (d, J = 6.5 Hz, 3H), 
1.11 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.5, 3H). 
 
13C NMR (125 MHz, CD3OD) 
δ 172.6, 158.7, 145.4, 145.3, 142.6, 137.4, 135.0, 134.5, 134.1, 134.0, 133.9, 133.4, 
133.2, 132.7, 128.8, 128.2, 126.3, 120.9, 102.3, 98.6, 79.0, 75.8, 75.4, 75.1, 74.6, 72.3, 
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71.9, 71.5, 71.2, 68.8, 68.3, 67.9, 66.8, 58.3, 46.2, 44.7, 43.3, 43.1, 41.5, 36.0, 35.3, 30.4, 
18.9, 18.3, 17.9, 12.2. 
 
HRMS (ESI) 
calculated for C63H86INO17 (M + Na)+: 1278.4838 
found:      1278.4817 
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41-methyl 2.24 
Prior to the reaction, 2.35 was azeotropically dried via coevaporation with acetonitrile (3 x 10 
mL) and left under vacuum for a minimum of eight hours. The resulting yellow solid (50 mg, 
0.0398 mmol, 1 eq) was dissolved in DMSO (1.3 mL) at 23 °C and sodium borohydride (7.5 mg, 
0.199 mmol, 5 eq) was added.  The solution was then stirred for 8.5 hours and subsequently 
quenched with the addition of saturated aqueous sodium bicarbonate (1 mL).  The resulting 
emulsion was diluted with water (25 mL) and extracted with CH2Cl2:MeOH 5:1 (5 x 10 mL).  
The combined organic phases were washed with brine (1 x 20 mL), dried over sodium sulfate 
and concentrated in vacuo. Purification of the residue by flash chromatography (SiO2; 
DCM:MeOH 20:1 → 10:1) yielded 2.24 as a yellow solid (26 mg 0.023 mmol, 58%). 
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TLC (CH2Cl2:MeOH 10:1) 
 Rf = 0.5, stained by anisaldehyde 
 
HPLC 
tR = 22.59 min; flow rate = 4 mL/min, gradient of 5 → 95% MeCN in 5 mM ammonium 
acetate over 25 min. 
 
1H NMR (500 MHz, CD3OD) 
δ 7.79 (d, J = 7.5 Hz, 2H), 7.68 (t, J = 6.5 Hz, 2H), 7.39 (t, J = 7 Hz, 2H), 7.31 (t, 7.5 Hz, 
2H), 6.44-6.15 (m, 12H), 5.83 (dd, J = 8, 15 Hz, 1H), 5.44 (dd, J = 10, 14 Hz, 1H), 5.28 
(bs, 1H), 4.61 (s, 1H), 4.49 (dt, J = 2.5, 8.5 Hz, 1H), 4.40-4.33 (m, 2H), 4.23 (t, J = 7 Hz, 
1H), 4.18-4.13 (m, 1H), 3.94-3.89 (m, 3H), 3.81 (d, J = 3 Hz, 1H), 3.72-3.67 (m, 2H), 
3.65-3.62 (m, 1H), 3.59-3.52 (m, 4H), 3.27 (dd, J = 6, 8 Hz, 1H), 3.22 (dd, J = 1.5, 12.5 
Hz, 1H), 3.16 (s, 3H), 2.38 (app dd, J = 9.5, 16 Hz, 1H), 2.29 (dd, J = 9, 16.5 Hz, 1H), 
2.22 (dd, J = 3, 16.5 Hz, 1H), 2.09 (dd, J = 9, 13.5 Hz, 1H), 2.04-1.97 (m, 2H), 1.90-1.81 
(m, 2H), 1.72-1.65 (m, 2H), 1.55-1.39 (m, 8H), 1.28 (d, J =5.5 Hz, 3H), 1.19 (d, J = 6 Hz, 
3H), 1.11 (d, J = 6 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7 Hz, 3H).  
 
13C NMR (125 MHz, CD3OD) 
δ 171.5, 157.6, 144.2, 144.1, 141.4, 136.2, 135.8, 133.9, 133.5, 133.4, 133.3, 133.0, 
132.6, 132.4, 132.0, 130.9, 127.6, 127.0, 125.1, 125.0, 119.8, 107.7, 101.3, 98.4, 76.4, 
74.7, 73.7, 71.4, 71.2, 70.6, 70.3, 70.0, 69.7, 69.1, 67.7, 67.5, 67.1, 66.7, 57.1, 43.6, 42.7, 
42.0, 41.8, 41.4, 40.2, 35.0, 29.6, 28.9, 17.8, 17.0, 16.2, 12.1, 11.1. 
 
HRMS (ESI)  
 calculated for C63H87NO17 (M + Na)+: 1152.5872 
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found:      1152.5852 
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N-Fmoc-41-methyl amphotericin B 2.29 
To a stirred solution of 2.24 (9 mg, 0.008 mmol) in THF:H2O 2:1 (1 mL) at 23 °C was added 
camphorsulfonic acid (0.6 mg, 0.002 mmol, 0.25 eq).  The solution was stirred for 30 minutes 
and was then diluted with THF (1 mL) and quenched by the addition of solid sodium 
bicarbonate.  The solids were removed by filtration through a pad of Celite and the filtrate was 
concentrated in vacuo to give 2.29 as a yellow solid (9 mg, 0.008 mmol, ~100%). This material 
was used in the next step without further purification. Alternatively, 2.29 was purified by 
preparative RP-HPLC (Waters SunFire Prep C18 OBD 5 micron 30 x 150 mm; 300 µL injection 
volume, 25 mL/min flow rate 1:19 → 19:1 MeCN:10mM NH4OAc, over 25 minutes) for use in 
NMR studies. 
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HPLC 
tR = 25.1 minutes; flow rate = 25 mL/min, gradient of 5 → 95% MeCN in 5 mM 
ammonium acetate over 25 min. 
 
1H NMR (600 MHz, pyridine d-5:CD3OD 10:1) 
δ 7.85 (d, J = 7.2 Hz, 2H), 7.71 (dd, J = 6, 8.5 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 6.74 (m, 
2H), 6.60-6.34 (m, 11H), 5.77 (app d, J36,37 = 1.8 Hz, 1H, H-37), 5.54 (dd, J32,33 = 15 Hz 
J33,34 = 10.0, 1H, H-33), 4.97 (app s, J1’,2’ = 1.6 Hz, 1H, H-1’), 4.82-4.78 (m, J10e,11 = 10.4 
Hz, J11,12e = 11.0 Hz, J18a,19 = 2.5 Hz, J18e,19 = 4.6 Hz, J19,20 = 8.0 Hz, 2H, H-11, H-19), 
4.62 (app t, J2a,3 = 1.8 Hz, J2e,3 = 9.1 Hz, J3,4a = 2.0 Hz, J3,4e = 10.1 Hz, 1H, H-3), 4.51-
4.43 (m, J16,17 = 10.4 Hz, J17,18a = 7.5 Hz, 3H, H-17, H-1’’(2)), 4.39 (app d, J1’,2’ = 1.6 Hz, 
1H, H-2’), 4.34 (dd, J2’,3’ = 3 Hz, J3’,4’  = 9.7 Hz, 1H, H-3’), 4.29 (t, J = 7.2 Hz, 1H, H-
2’’), 4.12-4.07 (m, J4a,5 = 1.0 Hz, J4e,5 = 9.6 Hz, J5,6a = 1.8 Hz, J5,6e = 10.7 Hz, J14e,15 = 2.6 
Hz, J14a,15 = 11.8 Hz, J15,16 = 11.2 Hz, 2H, H-5, H-15), 4.02-3.99 (m, J8,9 = 3.4 Hz, J9,10a = 
2.6 Hz, J9,10e = 10.7 Hz, J3’,4’ = 9.7 Hz, J4’,5’ = 9.1 Hz, 2H, H-9, H-4’), 3.73 (app dd, J4’,5’ 
= 9.1 Hz, J5’,6’  = 6.6 Hz, 1H, H-5’), 3.58 (app d, J7e,8 = 2.5 Hz, J7a,8 = 10.6 Hz, J8,9 = 3.4 
Hz, 1H, H-8), 3.43 (app d, J34,35 = 9.6 Hz, J35,36 = 2.5 Hz, 1H, H-35), 2.67 (app dd, J33,34 = 
10.0 Hz, J34,35 = 9.6 Hz, 1H, H-34), 2.60 (dd, J2a,2e = 16.8 Hz, J2e,3 = 9.1 Hz, 1H, H-2e), 
2.46 (app dd, J18a,18e = 16.8 Hz, J18e,19 = 4.6 Hz, 1H, H-18e), 2.44-2.40 (m, J2a,3 = 1.8 Hz, 
J14e,15 = 2.6 Hz, 2H, H-2a, H-14e), 2.36-2.33 (m, J6e,7e = 13.4 Hz, J7e,8 = 2.5 Hz, 1H, H-
7e), 2.17-2.07 (m, J9,10e = 10.7 Hz, J10e,11 = 10.4 Hz, J35,36 = 2.5 Hz, J36,37 = 1.8 Hz, 2H, 
H-10e, H-36), 2.02-1.90 (m, J5,6e = 10.7 Hz, J6e,7a = 4.4 Hz, J6e,7e = 13.4 Hz, J11,12e = 11.0 
Hz, J17,18a = 7.5 Hz, J18a,19 = 2.5 Hz, 3H, H-6e, H-12e, H-18a), 1.81-1.76 (m, J3,4e = 10.1 
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Hz, J4e,5 = 9.6 Hz, J6e,7a = 4.4 Hz, J6a,7a = 12.7 Hz, J7a,8 = 10.6 Hz, 3H, H-4e, H-7a, H12a), 
1.73-1.69 (m, J5,6a = 1.8 Hz, J6a,7a = 12.7 Hz, J14a,15 = 11.8 Hz, 2H, H-6a, H-14a), 1.62-
1.60 (m, J3,4a = 2.0 Hz, J4a,5 = 1.0 Hz, J15,16 = 11.2 Hz, J16,17 = 10.4 Hz, 2H, H-4a, H-16), 
1.56 (d, J5’,6’ = 6.6 Hz, 3H, H-6’), 1.55-1.52 (m, J9,10a = 2.6 Hz, 1H, H-10a), 1.44 (d, J37,38 
= 6.6 Hz, 3H, H-38), 1.30 (d, J34,40 = 6.6 Hz, 3H, H-40), 1.24 (d, J36,39 = 7 Hz, 3H, H-39), 
1.23 (d, J16,41 = 5.2 Hz, 3H, H-41).1 
  
13C NMR (150 MHz, pyridine d-5:CD3OD 10:1) 
δ 172.2, 158.0, 145.1, 144.9, 142.0, 141.9, 138.2, 137.6, 134.9, 134.8, 134.5, 134.1, 
133.7, 133.5, 133.4, 133.2, 132.9, 130.3, 128.3, 127.8, 126.1, 123.6, 126.0, 120.7, 108.6, 
99.6, 98.3, 78.8, 78.1, 76.3, 75.3, 75.0, 72.2, 71.9, 71.5, 70.4, 69.7, 69.5, 68.5, 67.6, 67.1, 
58.7, 48.1, 45.1, 44.2, 43.1, 41.1, 36.6, 30.3, 19.1, 18.8, 17.5, 14.1, 12.8. 
 
HRMS (ESI)  
calculated for C62H85NO17 (M + Na)+: 1138.5715 
found:      1138.5734 
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piperidine, DMSO:MeOH
4:1, 3 h, 23 °C, HPLC;
56% over 2 steps
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C(41)-Methyl amphotericin B 2.4 
To a stirred solution of 2.24 (9 mg, 0.008 mmol) in DMSO:MeOH 15:2 (380 µL) was added 
piperidine (0.02 mmol, 2 µL, 2 eq). The solution was stirred for 3 hours and was then diluted 
with THF (1 mL) and purified by prep RP-HPLC (Waters SunFire Prep C18 OBD 5 micron 30 x 
150 mm; 300 µL injection volume, 25 mL/min flow rate 1:19 → 19:1 MeCN:10mM NH4OAc, 
over 25 minutes) to afford C(41)-methyl amphotericin B (4) as a yellow powder (4 mg, 0.0045 
mmol, 56% over 2 steps). 
                                                 
1 Two of the Fmoc protons were obscured by the pyridine solvent peak. 
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HPLC 
tR = 21.7 minutes; flow rate = 25 mL/min, gradient of 5 → 95% MeCN in 5 mM 
ammonium acetate over 25 min. 
 
1H NMR (500 MHz, pyridine d-5:CD2OD 10:1) 
δ 6.78-6.71 (m, 2H), 6.58-6.37 (m, 9H), 6.43-6.35 (m, 2H), 5.77 (app d, J = 5.5 Hz, 1H), 
5.54 (dd, J = 10, 15 Hz, 1H), 4.95 (s, 1H), 4.81-4.77 (m, 2H), 4.61 (dt, J = 3, 12.5 Hz, 
1H), 4.45-4.40 (m, 2H), 4.35 (d, J = 2.5 Hz, 1H), 4.11-4.03 (m, 2H), 4.00 (app d, J = 11 
Hz, 1H), 3.77 (t, J = 9 Hz, 1H), 3.66-3.58 (m, 2H), 3.57 (app d, J = 11 Hz, 1H) 3.42 (app 
d, J = 9.5 Hz, 1H), 2.66 (app dd, J = 7, 9.5 Hz, 1H), 2.60 (dd, J = 9.5, 16.5 Hz, 1H), 2.49 
(dd, J = 5.5, 14.5 Hz, 1H), 2.41 (app dd, J = 7.5, 12 Hz, 2H), 2.39-2.35 (m, 1H), 2.10 
(app dd, J = 7.5, 15.5, 2H), 1.95-1.88 (m, 3H), 1.81-1.72 (m, 3H), 1.70-1.67 (m, 2H), 
1.66-1.59 (m, 2H), 1.52 (d, J = 6 Hz, 3H), 1.44 (d, J = 6.5 Hz, 3H), 1.30 (d, J = 6.5 Hz, 
3H), 1.24 (d, J = 7 Hz, 3H), 1.22 (d, J = 6.5 Hz, 3H). 
 
HRMS (ESI) 
 calculated for C47H75NO15 (M + Na)+: 894.5191 
found:      894.5182 
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Part 2. NMR Studies 
 
Selection of compounds for NMR analysis. MeAmdeB 2.3 was used directly for NMR studies. 
Compounds 2.1, 2.2, and 2.4 were not amenable to high resolution NMR analysis due to their 
poor solubilities in appropriate NMR solvents. However, it has been demonstrated that AmB 
derivatives having covalent modifications of the carboxylic acid or amine functional groups have 
the same ground state conformation as judged by NMR26 or X-ray crystallographic analysis,27 
respectively. Therefore, we chose suitably protected analogs AmB N-acyl methyl ester 2.27 
AmdeB allyl ester 2.30, and N-Fmoc MeAmB 2.29 for the conformational analysis of 2.1, 2.2, 
and 2.4, respectively.  
 
gCOSY NMR spectra. 500 MHz and 600 MHz gCOSY NMR spectra were acquired at 30 °C 
with 2048 points, 256 or 512 increments and 1, 4, or 8 transients. Spectra were processed on a 
SUN Microsystems SPARCstation Ultra 5 computer using Varian VNMR software, version 6.1, 
revision C, with zero-filling to 4096 x 4096 and sine bell apodization such that sb = at/2 and sb1 
= ni/(2*sw1).  
Figure 2.5. Representative chromatogram of HPLC purified MeAmB. 
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H-H NOESY NMR spectra. Samples for NOESY NMR experiments were prepared in an 
Innovative Technologies, Inc. glove box using a NMR tube sealed with a PTFE screw cap. 
Sealed ampules of pyridine d-5 and CD3OD with 0.03% tetramethylsilane were used as solvents 
for these experiments. 600 MHz NOESY spectra were acquired at 30 °C with 2048 points, 256 
increments, 8 transients per increment, τmix = 0.7 s, and an interscan delay (d1) of 3*T1 (standard 
T1 relaxation experiments were performed for each compound). Spectra were processed using 
nmrPipe28 as follows: 1) 4 points back prediction, 2) 90° shifted sinebell apodization, 3) zero-
filling to 8192 points, 4) Fourier transformation and phasing, 5) linear prediction to 512 points, 
6) 90° shifted sinebell apodization, 7) zero-filling to 2048 points, and 8) Fourier transformation 
and phasing. The Sparky program,29 version 3.113 was used for peak-picking and integration of 
crosspeaks.  
 
Phase-sensitive COSY (COSYPS) NMR spectra. 500 MHz COSYPS spectra were acquired at 
30 °C with 2048 points, 256 increments, and 4 transients per increment. 600 MHz COSYPS 
spectra were acquired at 30 °C with 2458 points, 308 increments and 8 transients per increment. 
All COSYPS spectra were acquired with sufficient interscan delay to allow for full spin-
relaxation (d1 = 23.2 seconds, as determined by T1 relaxation experiments, was sufficient for all 
compounds). 
 
Gradient HMBC NMR spectrum. A gradient HMBC spectrum of 2.27 was acquired at 23 °C 
with 2048 points, 280 increments, and 128 transients. Parameters for C-H coupling were set such 
that j1xh = 140 Hz and jnxh = 8 Hz.  The spectrum was processed on a SUN Microsystems 
SPARCstation Ultra 5 computer using Varian VNMR software, version 6.1 revision C, with 
zero-filling to 1024 points in the indirect dimension and sinebell apodization such that sb = at/2 
and sb1 = ni/(2*sw1). 
 
COSYPS processing and 3J determination. Raw COSYPS data were processed as described 
by Bax and coworkers20 to produce a diagonal-suppressed spectrum and a diagonal-only 
spectrum (Representative spectra for AmdeB allyl ester 2.30 are shown on page 36). Amplitude-
constrained multiplet evaluation (ACME),3 was used to determine 3J H-H coupling constants. 
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Figure 2.6. Diagonal-suppressed COSYPS spectrum of AmdeB allyl ester 2.30. Adapted with 
permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 13804-
13805. Copyright 2007 American Chemical Society. 
Figure 2.7. Diagonal-only COSYPS spectrum of Amde B allyl ester 2.30. Adapted with permission 
from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 13804-13805. 
Copyright 2007 American Chemical Society. 
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Crosspeak Fitting. The ACME method for determining J values from COSYPS spectra is 
described in detail by Delaglio et al.3 Briefly, the ACME program can accurately integrate the 
crosspeaks of a COSYPS spectrum provided the experiment is run with interscan delay time 
sufficient for the spins to fully relax. ACME integrates selected peaks from the diagonal-only 
spectrum and the resulting integration values are used to integrate crosspeaks in the diagonal-
suppressed spectrum. The figure on this page shows the results of fitting three peaks from the 
COSYPS diagonal of AmdeB allyl ester 2.30. Panels A, B, and C contain; A) the selected region 
of the spectrum (with peaks for fitting labeled 1 and 2), B) simulated peaks calculated in the 
fitting process, C) the residual between the experimental and calculated peaks. Therefore, in an 
accurate simulation, no residual is present for the selected peaks. Through this process, the 
average integration of selected peaks may be used to integrate crosspeaks from the diagonal-
suppressed spectrum. 
 
Figure 2.8. ACME results for fitting the AmdeB allyl ester 2.30 diagonal. A) The selected spectral region with 
peaks for fitting labeled 1 and 2. B) Simulated peaks calculated in fitting process. C) Residual between panels A) 
and B). Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 
13804-13805. Copyright 2007 American Chemical Society. 
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The fine structure of crosspeaks in a COSYPS spectrum can be used to obtain coupling constants 
in a manner analogous to obtaining coupling constants from a one-dimensional multiplet. In a 
two-dimensional crosspeak, the spacing between antiphase portions of the crosspeak correspond 
to the J value for the associated spins. The ACME method employs the reference integration 
from the diagonal in a peak-fitting algorithm that integrates selected crosspeaks and calculates 
coupling constants. The figure on this page shows the results from the fitting algorithm applied 
to the cross-peak corresponding to protons H-18a and H-17 in AmdeB allyl ester 2.30. Panel A 
again contains the selected peak from the spectrum. Panel B depicts the simulated crosspeak, and 
Panel C displays the residual. The lack of any significant residual is consistent with accurate 
reproduction of the multiplet fine structure in the fitting process. Similar analysis for each 
crosspeak in the spectra of compounds 2.27, 2.3, 2.29 and 2.30 was used to derive the coupling 
constants from which dihedral constraints were calculated.  
 
 
Figure 2.9. Calculation of 3J for H-18a(pseudoaxial) and H-17 for AmdeB allyl ester 2.30. ACME accurately 
reproduces the fine structure of the multiplet with no residual between the experimental and calculated peaks. 
Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 
13804-13805. Copyright 2007 American Chemical Society. 
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Dihedral angles were calculated from H-H 3J values according to Altona’s extended Karplus 
equation18 using the “HLA (4 substituents)” setting in the MestReJ software.30 However, each 3J 
gives rise to 4 possible solutions to the Karplus equation. Methods for choosing the appropriate 
value are well-precedented. For example, in the context of conformational analysis of the 
erythronolide B lactone, Aurichio31 and Egan32 chose dihedral values consistent with NOE data 
and the erythronolide B crystal structure, respectively. For our analyses, we chose angles 
consistent with both NOESY data and the AmB crystal structure.5 In some cases, two solutions 
to the Karplus equation were consistent with both NOESY and crystal structure data, and both 
solutions were included. The selected dihedral angles (± 30°) were used as constraints in Monte 
Carlo conformational searches (see Part 3).  
 
Part 3. Energy Minimization Calculations 
 
NMR-Restrained Model Structures.  Monte Carlo conformational searches were performed 
using the Molecular Operating Environment program (MOE), Version 2006.08,33 with the 
empirical MMFF94x force field and a Born solvation model with no distance cutoffs for non-
bonded interactions. Initial atomic coordinates and structure files were generated from the AmB 
crystal structure using MOE. NMR-derived distance and dihedral constraints were set with a 
weighting factor of 200. 3500 random conformations were generated and minimized with 
Gaussian distribution of dihedrals biased towards multiples of 30°, dihedral minimization (RMS 
= 100), 0.001 Cartesian minimization RMS gradient, 0.0001 Cartesian perturbation, 0.1 RMS 
tolerance, a maximum of 2000 energy minimization steps for each minimization, a failure limit 
of 5000, no chiral inversion, no rotation about π bonds or amide bonds, and an energy cutoff of 5 
kcal/mol. Force field partial charges were calculated before each minimization. Default values 
were used for all other parameters. 
     
Consistent with protein structural analysis techniques,34 each H-H dihedral was constrained to 
the selected value ± 30º. When two solutions to the Karplus equation were selected, both values 
(± 30º) were allowed. The table on page 40 lists the dihedral constraints used in the 
conformational searching. Consistent with the standard convention for dihedral angles, values for 
the dihedral, θ, were defined over the range -180° < θ ≤ 180°. Consistent with the known trans-
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configuration of the seven double bonds of the polyene moiety, the π-bonds were constrained to 
180 ± 10°. 
 
Interproton distances were constrained for proton pairs exhibiting NOE correlations, with the 
lower limit set at 1.8 Å (twice the hydrogen van der Waals radius), and the upper limit set at 5.0 
Å.  The table on page 41 lists the NOE correlations used for conformational searching, and the 
figures on pages 42-45 depict these correlations (red lines indicate NOE correlations) Notably, 
all four compounds contain a diagnostic series transannular NOEs between protons of the polyol 
and those of the polyene. 
 
The Monte Carlo conformational search explores conformational space by randomly perturbing 
all dihedral angles in the molecule and then minimizing the resulting structures (taking into 
account the restraints as described above). MOE repeated this process 3500 times, and the lowest 
energy conformation of each compound was used in rigid root mean square (RMS) atom 
alignment (see below). 
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Figure 2.10. Dihedral constraints used in conformational searches using MOE. Also shown are the 
coupling constants (calculated by ACME) from which the dihedral constraints were derived. Adapted 
with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 13804-
13805. Copyright 2007 American Chemical Society. 
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Figure 2.11. Observed NOE correlations used to derive distance constraints in conformational searches 
using MOE. Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. 
Soc. 2007, 129, 13804-13805. Copyright 2007 American Chemical Society. 
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Figure 2.12. NOE correlations for N-acyl AmB Methyl ester 2.27. For clarity, appendages other than 
protons have been removed from the macrolide skeleton. Selected carbon atoms are numbered. 
Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 
129, 13804-13805. Copyright 2007 American Chemical Society. 
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Figure 2.13. NOE correlations for MeAmdeB 2.3. For clarity, appendages other than protons have 
been removed from the macrolide skeleton. Selected carbon atoms are numbered. Adapted with 
permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 
13804-13805. Copyright 2007 American Chemical Society. 
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Figure 2.14. NOE correlations for AmdeB allyl ester 2.30. For clarity, appendages other than protons 
have been removed from the macrolide skeleton. Selected carbon atoms are numbered. Adapted with 
permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 2007, 129, 13804-
13805. Copyright 2007 American Chemical Society. 
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Figure 2.15. NOE correlations for N-Fmoc MeAmB 2.29. For clarity, appendages other than 
protons have been removed from the macrolide skeleton. Selected carbon atoms are numbered. 
Adapted with permission from Palacios, D.S.; Anderson, T.M.; Burke, M.D. J. Am. Chem. Soc. 
2007, 129, 13804-13805. Copyright 2007 American Chemical Society. 
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Rigid RMS atom alignment for NMR-restrained model structures. Only the atoms of the 
macrolactone ring and the cyclic hemiketal were used for RMS alignment. All other atoms were 
deleted from the lowest-energy conformers of 2.27, 2, 20, and 22, and the resulting skeletons 
representing the ground-state conformations of AmB 2.1, MeAmB 2.4, AmdeB 2.2, and 
MeAmdeB 2.3, respectively were saved as MDL MOL files (*.mol) and imported into the 
Cerius2 program, Version 4.11,35 with no energy minimization or calculation of charges. Rigid 
RMS atom alignment revealed RMSD = 0.081 Å for the four structures. The aligned structures 
were saved as PDB files (*.pdb), and the overlay image (Figure 2.2) was generated using 
VMD.36 
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Chapter 3 
Functional Group Deletions Reveal the Mycosamine-Dependent Sterol Binding of  
Amphotericin B 
 
Aiming to definitively test the three specific hypotheses for the mechanistic role(s) 
played by the C(41) carboxylate and C(19) mycosamine, a series of biological and biophysical 
assays were developed in which to study our functional group deficient derivatives. The 
experiments focused on four key functional properties: antifungal activity, ion channel 
formation, membrane binding and membrane embedded sterol binding. The results of these 
investigations conclusively demonstrated that, in stark contrast to the leading model for AmB’s 
mechanism of action, oxygenation at C(41) is not required for potent antifungal or ion channel 
activity. Alternatively, mycosamine was shown to be absolutely required for both biological 
activity and the capacity to form ion channels. Furthermore, using an isothermal titration 
calorimetry (ITC) based assay, we obtained the first conclusive evidence for a direct AmB-
ergosterol interaction, thereby resolving the long-standing debate regarding the nature of AmB’s 
sterol dependency. Moreover, we found that mycosamine, but not the carboxylate, is absolutely 
required to promote this binding event. These results therefore established a new functional role 
for a glycoside appended to a small molecule natural product, i.e. the mediation of a functionally 
vital small molecule-small molecule interaction. Based upon these results, and related studies 
with another natural product, natamycin, we proposed a novel, potentially general, two 
mechanism model to account for AmB’s potent antifungal activity. Ian Dailey performed the 
experiments shown in Figures 3.10, 3.11, 3.12 and 3.13 and contributed to the development of 
the ITC sterol binding assays. David M. Seibert assisted with the MIC assays shown in Figure 
3.3 and helped with the development of the SEC-based liposome binding assay in Figure 3.8. 
Brandon C. Wilcock prepared additional amphoteronolide B for these experiments. Portions of 
this chapter were adapted from Palacios, D.S.; Dailey, I.; Seibert, D.M.; Wilcock, B.C.; Burke, 
M.D. Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738.  
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3-1 BACKGROUND 
 Chapter 2 presented the synthesis and three-dimensional characterization of MeAmB, 
AmdeB and MeAmdeB. This represented the successful completion of the first two modules of 
the functional group deletion algorithm presented in Chapter 1. Thus, we turned our attention to 
the final component, the biophysical and biological investigation of AmdeB, MeAmdeB, and 
MeAmB. As discussed in Chapter 1, many investigations have probed the function(s) of the 
C(41) carboxylate and C(19) mycosamine but the role(s) of these two chemical groups have yet 
to be definitively established. Therefore, we designed a series of assays to unambiguously 
evaluate the three hypotheses shown in Figure 3.1 using MeAmB, AmdeB and MeAmdeB as 
mechanistic probes. The development, application and results of these assays will be discussed in 
the succeeding sections.  
 
 
 
 
Figure 3.1 Three proposals for the role of the C(41) carboxylate and C(19) mycosamine in the antifungal 
mechanism of AmB. As is discussed in more depth in Chapter 1, it has been hypothesized that the acid and 
mycosamine A) form an intermolecular salt-bridge/hydrogen bond that stabilizes the AmB ion channel, B) 
interact electrostatically with the zwitterionic phospholipid headgroup and C) promote sterol binding by 
hydrogen bonding to the sterol 3β hydroxyl group. Adapted from Palacios, et al Proc. Natl. Acad. Sci. USA 
2011, 108, 6733-6738 Copyright 2011, National Academy of Sciences. 
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3-2 EXTINCTION COEFFECIENT DETERMINATION 
 The syntheses of MeAmB, AmdeB and MeAmdeB are not trivial, requiring multiple 
HPLC purification steps and up to two weeks to fully complete. With this in mind, the 
conservation of these molecules in the course of assay development and execution was very 
important. Accordingly, we determined the extinction coefficient of AmB,1 MeAmB, AmdeB 
and MeAmdeB and then split the compounds up into approximately 100 microgram quantities.  
The extinction coefficient for each molecule is shown is Figure 3.2. Interestingly, we found that 
the identity of the chemical groups at C(41) and C(19) had a large impact on the extinction 
coefficient of the polyene, but this effect is difficult to rationalize. Prior to running an 
experiment, an appropriate vial(s) was removed from the freezer, and the compound was 
quantified spectrophotometrically after being dissolved in DMSO. By creating a depository of 
multiple samples, the danger of catastrophic loss was precluded, and potentially harmful freeze-
thaw cycles were also avoided. 
 
3-3 ANTIFUNGAL ACTIVITY 
 Prior to pursuing any biophysical experiments, we wanted to first determine the 
fungicidal properties of HPLC purified MeAmB, AmdeB and MeAmdeB. As discussed in 
Chapter 2, the biological activities of these molecules had been minimally investigated prior to  
Figure 3.2. The experimentally determined extinction coefficients of AmB, MeAmB, AmdeB and MeAmdeB.  
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our studies. Towards this end, we employed a disk diffusion assay2 for the qualitative evaluation 
of antimicrobial activity against S. cerevisiae. The results of this experiment are shown in Figure 
3-3. Confirming the validity of the assay, AmB potently inhibits the growth of S. cerevisiae as 
demonstrated by the zone of growth inhibition around the paper disk. Next, neither aglycone 
displayed any antifungal activity, results consistent with the proposed critical role(s) of 
mycosamine. However, counter to the leading models, MeAmB displayed roughly equipotent 
antifungal activity to the natural product in this assay. A subsequent broth mircodilution 
minimum inhibitory concentration (MIC) assay,3 confirmed the results of the disk diffusion 
assay, and established that AmB and MeAmB are indeed quantitatively equipotent against both 
S. cerevisiae and the opportunistic pathogen C. albicans. This assay also showed that, 
remarkably, the two molecules lacking mycosamine remained completely inactive even at 
concentrations 100-200 fold higher than the MIC of AmB. Thus, the mycosamine appendage, but 
not oxidation at C(41), is strictly required for antifungal activity. With this data in hand, we set 
out to systematically evaluate the role(s) of the C(41) carboxylate and C(19) mycosamine in each 
of the three proposed mechanisms shown in Figure 3.1, beginning with ion channel formation.  
 
 
 
Figure 3.3 Antifungal activity of AmB and the three functional group deficient derivatives against S. cerevisiae 
in a disk diffusion assay and S. cerevisiae and C. albicans in an MIC broth microdilution assay. The MIC is 
defined as the lowest concentration of compound that completely inhibits yeast growth. Adapted from Palacios, 
et al Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738 Copyright 2011, National Academy of Sciences. 
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3-4 ION CHANNEL FORMATION  
 To test whether the ring of polar interactions shown in Figure 3.1A is required for ion 
channel formation, we first performed a potassium efflux assay from live S. cerevisiae cells.4 
This assay employed a commercially available valiomycin-based potassium selective ion probe 
to detect the cellular efflux of this ion. As shown in Figure 3.4A, both AmB and MeAmB rapidly 
caused the loss of intracellular potassium, whereas the two aglycones showed no activity beyond 
the DMSO vehicle. In an attempt to more generally detect the electrochemical disruption of S. 
cerevisiae by AmB and MeAmB, we also tried experiments using the fluorescent potentiometric 
probe 3,3ʹ′-dipropylthiacarbocyanine iodide (diS-C3(5)).5 This emissive dye is sensitive to the 
electrochemical potential of live cells and, promisingly, it has been effective for studying the 
selective permeabilization of prokaryotic cell membranes by small molecules.6 In addition, diS-
C3(5) was reported to be compatible with S. cerevisiae,7 but, despite this potential, we were 
unable to develop a reliable assay for cellular depolarization with diS-C3(5).  
 
 
 
 
 
 
 
 
 
With the fluorescence-based assay abandoned, we returned to the potentiometric 
potassium efflux platform. To remove potentially complicating factors present with yeast, such 
as cellular proteins and the β-1,3 glucan cell wall, we also performed this assay using 200 nm 
egg yolk phosphatidylcholine (EYPC) liposomes loaded with 10 percent ergosterol (Figure 
Figure 3.4. Potassium efflux from A. S. cerevisiae and B. 10 percent ergosterol EYPC liposomes demonstrate 
the membrane permeabilizing activity of AmB and MeAmB but not AmdeB or MeAmdeB. The concentration of 
each molecule is 3 µM in the S. cerevisiae assay and 1 µM in the EYPC assay. Adapted from Palacios, et al 
Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738 Copyright 2011, National Academy of Sciences. 
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3.4B).8 Consistent with the results of the S. cerevisiae potassium efflux assay, AmB and MeAmB 
displayed potent membrane permeabilizing activity while AmdeB and MeAmdeB failed to elicit 
detectable levels of ionic flux. While the potentiometric experiments were extremely useful and 
convenient for showing the inability of AmdeB and MeAmdeB to permeabilize membranes, the 
resolution of this assay is insufficient to distinguish between gross membrane disruption and 
discrete ion channel formation. Thus, a possible and valid interpretation of the efflux data is that 
MeAmB is not actually forming ion channels, but is rather acting as a detergent to non-
specifically damage phospholipid bilayers. Single AmB ion channels have been observed 
previously using voltage clamp planar lipid bilayer technology,9 so we decided to acquire this 
technology for a definitive clarification of the potential role of the salt bridge in ion channel 
formation.  
The planar lipid bilayer (also referred to as a black lipid membrane or BLM) is a 
commonly employed electrophysiological technique to separate two aqueous compartments by a 
small patch of membrane.10 This technology is convenient for the study of channel forming 
species such as AmB because both aqueous chambers are easily accessible and can be 
manipulated to suit the experiment but are electrically isolated by the lipid bilayer. The original 
and still ubiquitously employed method for forming planar lipid bilayers is the painting 
technique developed by Muller in 1962.11 This procedure employs a solution of lipids in a non-
polar solvent, usually n-decane, which is successively applied to a small (about 100 microns) 
hole in a non-polar substrate using a glass applicator. From this “painting” process12, lipid 
bilayers spontaneously form across the hole, and the integrity of these newly formed bilayers can 
be investigated using the electrical components of the instrument. One of the drawbacks of 
planar lipid bilayers is their physical fragility. These bilayers rarely persist for more than one 
hour under standard experimental conditions, and relatively small mechanical disruptions (such 
as bumping into the instrument) are sufficient to rupture the bilayer.  
The other key component of the planar lipid bilayer system is the voltage clamp, which is 
required to investigate the formation and electrophysiological properties of ion channels. This 
technology has proven to be a robust tool for electrophysiology research since it was first 
introduced in the late 1940’s for studies of the giant squid axon.13 The essential function of the 
voltage clamp is to control the membrane potential (i.e. “clamping”), with the magnitude of the 
membrane potential being chosen by the operator to suit the experiment. When an ion channel 
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forms in the planar lipid bilayer and ions flow through the newly formed pore, the membrane 
potential is altered because of the direct, Ohmic14 relationship between current and voltage. The 
voltage clamp then precisely applies amperage to the system to counteract the current resulting 
from electrolyte flow through the ion channel and thereby return the membrane voltage to the 
preset resting value. Thus, it is this negative feedback that is key to the function of the voltage 
clamp, and the method by which it can precisely provide the electrophysiological characteristics 
of protein or small molecule ion channels.15 The exquisite sensitivity of the voltage clamp 
(detection in the picoamp range) system requires that these experiments be housed in a faraday 
cage to exclude extraneous electrical signals.       
Applying this technology to the study of AmB, MeAmB, AmdeB and MeAmdeB 
required that significant technical hurdles be overcome. After initially building the instrument16 
in Roger Adams Lab, a stable baseline for an unmodified lipid bilayer could not be achieved. 
While a membrane could be formed, as indicated by the characteristic changes in capacitance 
and current consistent with bilayer formation that detected by the instrument, the baseline 
appeared to have a sinusoidal noise associated with it. This roll in the baseline was suggestive of 
a repetitive mechanical vibration, and we suspected that the sound of the vacuum pumps and/or 
fume hoods was the source of the unstable baseline. However, turning off all of the vacuum 
pumps and fume hoods in the room did not correct the rolling baseline. Following this, we 
suspected that the instrument was picking up motions of the building through the bench it was 
placed on. With this working hypothesis, we had a winch installed that could suspend the 
instrument from the ceiling on a concrete slab, but the unstable baseline persisted. Upon the 
failure of the winch setup, we discovered that, directly above where the instrument was located, 
were the pumps to run the fume hoods present in Roger Adams Lab and this was the source of 
the mechanical noise that produced the unstable baseline. Thus, Roger Adams Lab proved to be 
unsuitable for this very sensitive equipment, and so the instrument was disassembled and moved 
to a temporary location in the basement of the Institute for Genomic Biology. After being 
moved, the system was rebuilt and planar lipid bilayers with a flat, stable baseline could be 
reproducibly formed.  
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The initial experiments with AmB utilized the standard experimental setup, consisting of 
a Delrin® cup with a precisely drilled hole that supports the planar lipid bilayer. As shown in 
Figure 3-5A, the cup conveniently fits into a complementary cell and it can also be used multiple 
times without physical degradation of the hole, providing highly reproducible bilayer formation. 
It is this ease of use that makes this particular setup advantageous, but it turned out to not be 
compatible for experiments with AmB. The poor solubility of AmB prevented us from 
effectively cleaning out the Delrin® cup, and the AmB contaminated cups could not be used for 
further experimentation. We tried to use harsh cleaners and/or detergents to remove the AmB, 
but these treatments physically degraded the aperture, making the cups useless. The solution we 
devised for this problem is shown in Figure 3-5B. This setup uses a home built Delrin® cell17 
with a small “V” cut out of a partition that separates two chambers. A small, thin (125 µM) sheet 
of Teflon® with an approximately 100 µM hole burned into it18 is placed over this cut and is 
adhered to the walls of the partition with vacuum grease. We could readily and reproducibly 
form planar lipid bilayers using this setup and, at the conclusion of an experiment, the Telfon® 
sheet was simply discarded, obviating the threat of compound carryover.  
 
Figure 3.5. A. Photograph of the conventional setup for planar lipid bilayer experiments. The Delrin® cup with a 
200 µM hole drilled into it is placed into the larger, back chamber of the cell (The hole is too small to be visible 
in the picture). Once a bilayer is formed the front  (cis) and back (trans) aqueous solutions are electrically 
isolated by the phospholipid bilayer. B. Picture of the home-built Delrin® cell used for the AmB experiments. 
The notch in the partition where the Teflon® sheet is placed is visible (The Teflon® sheet is not shown).  
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Once the system had been fully setup and validated we were able to study the channel 
forming capacity of AmB, MeAmB, AmdeB and MeAmdeB. For these studies, we used a 
mixture of pig brain phosphatidylcholine and pig brain phosphatidylethanolamine to form the 
planar bilayers, because this particular lipid mixture was used in prior studies with AmB.10 
Representative results from these experiments are shown in Figure 3-6. We routinely observed 
single ion channel formation for AmB and MeAmB, but channel activity was never observed for 
either of the two aglycones. The concentrations of AmB and MeAmB required to observe 
channel activity varied based upon the lot number and age of the lipids used to make the 
membrane. For AmB, single ion channels were observed at concentrations between 0.5 and 5 
nM, while MeAmB displayed single channel activity between 30 and 80 nM. When the 
concentration of MeAmdeB was raised to 100 nm in an attempt to see channel activity, we 
Figure 3.6. Representative single channel BLM recordings of A. AmB, (10 nm); B. MeAmB, (75 nm); C. 
AmdeB, (100 nm) and D. MeAmdeB (50 nm). Planar lipid bilayers were unstable in the presence of 100 nm 
MeAmdeB. Adapted from Palacios, et al Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738 Copyright 2011, 
National Academy of Sciences. 
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instead only observed gross membrane destruction, as evidenced by an abrupt change from zero 
current to an offscale reading.  
Based upon the results described in this section, we have conclusively demonstrated that 
the predicted ring of charged interactions shown in Figure 3.1A that were proposed to be critical 
for ion channel formation and antifungal activity is not required for either. Conversely, a 
different and vital role for the mycosamine appendage in ion channel formation is apparent from 
the total lack of channel activity observed for AmdeB and MeAmdeB. Intriguingly, variations 
were seen between the electrophysiological characteristics of AmB and MeAmB during the 
course of the planar lipid bilayer studies, as can be clearly viewed in Figure 3-6. Furthermore, 
the permeabilizing activities of these two compounds against S. cerevisiae are also visibly 
distinct (Figure 3-5A). The differences in ion channel behavior between AmB and MeAmB were 
not investigated in a quantitative fashion, however, and this remains an interesting preliminary 
observation that merits a more extensive inquiry.   
 
3-5 PHOSPHOLIPID MEMBRANE BINDING 
 One possible explanation for the lack of channel and biological activity of AmdeB and 
MeAmdeB is that these molecules are not capable of inserting into phospholipid bilayers. This 
would be consistent with the hypothesis that electrostatic interactions between mycosamine and 
Figure 3.7. A. Binding of AmB, MeAmB, AmdeB and MeAmdeB to live S. cerevisiae cells. B. When the 
experiment was run in the absence of S. cerevisiae greater than 90% of each compound was recovered. Adapted 
from Palacios, et al Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738 Copyright 2011, National Academy of 
Sciences. 
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zwitterionic phospholipid headgroups anchor AmB into the bilayer membrane (Figure 3-1B). To 
test this proposal, we first analyzed the binding of AmB, MeAmB, AmdeB and MeAmdeB to 
live S. cerevisiae cells.19 The degree of binding was analyzed by incubating the cells separately 
with each molecule, followed by centrifugation of the yeast and spectrophotometric 
quantification of the amount of compound remaining in the supernatant. As shown in Figure 3-
7A, all four compounds readily bind S. cerevisiae by this centrifugation-based assay. To ensure 
that the compounds were not simply adhering to the walls of the polyethylene microcentrifuge 
tubes or decomposing during the course of the experiment, we also performed this experiment in 
the absence of S. cerevisiae and found that greater than ninety percent of each compound was 
recovered in this control experiment (Figure 3-7B). 
Ergosterol containing EYPC liposomes were next utilized to determine the ability of 
these four compounds to partition directly into naked phospholipid bilayers. The partitioning of 
AmB into sterol-containing20 and sterol-free liposomes21 has previously been determined, but 
these studies relied on changes in measureable physiochemical properties (such as the electronic 
absorption spectrum of AmB) to measure lipid binding. These methods therefore rely on 
assumptions regarding the origins of the observed physiochemical changes, for example that the 
change in λmax is directly correlated to lipid binding. In contrast, physically separating bound and 
unbound molecules, as was done with the S. cerevisiae assay, is advantageous because no such 
assumptions have to be made, since the amount of bound or unbound compound is directly 
quantified.22 Accordingly, we first attempted to directly translate the S. cerevisiae experiment to 
200 nm EYPC liposomes, but under the intense centrifugation conditions required to pellet these 
liposomes (70,000 g for at least an hour) over fifty percent of the AmB also precipitated in the 
liposome-free control experiments. To combat this issue, we used the dibrominated lipid 1-
oleoyl-2-(9,10-dibromostearoyl)-sn-glycero-3-phosphocholine (OPBC), which, due to the 
increased density of the dibrominated acyl chain, can be precipitated using milder centrifugation 
conditions.23 Even under these more gentle conditions, though, a significant degree of AmB 
precipitation was still observed, which we attributed to the known propensity of AmB to form 
large, multi-molecular aggregates in aqueous solution.24 Aiming to circumvent the continued 
precipitation of AmB, we developed a size exclusion chromatography (SEC) based assay to 
measure membrane partitioning.25 In this experiment, after incubating each small molecule with 
a suspension of liposomes, the mixture was purified by SEC and any unbound small molecules 
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were retained on the column while the liposomes rapidly elute and were collected. The amount 
of drug inserted into the bilayer could then be directly measured by dissolving the post-column 
liposome suspension in an organic solvent and spectrophotometrically quantifying the now 
solution-phase drug. As shown in Figure 3-8A, all four compounds bound equally to the 
ergosterol containing model membranes, confirming the results of the S. cerevisiae binding 
assay. We also determined that these molecules effectively partition into sterol-free liposomes 
(Figure 3-8B). Importantly, when AmB, MeAmB, AmdeB and MeAmdeB were independently 
loaded onto the SEC column in the absence of liposomes, less than ten percent of each 
compound eluted at the same retention time as the EYPC liposomes (Figure 3-8C).  
The finding that AmB and the functional group deficient derivatives readily bind 
phospholipid bilayers has two important implications. One, it has been proposed that AmB 
alternatively exerts its antifungal activity via autooxidation of the polyene subunit, an event that 
triggers a radical chain process which chemically damages cellular membranes.26 However, 
given our result with the aglycones, which both readily bind S. cerevisiae and retain the 
Figure 3.8. A. Binding of AmB, MeAmB, 
AmdeB and MeAmdeB to EYPC liposomes 
loaded with 10 percent ergosterol. B. Binding of 
AmB, MeAmB, AmdeB, and MeAmdeB to sterol-
free EYPC liposomes.  C. Less than 10 percent of 
each molecule loaded onto an SEC column in the 
absence of liposomes elutes at the retention time 
of the liposomes. Error bars for A. and B. 
represent the standard deviation of the experiment. 
Adapted from Palacios, et al Proc. Natl. Acad. Sci. 
USA 2011, 108, 6733-6738 Copyright 2011, 
National Academy of Sciences.   
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putatively redox active polyene but yet are completely lacking in antifungal activity, strongly 
argues against the autooxidation mechanism as the main source of AmB’s antifungal activity. In 
addition, the hypothetical polar interactions between the C(41) carboxylate and/or mycosamine 
and the charged phospholipid headgroups are not required for AmB to effectively partition into 
sterol containing or sterol free membranes. The insertion of AmB and the functional group 
deficient derivatives into phospholipid bilayers is instead, similar to many antimicrobial peptides 
and detergents, most likely driven primarily by the hydrophobic effect.27 
 
3-6 STEROL BINDING 
 Definitively testing the hypothesis that the C(41) carboxylate and/or C(19) mycosamine 
are required bind membrane sterols (Figure 3-1C) has proven to be very difficult. Whether or not 
AmB even directly binds sterols, or if AmB is dependent on sterol-mediated global changes in 
membrane properties remains an issue of significant debate in the literature (See Chapter 1 for a 
more in depth discussion). Recently, an isothermal titration calorimetry (ITC) based assay was 
developed and used to test the sterol binding ability of natamycin,28 a mycosamine containing 
polyene macrolide related to AmB. We predicted that this highly sensitive membrane embedded 
sterol binding assay, in combination with our functional group deficient derivatives, could be 
used to finally resolve this long-standing question. After adapting this assay for our own 
purposes, we initially looked at the interaction between AmB and three different 1-palmitoyl-2-
oleyl-sn-glycero-3-phosphocholine (POPC) liposome systems. The three model membranes we 
used were sterol-free, ten percent lanosterol and ten percent ergosterol (Figure 3.9). We chose to 
Figure 3.9. The structures of ergosterol, cholesterol and lanosterol. Ergosterol is the main sterol found in fungal 
cell membranes, cholesterol is the major mammalian sterol and lanosterol is the biosynthetic progenitor to both 
molecules. 
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also use lanosterol-loaded liposomes because, importantly, it has been shown in micropipette 
aspiration and solid-state NMR experiments that ergosterol and lanosterol have very similar 
macroscopic and molecular effects on POPC bilayers.29 Thus, if the dominant interaction 
between AmB and membrane sterols is the sterol-induced differential preoganization of the 
membrane, the ITC data for ergosterol and lanosterol would be expected to also be similar.  
 
 
 
 
 
 
The results of these experiments are shown in Figure 3-10. The titration of AmB with 
sterol-free POPC liposomes (Figure 3-10A) produced a very small net exotherm, and a similar 
small heat was also observed when titrating AmB with 10 percent lanosterol containing 
liposomes (Figure 3-10B). Conversely, when 10 percent ergosterol containing liposomes were 
added to a solution of AmB, we observed a marked increase in the net exotherm, consistent with 
Figure. 3.10. A. Representative thermogram of 
AmB titrated with sterol-free POPC liposomes. B. 
Representative thermogram of AmB titrated with 
lanosterol containing liposomes. C. 
Representative thermogram of AmB titrated with 
ergosterol containing liposomes. D. Summary of 
the ITC data, showing the increase in heats 
between sterol-free and ergosterol containing 
liposomes but not lanosterol containing 
liposomes. Adapted from Palacios, et al Proc. 
Natl. Acad. Sci. USA 2011, 108, 6733-6738 
Copyright 2011, National Academy of Sciences. 
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a direct AmB-ergosterol binding interaction (Figures 3-10C and 3-10D). Further supporting this 
conclusion is the lanosterol experiment, which clearly demonstrates that sterol dependent global 
membrane properties do not lead to an increase in the net exotherm beyond sterol-free 
membranes. Therefore, these results provide the first conclusive evidence that AmB and 
ergosterol participate in a direct small molecule-small molecule binding interaction.  
These ITC experiments have therefore finally resolved the long-standing debate between 
the indirect sterol binding hypothesis and the direct sterol binding hypothesis. The definitive 
clarification of this lasting issue highlights the power of the synthesis-enabled functional group 
deletion strategy to reveal the function of complex small molecules. Thus, this experimental 
strategy holds much promise as a general approach for probing other interesting mechanistic 
questions.30     
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Figure. 3.11. A. Representative thermograms of AmB 
titrated with sterol-free and ergosterol-loaded 
liposomes. B. Representative thermograms of 
MeAmB titrated with sterol-free and ergosterol-loaded 
liposomes. C. Summary of data, showing the increase 
in heats between sterol-free and ergosterol containing 
liposomes. Adapted from Palacios, et al Proc. Natl. 
Acad. Sci. USA 2011, 108, 6733-6738 Copyright 
2011, National Academy of Sciences. 
Figure 3.12. A. Representative thermograms of AmdeB titrated 
with sterol-free and ergosterol-loaded liposomes. B. 
Representative thermograms of MeAmdeB titrated with sterol-
free and ergosterol-containing liposomes. C. Summary of data 
showing that the net exotherm did not change in the presence 
of ergosterol. Adapted from Palacios, et al Proc. Natl. Acad. 
Sci. USA 2011, 108, 6733-6738 Copyright 2011, National 
Academy of Sciences. 
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Following the establishment of the AmB-ergosterol interaction, we moved forward to 
look at the sterol binding capacity of the functional group deficient derivatives to probe the role 
of the carboxylate and mycosamine in sterol binding (Figures 3-11 and 3-12). First, we repeated 
the ergosterol binding experiment with AmB and EYPC liposomes with and without 10 percent 
ergosterol. We changed to EYPC lipids at this point because the binding and efflux assays were 
performed using this liposome system. The ITC experiment with the EYPC liposomes gave 
similar results for AmB (Figure 3-11A) as for the POPC liposomes, so we then assayed the 
sterol-binding capacity of MeAmB. As shown in Figure 3-11B, changing from sterol-free to 10 
percent ergosterol liposomes also produced a dramatic increase in the net exotherm for MeAmB, 
in a manner analogous to AmB. For MeAmB, the observed heats in microcals were significantly 
greater for both the sterol free and ergosterol containing liposomes than the corresponding values 
for AmB, but the difference in these heats is statistically the same for both AmB and MeAmB 
two compounds (Figure 3-11C). Therefore, based upon this ITC data, oxidation at C(41) is not 
required to bind ergosterol.  
Subsequent examination of the ergosterol binding ability of AmdeB and MeAmdeB 
produced strikingly different results. For example, unlike the previous three ITC experiments, 
titrating AmdeB with ten percent ergosterol loaded liposomes did not produce an increase in the 
net exotherm relative to the sterol free system (Figure 3-12A). Similarly, no differences between 
the two exotherms were observed in the titration experiments with MeAmdeB (Figure 3-12B). 
Indeed, for both AmdeB and MeAmdeB, the numerical difference between the evolved heat for 
sterol free and ten percent ergosterol liposomes is within experimental error of zero (Figure 3-
12C). Thus, the results with the aglycones clearly demonstrate that mycosamine is absolutely 
required to bind ergosterol, and this represents a previously unknown role for a glycoside 
appended to a small molecule natural product, i.e. the mediation of a functionally vital small 
molecule-small molecule binding interaction.31  
The demonstration that AmB directly interacts with ergosterol led us to question if AmB 
also binds cholesterol, the main sterol found in mammalian cells, in a mycosamine dependent 
fashion. For the initial cholesterol ITC experiments, we used the same experimental protocol that 
had proven to be successful in establishing the AmB-ergosterol interaction, but we did not 
observe any cholesterol dependent changes in the net exotherm under these conditions. We 
attributed this effect to a possible lowered affinity of AmB for cholesterol, and so we altered the 
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experimental conditions in an attempt to record this binding event. We tripled the amount of 
AmB in the experiment (from 50 to 150 µM). We also increased the concentration of the 
liposomes injected into the AmB solution from 8 to 12 mM, to add more cholesterol to the 
system. Under these new, augmented conditions, we were able to observe the mycosamine-
dependent binding of AmB to cholesterol (Figure 3-13).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. A. Representative thermograms of AmB 
titrated with sterol-free and cholesterol-loaded 
liposomes under the more sensitive conditions B. 
Representative thermograms of AmdeB titrated with 
sterol-free and cholesterol-containing liposomes under 
the more sensitive conditions. C. Summary of data 
showing the net increase in the exotherm in the 
presence of cholesterol for AmB but not AmdeB. 
Adapted from Palacios, et al Proc. Natl. Acad. Sci. 
USA 2011, 108, 6733-6738 Copyright 2011, National 
Academy of Sciences. 
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3-7 DISCUSSION 
The results described in this chapter clearly and conclusively demonstrate that 
mycosamine is required for 1) binding sterols, 2) forming ion channels and 3) killing yeast. This 
suggests an intimate and causative link between sterol-dependent ion channel formation and 
antifungal activity. That is, of the four compounds tested, only those that could both bind 
ergosterol and form ion channels (AmB and MeAmB) also had the capacity to inhibit the growth 
of yeast. Accordingly, these experimental observations can be used to formulate two distinct 
hypotheses to explain the source of AmB’s antifungal activity. One, sterol binding is necessary 
for ion channel formation, but it is only ion channel activity that is responsible for killing yeast, 
and two, channel formation is one of multiple sterol-binding dependent mechanisms of action. 
Of these two mechanistic scenarios, we strongly favor the latter interpretation, for the following 
reasons. First, other mycosamine bearing polyene macrolides have been described that do not 
have the ability to form ion channels but display significant antifungal activity.28,32 Recently, a 
mechanistic investigation of the non-channel forming macrolide natamycin (Figure 3.14) led to 
the conclusion that this molecule has a different mechanism of action than AmB, and kills yeast 
cells by sequestering ergosterol and preventing the participation of this molecule in vital cellular 
events.28,33 For the purposes of direct comparison with our AmB results, we performed MIC, S. 
cerevisiae potassium efflux and ITC binding assays with natamycin, the results of these 
experiments are shown in Figure 3.14. In addition, an earlier examination of the relative 
Figure 3.14. Biophysical and 
biological Studies with the polyene 
macrolide natamycin (also called 
pimaricin). A. Structure of 
natamycin. The mycosamine and 
acid are conserved but the molecule 
is significantly shorter than AmB. B. 
Natamycin does not elicit the efflux 
of potassium from S. cerevisiae 
cells. C. Natamycin is actively 
fungicidal against S. cerevisiae and 
C. albicans, though it is not as 
active as AmB or MeAmB. D. 
Natamycin binds ergosterol as 
demonstrated by the ITC binding 
assay. Adapted from Palacios, et al 
Proc. Natl. Acad. Sci. USA 2011, 
108, 6733-6738 Copyright 2011, 
National Academy of Sciences. 
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antifungal and membrane permeabilizing activities of AmB and the related natural product 
nystatin found that these properties were disconnected in the yeast C. albicans.34 In this study, 
nystatin was more effective than AmB at increasing the membrane permeability of C. albicans, 
but was a less potent antifungal agent. A disassociation between membrane permeabilization and 
cell death has also been described for some AmB-resistant C. albicans mutants.35 In these 
mutants, AmB induced ionic efflux did not necessarily also lead to cell death.  
We herein propose a unifying model that is consistent with of all this data. We propose  
that AmB kills yeast cells through two, complementary mechanisms of action.36 The first 
mechanism, shared in common with natamycin, is the binding and sequestering of ergosterol 
from vital physiological functions, and the second mode of action is the formation of a 
supramolecular transmembrane AmB ion channel that disrupts the cellular electrochemical 
gradient. This two mechanism model may prove to be generally applicable to explain the 
biological activity of the entire class of antifungal polyene macrolides, and requires further 
exploration.  
  
 
 
 
 
Figure 3.15. A proposed general model for the mechanism of action of antifungal polyene macrolides, this 
model proposes two complementary mechanisms: 1) The mycosamine-mediated binding of ergosterol, 
preventing the sterol from participating in vital cellular physiology and 2) Sterol and mycosamine dependent 
ion channel formation. Adapted from Palacios, et al Proc. Natl. Acad. Sci. USA 2011, 108, 6733-6738 
Copyright 2011, National Academy of Sciences. 
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It is interesting to note that a similar two-mechanism model is hypothesized to be 
operative for the antibacterial lantibiotic nisin.37 Nisin is a peptidic natural product widely used 
industrially to prevent the spoilage of food and it exerts its antibiotic activity by forming pores in 
bacterial membranes in a lipid II dependent fashion.38 In addition, much like natamycin, the 
related, shorter lantibiotic mutacin cannot form pores because of its smaller size,39 but retains 
antibacterial activity by binding to lipid II. As a final striking overlap between the small 
molecule and peptide systems, both of the channel forming molecules, AmB and nisin, are more 
potent against their respective microorganism targets than their non-channel forming relatives, 
natamycin and mutacin. Thus, the polyene macrolides and lantibiotics appear to have 
convergently evolved a similar dual mechanism to achieve highly potent, difficult to resist 
antimicrobial activity. More recent studies with natamycin were accompanied by similar 
speculations.40 
 
3-8 THESIS SUMMARY 
 This thesis describes the articulation and initial application of the functional group 
deletion strategy as applied to the clinically vital antimycotic amphotericin B. This strategy is 
composed of three experimental modules: the synthesis of functional group knockouts, 
determination of the ground state conformation of the derivatives, and biophysical and biological 
investigation into the functional consequences of these deletions. The first chemical moieties that 
were marked for deletion were the C(41) carboxylate and C(19) mycosamine, both of which had 
been proposed to be critical for the antifungal activity of AmB. Three synthetic derivatives were 
therefore targeted: C(41)-Methyl amphotericin B, amphoteronolide B and C(41)-methyl 
amphoteronolide B. To access these molecules, a flexible degradative synthesis from the natural 
product was developed and executed to provide greater than 10 mg of each compound and in 
greater than ninety percent purity after preparative HPLC purification. The highlights of these 
syntheses are the modular strategy that maximizes the number of common synthetic 
intermediates and reaction conditions, and the selective removal of the acid and mycosamine 
under mild, high yielding conditions, thereby enabling excellent synthetic throughput and 
efficiency. Next, extensive two-dimensional NMR experiments with AmB, MeAmB, AmdeB 
and MeAmdeB were used to calculate the ground state conformation of these four molecules. It 
was determined that the conformation of the macrolactone was completely conserved in the 
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functional deficient derivatives, facilitating interpretation of the biophysical and biological 
experiments.  
 The third element of the functional group deletion strategy was then enacted, the 
biophysical and biological investigation of the functional group deficient derivatives. Through a 
series of assays to test biological activity, ion channel formation, membrane binding and 
membrane embedded sterol binding, we gained key insights into AmB’s molecular mechanisms 
of action. For example, we found that, contradictory to the leading hypothesis for AmB’s 
mechanism of action, oxygenation at C(41) is not required for potent ion channel or antifungal 
activity. In addition, we also discovered that the C(41) carboxylate is not required for membrane 
binding or ergosterol binding. However, experiments with AmdeB and MeAmdeB demonstrated 
the absolute requirement of mycosamine for biological activity, ion channel formation and sterol 
binding. Based upon these results and parallel studies with natamycin, we proposed a novel, 
potentially general model in which AmB exhibits two, distinct mechanisms of antifungal 
activity: sterol sequestration and sterol-dependent ion channel formation.   
 Collectively, the studies described in this thesis significantly advance the mechanistic 
understanding of this fascinating natural product. With these results as a foundation, it is possible 
that further mechanistic elucidation of AmB could yield a strategy to rationally design a less 
toxic analogue of this medically indispensible antifungal agent. In addition, the prospect of 
molecular prosthetics, small molecule mimics of protein function, is further strengthened by the 
more refined comprehension of this prototypical small molecule ion channel. Finally, this thesis 
is a powerful demonstration for the capacity of the functional group deletion strategy and 
synthetic organic chemistry to illuminate even the most elusive aspects of small molecule 
function.  
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3-9 EXPERIMENTAL SECTION 
 
Materials. Commercially available materials were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), Fisher Scientific (Hampton, NH), Avanti Polar Lipids (Alabaster, AL), and 
Small Parts Inc. (Miramar, FL) and were used without further purification unless noted 
otherwise. Amphotericin B was a generous gift from Bristol-Myers Squibb and was purified by 
preparative RP-HPLC using an Agilent (Santa Clara, CA) 1100 series HPLC system equipped 
with a Waters (Milford, MA) Sunfire Prep C18 30 x 150 mm column, as described previously. 
Ergosterol was recrystallized from ethyl acetate. Water was obtained from a Millipore (Billerica, 
MA) Gradient A10 water purification system. Amphotericin B derivatives were prepared and 
purified as described in Chapter 2. 
 
General procedure for extinction coefficient determination. Several milligrams of dried 
compound were massed in a tared vial using a Mettler Toledo MT5 microbalance. This sample 
was then dissolved in DMSO to create a concentrated stock solution. From this concentrated 
stock, a 1 mM solution in DMSO was prepared and this 1 mM solution was used to prepare the 
following serial dilution in DMSO: 800 µM, 500 µM, 300 µM, 100 µM and 50 µM. Then, each 
of the serial dilution solutions (including the 1 mM solution) was added to 450 µL of methanol. 
The methanol samples were prepared in triplicate and analyzed by UV/Vis spectroscopy. The 
average absorbance and standard deviation for each sample was then plotted against 
concentration. The data was fitted with a linear least squares fit using Excel and the slope of the 
fitted line was used as the extinction coefficient.41 
 
Antifungal Assays 
Growth Conditions for S. cerevisiae.   
S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
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cultures were maintained at 30 °C in an incubator.  
Growth Conditions for C. albicans. 
C. albicans was cultured in a similar manner to S. cerevisiae except both liquid and solid 
cultures were incubated at 37 °C. 
 
Disk Diffusion Assay.  
Protocols for disk diffusion assays were adapted from the Clinical and Laboratory 
Standards Institute document M2-A8.2 S. cerevisiae were streaked on YPD agar plates with an 
inoculating loop and incubated at 30 ºC until individual colonies could be identified by eye (~ 24 
h). Five individual colonies were transferred from the agar plate with a sterile pipette tip to liquid 
YPD medium. The liquid culture was incubated overnight at 30 ºC in a shaker incubator (200 
rpm). The saturated cell culture was diluted with YPD medium to an OD600 of 0.1 (~ 5 x 106 
cfu/mL) as measured on a Shimadzu PharmaSpec UV-1700 UV/Visible spectrophotometer. This 
culture was used to inoculate an YPD plate by streaking the entire plate with a sterile cotton tip 
applicator three times, turning the plate approximately 60 °C after each application and finishing 
by swabbing the rim of the agar. The plate was allowed to dry for approximately 2 to 3 minutes 
before application of paper disks impregnated with compounds 3.1-3.4. The disks were prepared 
in the following manner: 10 microliters of a 4 mg/ml solution of each compound in DMSO was 
added to a sterile 9 mm disk of Whatman 4 filter paper. Controls were prepared in a similar 
manner using only DMSO. The disks were then placed on the agar and gently pressed with 
forceps. All disks, including DMSO controls, were added within 15 minutes of inoculation. After 
disks were added to the plate the plate was inverted and incubated at 30 °C for 48 hours prior to 
assessment. Those compounds which showed a visible zone of growth inhibition were judged to 
be active. This experiment was repeated and yielded the same results. The assay for C. albicans 
was performed similarly except the liquid and solid cultures were incubated at 37 °C instead of 
30 °C. 
 
Broth Microdilution Minimum Inhibitory Concentration (MIC) Assay.  
The protocol for the broth microdilution assay was adapted from the Clinical and 
Laboratory Standards Institute document M27-A2.3 50 mL of YPD media was inoculated and 
incubated overnight at either 30 °C (S. cerevisiae) or 37 °C (C. albicans) in a shaker incubator. 
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The cell suspension was then diluted with YPD to an OD600 of 0.10 (~5 x 106 cfu/mL) as 
measured by a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. The 
yeast suspension was diluted 10-fold with YPD, and 195 µL aliquots of the dilute cell suspension 
were added to sterile Falcon (Franklin Lakes, NJ) Microtest 96 well plates in triplicate. 
Compounds were prepared either as 400 µM (AmB, MeAmB) or 2 mM (AmdeB, MeAmdeB) 
stock solutions in DMSO and serially diluted to the following concentrations with DMSO: 1600, 
1200, 800, 400, 320, 240, 200, 160, 120, 80, 40, 20, 10 and 5 µM. 5 µL aliquots of each solution 
were added to the 96 well plate in triplicate, with each column representing a different 
concentration of the test compound. The concentration of DMSO in each well was 2.5% and a 
control well to confirm viability using only 2.5% DMSO was also performed in triplicate. This 
40-fold dilution gave the following final concentrations: 50, 40, 30, 20, 10, 8, 6, 4, 1, 0.5, 0.25 
and 0.125 µM. The plates were covered and incubated at 30 °C (S. cerevisiae) or 37 °C (C. 
albicans) for 24 hours prior to analysis. The MIC was determined to be the concentration of 
compound that resulted in no visible growth of the yeast. The experiments were performed in 
duplicate and the reported MIC represents an average of two experiments.   
 
Potassium Efflux Assays 
General Information. 
 Ion selective measurements were obtained using a Denver Instruments (Denver, CO) 
Model 225 pH meter equipped with a Denver Instruments potassium selective electrode. The pH 
meter was connected to a desktop computer by an RS232 connection and the data were collected 
using Labtronics (Guleph, Ontario) Collect SL software. The electrode was conditioned in a 
1000 ppm KCl standard solution overnight prior to ion selective measurements. Measurements 
were made on 15 mL solutions that were magnetically stirred in 40 mL I-Chem (Rockwood, TN) 
vials incubated in a 30 °C stirred water bath (S. cerevisiae) or at 23 °C (LUVs). The instrument 
was calibrated daily with KCl standard solutions to 10, 100, and 1000 ppm potassium. The 
potassium concentration was sampled every 30 seconds throughout the course of the efflux 
experiments.  
 
Potassium Efflux from S. cerevisiae. 
 The protocol to determine potassium efflux from S. cerevisiae was adapted from a similar 
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experiment utilizing C. albicans.4 An overnight culture of S. cerevisiae in YPD was centrifuged 
at 1200 g for 5 minutes at 4 °C. The supernatant was decanted and the cells were washed twice 
with sterile water. After the second wash step, the cells were suspended in 150 mM NaCl, 5 mM 
HEPES pH 7.4 (Na buffer) to an OD600 of 1.5 (~1x109 CFU/mL). A 15 mL sample of the cell 
suspension was then incubated in a 30 °C water bath with stirring for approximately 10 minutes 
before data collection. The probe was then inserted and data was collected for 5 minutes before 
adding 150 µL of the compound in question as a 300 µM solution in DMSO. The cell suspension 
was stirred and data were collected for 30 minutes and then 150 µL of a 1% aqueous solution of 
digitonin was added to effect complete potassium release and data were collected for an 
additional 15 minutes. The experiment was performed independently three times for each small 
molecule.  
 
Data Analysis. 
 The data from each run was normalized to the percent of total potassium release, from 0 
to 100%. Thus for each experiment a scaling factor S was calculated using the following 
relationship: 
    
Each concentration data point was then normalized by entering into the above formula as 
“[K]final” before plotting as a function of time. 
 
Efflux from 10% ergosterol LUVs. 
LUV Preparation.  
Egg yolk phosphatidylcholine (EYPC) was obtained as a 10 mg/mL solution in CHCl3 
from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 °C under an atmosphere of dry 
argon and used within 3 months. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at -20 °C under an atmosphere of dry argon. Prior to preparing a lipid film, 
the solutions were warmed to ambient temperature to prevent condensation from contaminating 
the solutions. A 13 x 100 mm test tube was charged with 1.6 mL EYPC and 230 µL of the 
ergosterol solution. The solvent was removed with a gentle stream of nitrogen and the resulting 
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lipid film was stored under high vacuum for a minimum of eight hours prior to use. The film was 
then hydrated with 1 mL of 150 mM KCl, 5 mM HEPES pH 7.4 (K buffer) and vortexed 
vigorously for approximately 1 minute to form a suspension of multilamellar vesicles (MLVs). 
The resulting lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and 
the syringe was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then 
passed through a 0.20 µm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly 
formed large unilamellar vesicle (LUV) suspension being collected in the syringe that did not 
contain the original suspension of MLVs to prevent the carryover of MLVs into the LUV 
solution. To obtain a sufficient quantity of LUVs, three independent 1 mL preparations were 
pooled together for the dialysis and subsequent potassium efflux experiments. The newly formed 
LUVs were dialyzed using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes. 
The samples were dialyzed three times against 600 mL of Na buffer. The first two dialyses were 
two hours long, while the final dialysis was performed overnight.  
 
Determination of Phosphorus Content.  
Determination of total phosphorus was adapted from the report of Chen and coworkers.42 
The LUV solution was diluted tenfold with Na buffer and three 10 µL samples of the diluted 
LUV suspension were added to three separate 7 mL vials. Subsequently, the solvent was 
removed with a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that 
was used as a blank, was added 450 µL of 8.9 M H2SO4. The four samples were incubated open 
to ambient atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 23 
°C and cooled for 5 minutes. After cooling, 150 µL of 30% w/v aqueous hydrogen peroxide was 
added to each sample, and the vials were returned to the 225 °C heating block for 30 minutes. 
The samples were then removed to 23 °C and cooled for 5 minutes before the addition of 3.9 mL 
water. Then 500 µL of 2.5% w/v ammonium molybdate was added to each vial and the resulting 
mixtures were then vortexed briefly and vigorously five times. Subsequently, 500 µL of 10% w/v 
ascorbic acid was added to each vial and the resulting mixtures were then vortexed briefly and 
vigorously five times. The vials were enclosed with a PTFE lined cap and then placed in a 100 
°C aluminum heating block for 7 minutes. The samples were removed to 23 °C and cooled for 
approximately 15 minutes prior to analysis by UV/Vis spectroscopy. Total phosphorus was 
determined by observing the absorbance at 820 nm and comparing this value to a standard curve 
 122 
obtained through this method and a standard phosphorus solution of known concentration. 
 
Determination of Ergosterol Content.  
Ergosterol content was determined spectrophotometrically. The LUV solution was 
diluted tenfold with Na buffer, and 50 µL of the dilute LUV suspension was added to 450 µL 
2:18:9 hexane:isopropanol:water (v/v/v). Three independent samples were prepared and then 
vortexed vigorously for approximately one minute. The solutions were then analyzed by UV/Vis 
spectroscopy and the concentration of ergosterol in solution was determined by the extinction 
coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was compared to the concentration 
of phosphorus to determine the percent sterol content. The extinction coefficient was determined 
independently in the above ternary solvent system. LUVs prepared by this method contained 
between 7 and 14% ergosterol.  
 
Efflux from LUVs.  
The LUV solutions were adjusted to 1 mM in phosphorus using Na buffer. 15 mL of the 
1 mM LUV suspension was added to a 40 mL I-Chem vial and the solution was gently stirred. 
The potassium ISE probe was inserted and data were collected for one minute prior to the 
addition of the compound. Then, 150 µL of a 100 µM DMSO solution of the compound in 
question was added and data were collected for five minutes. Then to effect complete potassium 
release, 150 µL of a 10% v/v solution of triton X-100 was added and data were collected for an 
additional five minutes. The experiment was duplicated with similar results. 
 
Data Analysis. 
 The data from each run were analyzed in the same manner as the efflux data from S. 
cerevisiae. 
 
Planar Lipid Bilayer Experiments 
General Information.  
All data were acquired using a Warner Instruments (Hamden, CT) BC-535 amplifier and 
the data were filtered using a built in 4 pole Bessel filter with a cutoff frequency of 5 kHz. The 
headstage and delrin cell were housed within a Warner Instruments model FC-1 Faraday cage. 
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The solutions were stirred using a Warner Instruments SUNstir-3 stirplate. The signal was passed 
through a Warner Instruments low pass 8 pole Bessel filter with a frequency cutoff of 1 kHz. The 
filtered data were sampled at a rate of 10 kHz using a Molecular Devices (Sunnyvale, CA) 
Digidata 1440 data acquisition system and the data were analyzed using Molecular Devices 
pClamp 10 software. Following acquisition, the data were digitally filtered to 20 Hz. Salt bridges 
were prepared monthly and were fabricated from 1.5 mm OD, 0.86 mm ID borosilicate capillary 
tubing and were filled with 1 M aqueous KCl with 2.5% agar. Prior to a day’s experiments, silver 
electrodes were plated by submerging in commercial bleach for 15 to 30 minutes. The electrodes 
were plated periodically throughout the day. 
 
Preparation of Teflon® Sheets.  
Prior to use, Teflon® sheets of 125 µM thickness (Small Parts Inc, Miramar, FL) were 
washed sequentially with 10 mM tribasic sodium phosphate, 1% HCl and then MilliQ water. 
Pores of approximately 100-150 µm in diameter were formed with the spark method43 using a 
home built sparking apparatus. The Teflon® sheet was scored with a sewing needle and then the 
sheet was placed on a grounded sheet of copper and the Teflon® was sparked 10 times. The sheet 
was then flipped over and sparked an additional 10 times. Pore sizes were analyzed via light 
microscopy. 
 
Preparation of Lipid Solution.   
Lipids were obtained from Avanti Polar Lipids as 10 mg/ml solutions in CHCl3. The 
solutions were stored at -20 °C under dry argon and used within 3 months. A 4 mg/mL solution 
of ergosterol in CHCl3 was prepared monthly and stored at -20 °C under dry argon. Lipid films 
were prepared by charging a 12 x 75 mm test tube with 40 µL porcine brain phosphatidylcholine, 
20 µL porcine brain phosphatidylethanolamine and 3.8 µL ergosterol. The solvent was removed 
with a gentle stream of nitrogen. The lipid film was then dissolved in 30 µL n-decane to give the 
20 mg/ml solution of lipids used for the electrophysiology experiments. The decane solutions 
were used within 3 hours of preparation.  
 
Formation of planar lipid bilayers.  
Teflon® sheets were cut to approximately 1 cm2 and adhered to a home fabricated delrin 
 124 
cell17 using Dow Corning (Midland, MI) high vacuum grease. The area around the hole was then 
primed with the decane lipid solution. The primed sheet was left to stand for approximately 10 
minutes such that some of the decane evaporated. Then 3.5 mL of 2 M KCl, 10 mM potassium 
phosphate pH 7.0 buffer was added to each chamber. The membrane was formed by sequential 
vertical swabs across the hole using a flame polished glass applicator that had been previously 
dipped into the lipid solution. The formation of a membrane was detected by a reduction in the 
current to 0 pA. The integrity of this membrane was confirmed by applying a potential of 150 
mV for approximately one minute. If the current increased by >1 pA upon voltage introduction, 
the membrane was rejected. Membranes were between 20 and 45 pF in size.  
 
Interrogating Channel Formation.  
If the membrane was acceptable, 3.5 µL of a compound in DMSO was added to both 
chambers and the solutions were stirred with zero applied potential for 10 minutes. After 10 
minutes the stirring was stopped, and 150 mV of potential was applied across the membrane. The 
formation of single AmB channels under similar conditions has been well documented.9,44 The 
concentration of AmB and MeAmB required to observe channel activity varied based upon the 
lot number and age of the lipids used to make the membrane. For AmB, single channel formation 
was observed at concentrations between 0.5 and 5 nM while MeAmB displayed single channel 
activity between 30 and 80 nM. The concentration of MeAmdeB was raised to 1000 nM without 
observing any channel activity. At concentrations greater than 100 nM MeAmdeB and AmdeB 
tended to grossly destroy the membrane, as evidenced by an abrupt change from zero current to 
an offscale reading. To verify the inability of MeAmdeB and AmdeB to form channels, 5 
independent experiments were performed at concentrations ranging from 50 to 100 nM, each 
with 15 minutes of applied potential. In every case, AmdeB and MeAmdeB failed to produce 
channel activity. These same conditions consistently led to channel formation with AmB and 
MeAmB.  
 
Yeast Binding Assay 
Determination of Binding. 
The yeast binding assay was adapted from the report by Kobayashi and coworkers that 
demonstrated binding of AmB to intact S. cerevisiae cells.19 10 mL of an overnight culture of S. 
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cerevisiae in YPD was centrifuged at 1200 g for 5 min at 4 °C. The supernatant was decanted, 
and the cells were washed twice with sterile water using the same centrifuge conditions. The 
washed cells were then suspended in sterile water to an OD600 of 0.10 (∼5x106 CFU/mL), and 
990 µl of this suspension was added to a 1.5 mL microcentrifuge tube. 10 µL of a 200 µM 
solution of compound in DMSO was added to the suspension, which was vortexed for 
approximately 10 seconds and then incubated at 30 °C for 15 minutes. The samples were 
subsequently centrifuged at 5000 RPM with a Savant HSC10K Speedfuge for 5 min to pellet the 
cells. The concentration of AmB in such aqueous solutions cannot be accurately determined 
because of aggregate formation.24 Thus, 950 µL of the supernatant was removed and incubated at 
-20 °C for approximately 20 minutes before being lyophilized overnight. The lyophilized sample 
was dissolved in 400 µL of MeOH and the concentration of compound in solution was 
determined by UV/Vis analysis using the known extinction coefficient of each compound.1 This 
analysis gives the percent recovery, the percent incorporation being equal to 1-(percent 
recovery). The samples were prepared in triplicate and the entire experiment was duplicated. The 
values represent the average of 5 or 6 trials plus or minus the standard deviation.  
 
Recovery Control. 
To ensure that the compounds were not binding to the walls of the microcentrifuge tube 
or decomposing during the course of the experiment, a control was run using the experimental 
protocol outlined above but substituting pure water for the S. cerevisiae suspension.  
 
LUV Binding Assay 
Preparation of LUVs.  
LUVs were prepared as described in the liposome efflux studies except dialysis was not 
performed and the newly extruded vesicles were purified via size exclusion chromatography 
using Sephadex G50-150 resin as the stationary phase and K buffer as the mobile phase. The 
concentration of phosphorus and the sterol content of the LUVs were determined as described 
above.  
 
LUV Binding.  
The partitioning of AmB into both sterol-containing45,46,47 and sterol-free48,49,50 LUVs has 
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been previously demonstrated. While many prior methods relied upon a measureable change of a 
physical property (such as electronic absorption spectra) upon the interaction of AmB with a 
phospholipid bilayer, the SEC based method is advantageous because it physically separates 
bound from unbound compound, and thereby avoids assumptions regarding the underpinnings of 
the observed spectral changes.22 A LUV solution of known phosphorus concentration was 
diluted to a concentration of 2.05 mM using K buffer, and the solution was gently vortexed. 
Then, a 975 µL sample of the LUV suspension was added to a 7 mL screw cap vial. 
Subsequently, 25 µL of a 0.8 mM DMSO solution of the compound under investigation was 
added and the sample was gently vortexed. The sample was then incubated at 30 °C for one hour. 
The sample was then purified via size exclusion chromatography using a 1.5 x 30 cm Sephadex 
G50-150 column, with K buffer as the mobile phase (LUVs typically eluted from the column 
between 9 and 11 ml of eluent). After the LUVs eluted from the column, the column was flushed 
with 100 mL of K buffer to remove any small molecules left on the resin. 
The concentration of the purified LUVs was then determined through analysis of 
phosphorus content, as described above. The concentration of compound within the lipid bilayer 
was determined by dissolving triplicate 50 µL samples of the LUV solution in 450 µL of 2:18:9 
hexane:isopropanol:water (v/v/v) and analyzing the sample by UV/Vis spectroscopy. The 
amount of compound incorporation was determined by comparing the final ratio of lipid to 
compound to the theoretical max of 100:1. The experiments were performed in quadruplicate for 
each compound; thus, the reported values represent the average of four runs plus or minus the 
standard deviation. The binding to sterol-free vesicles was determined in similar fashion except 
no ergosterol was added to the initial lipid film.  
 
LUV-free Control Studies. 
As a control, the same procedure described above was repeated without LUVs to 
determine the amount of compound that elutes from the column at the approximate elution 
volume of the LUVs (the LUVs typically eluted between 9 and 11 mL). Five fractions of 5 mL 
elution volume were collected, frozen and lyophilized overnight. Then, the resulting solid was 
suspended in 1 mL of MeOH and vortexed vigorously for approximately two minutes. The 
samples were then centrifuged at 4000 rpm with a Savant HSC10K Speedfuge for approximately 
30 minutes to pellet the inorganic salts. The supernatant was removed and analyzed by UV/Vis 
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spectroscopy to determine the amount of compound in solution.  
 
Isothermal Titration Calorimetry 
General Information. 
Experiments were performed using a VP-ITC isothermal titration calorimeter (MicroCal 
Inc., Piscataway, NJ).  Solutions of the compounds to be tested were prepared by diluting a 5.0 
mM stock solution of the compound in DMSO to 50 µM with K buffer. The final DMSO 
concentration in the solution was 1% v/v. LUVs were prepared and phosphorus and ergosterol 
content was quantified as described in Section VI. Ergosterol and lanosterol were also 
incorporated into POPC LUVs. The LUV solutions were diluted with buffer and DMSO to give a 
final phospholipid concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior 
to use, all solutions were degassed under vacuum at 17 °C for 10 minutes. The reference cell of 
the instrument was filled with a solution of 1% v/v DMSO/K buffer. 
 
Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 1.4399 mL or 1.4495 mL) which contained the 50 µM solution of the 
compound in question at 25 °C. The volume of the first injection was 1 µL. Consistent with 
standard procedure,27 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, forty 5 
µL injections of the LUV suspension were performed. The injection duration was 2.1 seconds 
and 10.3 seconds for the 1 µL and 5 µL injections, respectively. The spacing between each 
injection varied between 240 seconds and 480 seconds and was adjusted to allow the instrument 
to return to baseline before the next injection was made. The rate of stirring for each experiment 
was 300 or 310 rpm.  
 
Data Analysis. 
ORIGIN software (MicroCal, Inc.) was used for baseline determination and integration of 
the injection heats, and Microsoft Excel was used for subtraction of dilution heats and the 
calculation of overall heat evolved. To approximate the dilution heats, the final integrated heat 
from each run was subtracted from all the data for that particular experiment.28 The overall heat 
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evolved during the experiment was calculated using the following formula: 
€ 
µcaloverall = (Δhinjectioni − Δhinjectionn
i=1
n
∑ )  
Where i = injection number, n = total number of injections, 
€ 
Δhinjectioni = heat of the i
th injection, 
€ 
Δhinjectionn = the heat of the final injection of the experiment. 
 
Cholesterol Binding Experiments. 
In order to detect the relatively weaker binding between AmB and cholesterol the 
concentrations of small molecule and liposomes were increased for these experiments. Solutions 
of AmB and AmdeB were prepared by diluting a 15.0 mM stock solution of the compound in 
DMSO to 150 µM with 5 mM HEPES (pH = 7.4) buffer. The final DMSO concentration in the 
solution was 1% v/v. LUVs were prepared and phosphorus content was quantified as described 
in Section VI. Cholesterol content was assumed based upon the molar ratio of sterol to lipid in 
the preparation of the lipid films. The LUV solutions were diluted with 1% v/v DMSO/5 mM 
HEPES to give a final phospholipid concentration of 12.0 mM. Immediately prior to use, all 
solutions were degassed under vacuum at 17 °C for 10 minutes. The reference cell of the 
instrument was filled with a solution of 1% v/v DMSO/5 mM HEPES. 
 
Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 1.4399 mL or 1.4495 mL) which contained the 150 µM solution of 
AmB or AmdeB at 25 °C. The volume of the first injection was 1 µL. Consistent with standard 
procedure, due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, twenty 
10 µL injections of the LUV suspension were performed. The injection duration was 2.1 seconds 
and 20.6 seconds for the 1 µL and 10 µL injections, respectively. The spacing between each 
injection varied between 240 seconds and 360 seconds and was adjusted to allow the instrument 
to return to baseline before the next injection was made. The rate of stirring for each experiment 
was 300 or 310 rpm.  
 
Data Analysis. 
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 The data analysis for the cholesterol binding experiments was performed as described 
above for the ergosterol binding experiments. Representative thermograms for AmB and AmdeB 
are shown in Figure S5 A and B. The average and standard deviation from at least three 
independent experiments using either sterol-free or 10% cholesterol containing LUVs for AmB 
and AmdeB compounds is shown in Figure S5 C. 
 
Natamycin Experiments 
Antifungal Assay. 
 The antifungal assay for natamycin was run the in the same manner as described in 
Section II except the natamycin was dissolved in 85:15 DMSO:H2O rather than pure DMSO as 
for AmB and its derivatives. The MIC values for natamycin represent the average of two 
independent runs.  
 
Potassium Efflux Assay. 
 The potassium efflux assay was run in the same manner as described in Section III except 
the natamycin was dissolved in 85:15 DMSO:H2O rather than pure DMSO as for AmB and its 
derivatives. 
 
Isothermal Titration Calorimetry 
 Isothermal titration calorimetry experiments were run in as described in Section VII 
except for the preparation of the aqueous natamycin solution. Instead of diluting a 5 mM stock 
100 fold to achieve the 50 µM solution, 1.1 x 10-4 mmol of natamycin was added to a 4 mL vial 
as a solution in 85:15 DMSO:H2O. This solution was removed by leaving under high vacuum for 
several hours. The resulting natamycin film was dissolved in 22 µL 85:15 DMSO:H2O and then 
2.178 mL of K buffer was added to give the 50 µM solution used in the titration experiment. 
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